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  Abstract 
 
Aim  
The aim of this thesis was to describe the service use, clinical outcomes and prescribing change 
associated with the implementation of a complex intervention designed to improve care for 
people with depression in a primary care setting.  
Background 
Health systems have limited capacity to provide appropriate psychological and pharmacological 
treatments for people with depression. Although guidance on the treatment of depression in 
primary care in the UK was clarified by the National Institute for Clinical Excellence (NICE) in 
2004, it is generally acknowledged that the current diagnostic classification of depression is not 
satisfactory.  
Antidepressant prescriptions have continued to rise in Scotland since the mid-1990s, even 
though there is no indication that the incidence or prevalence of depression is increasing. There 
is limited access to psychological therapies.  Health services have not implemented consistent 
packages or systems of care in order to provide adequately for patient needs. Although the 
welfare of staff is critical to their therapeutic engagement with patients, this is rarely an explicit 
focus of health systems design.  
Method 
This thesis describes an observational study examining the implementation of a complex 
intervention to improve depression care called “Doing Well”. The intervention was based in 14 
General Practices in Renfrewshire, a mixed urban-rural area in Scotland. The catchment 
population for the study was 76,000 people. A small team of clinicians implemented a 
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programme for people with low mood, depression and adjustment disorder, based in primary 
care.  
This programme incorporated a number of changes to standard mental health care, including 
the following: no “severity threshold” for referral to secondary care; the routine use of an 
objective measure of depression severity with continuous outcome monitoring; a paperless 
clinical record; prompt access to guided self-help; prompt “step-up” care to more formal 
psychological therapy or medical care if indicated; and careful attention to staff training and 
satisfaction.  
Findings 
1501 out of 1584 people referred to the programme met inclusion criteria and were included in 
the study. Three hundred and thirty-two people (22%) did not attend any appointment; 320 
(21%) dropped out of treatment after at least one contact. One hundred and ninety-five people 
(13%) subsequently had their care transferred to other services (of which 43% were to 
secondary care mental health services), and 654 (44%) of patients completed treatment per 
protocol.  
There was good fidelity to the intended model of care, with patients in the “treatment 
complete” group receiving “brief interventions” of an average of five contacts. These contacts 
totalled 151 minutes over an average of 103 days of treatment. Referrals from GPs continued at 
a high and stable level throughout the period of the evaluation. Median waiting times of 15 days 
were satisfactory.  
The mean reduction in PHQ for patients completing treatment was 10.6 points, representing a 
reduction from baseline of 62%. Seventy-two percent of the treatment complete group showed 
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a PHQ drop greater or equal than 50%, compared with seven percent in the “disengaged” and 
ten percent in the “transfer of care” groups.  
Doing Well received a lower than expected proportion of referrals from deprived areas, and 
there was a small negative association between clinical outcome and living in a more deprived 
area.   
Defined daily doses of antidepressants in the practices that had access to the Doing Well clinical 
intervention increased less rapidly (5.3% between the 12 months to June 2004 and the 12 
months to June 2008) than in neighbouring areas or Scotland as a whole (15.8% over the same 
period). Gross ingredient costs of antidepressants in the Doing Well practices fell more 
substantially over this period (to 56% of baseline) than in Scotland as a whole (to 65% of 
baseline). Formulary compliance increased more rapidly in the Renfrewshire area than in a 
neighbouring area which used the same formulary, but had no contact with Doing Well.  
Conclusions 
It was feasible to implement and sustain a system of care for depression that was consistent 
with NICE guidance, including the provision of some form of psychological therapy (including 
guided self help) for all who needed it. Access to the service was acceptable, and retention 
within the service compares favourably with equivalent studies in other parts of the UK.  
Clinical outcomes were satisfactory, but it was not possible to compare with outcomes in usual 
care in this observational study. Doing Well practices showed a reduction in the rate of rise of 
antidepressant use, although did not stop the rise altogether. The implications of this form of 
“stepped care” for depression for service development are discussed.  
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1. Introduction 
 
1.1 The problem of depression 
1.1.1 Prevalence 
Depression is widely acknowledged to be a major global health problem.  
Characterised by low mood, reduced energy and loss of pleasure and interest, the 
condition is estimated to affect 5.8% of men and 9.5% of women world-wide each 
year,1 and 30-40% of people over their lifetime.2 Depression has been estimated to 
cause the largest non-fatal global burden of disease, accounting for almost 12% of all 
years lived with disability, and the fourth largest disease burden worldwide.3 It has 
been predicted that depression will be the second greatest contributor to global 
morbidity by 2020.4  
Depression is common in the United Kingdom, with a point prevalence of 2.8% for 
depression alone, and of 9.2% for mixed anxiety and depression.5 Seventy percent of 
the suicides in England in 2000 were thought to be related to depression: a total of 
2,507 deaths.6 
The total direct and indirect costs of depression and anxiety in the UK were estimated 
in 2006 to be £17 billion, or 1½% of GDP.7  The cost of depression alone in England in 
2000 was estimated to be £9 billion, of which £370 million represented direct 
treatment costs.6 There were an estimated 109.7 million working days lost due to 
depression in 2000.6 Eighteen percent of Scots say they have been diagnosed by a 
doctor as having depression at some point in their lives.8 
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Yet this common condition was considered to be a rarity only fifty years ago. Some 
authors argue that depression has always been common, but is only now being 
recognised as an “illness”. Others take a view that the rise of “depression” as a 
diagnosis is best understood as a social phenomenon, relating variously to social 
disintegration, the secularisation and commercialisation of culture, or the result of 
effective marketing of medicines by drug companies.9 These issues are discussed in 
greater depth in section 3.2.1 of the Literature Review on page 38. Whichever 
perspective is correct – and there is likely to be some truth in both views – health 
services have to provide an effective response for distressed people seeking help for 
emotional and mood problems.  
 
1.1.2 Service use and antidepressant prescribing 
Depression is typically an episodic, recurring disorder, with each episode lasting from 
a few months to a few years. About 20% of cases result in chronic illness.10 Depression 
is a significant reason for people to consult primary care services across the world. A 
large study surveying primary care attendees in 14 countries11 found point prevalence 
rates varying from 2.6% in Japan to 29.5% in Chile; the point prevalence for the UK site 
(Manchester) was 16.9%.  
In Scotland, 38.0 people per 1,000 practice population consulted their GP or practice 
nurse at least once for depression in the year 2006-7. Depression was the tenth 
commonest reason for Scots to consult their GP in 2006-7, with an estimated 94.8 
consultations per 1,000 practice population for this reason. This represents an 
estimated 503,700 consultations for Scotland during that period.12  
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Rates of antidepressant prescribing have increased significantly since the early 1990s 
in Europe13 and in  North America.14,15 In Scotland, the rate of antidepressant 
prescribing has increased rapidly, from 28.3 million Defined Daily Doses in 1992/3 to 
137.5 million in 2006/7.16 This increase in antidepressant use has occurred in the 
absence of any increase in the prevalence and incidence of depression reported 
changes in depression incidence and prevalence in Scotland, and does not relate to 
the number of patients consulting for depression, which appears to be falling.17 This 
information is summarised in Figure 1-1. 
 
Figure 1-1: Consultation rates and antidepressant use in Scotland for the period 
1992-8008. Blue line shows number of antidepressant items dispensed in 
millions;18 green line shows mean Defined Daily Doses of antidepressants 
prescribed per thousand population per day;18 red line shows Gross Ingredient 
Cost of antidepressants in £million per annum;18 purple lines shows number of 
patients consulting in primary care for depression at least once in the year per 
thousand population19  
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
number of items (M)
gross ingredient cost (£M)
defined daily dose/1000/day
patients consulting at least once/1000/y
22 Introduction 
 
 
Such national and international averages mask widespread variation at a local level. 
Data from primary care shows a 27-fold difference in the recorded incidence of 
depression between Continuous Morbidity Recording (CMR) practices in Scotland, and 
referral rates from primary care to specialist mental health services vary 9-fold.20 
Antidepressant prescribing also varies significantly, with a 4.6-fold ratio between the 
highest and lowest prescriber deciles in Scotland (after adjustment for age and gender 
differences in the practice populations and removing the outliers). About half of this 
variation can be explained or understood, as will be discussed in section 6.5.1.21 
Deprivation has a strong influence on the presentation of mental health problems in 
primary care, and socio-economic deprivation in Scotland is concentrated in the NHS 
Greater Glasgow & Clyde area. An estimated 11.7% of the population of Greater 
Glasgow and Clyde have mental health problems in the least deprived decile of the 
population, but this proportion rises to 19% in the most deprived decile. 
Antidepressant prescriptions are significantly higher in deprived compared to affluent 
practices,22  and deprivation is the factor that explains the largest amount of variation 
in prescribing.21 
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1.2 Health service responses to depression in Scotland 
This section provides a brief overview of the organisation of health services in 
Scotland during the period covered by this study (July 2004 to October 2006), and is 
intended for international readers not familiar with the Scottish health system.  
Most mental health services in Scotland are provided by the National Health Service 
(NHS); a minority of services are provided by the private sector, or managed by other 
agencies such as the voluntary sector and local authorities. The Cabinet Secretary for 
Health and Well Being is responsible for the Scottish Government Health Department 
and for the NHS in Scotland.  
Provision of healthcare in the NHS is the responsibility of 14 geographically-based NHS 
Boards and a number of National Special Health Boards. The geographically-based 
boards have responsibility for the delivery of NHS mental health services in primary 
and secondary care for their areas. “Special” Health Boards charged with health 
promotion (Health Scotland) and professional education for NHS staff (NHS Education 
Scotland) work with NHS Quality Improvement Scotland to promote health, prevent 
illness, and provide quality care through a well-trained workforce. 
The Scottish NHS is characterised by coordinated responsibility for the health care of a 
defined population, subject to democratic oversight. This is unusual in other health 
systems. Although superficially similar to Health Care Organisations (HCOs) in the 
United States, Health Boards in Scotland have relatively stable populations, are not for 
profit and only rarely subcontract out mental health care.23 The NHS in England has 
developed differently to that in Scotland since control of health was devolved to the 
Scottish Parliament in 1999. The Scottish system has not been exposed to 
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“marketisation” of management systems such as foundation hospitals or “payments 
by results”.24 
NHS agencies work jointly with other public bodies to promote health and provide 
quality care. Local Government has a duty to provide community care services to 
people with mental health problems, and the 2003 Mental Health Act also requires 
them to promote wellbeing and social inclusion for this group. This includes not just 
direct social care services, but also the provision of education, leisure services and 
housing.  
Community Health Partnerships are subdivisions of Health Boards in Scotland, and are 
responsible for the delivery of local NHS and joint services. They are typically co-
terminous with council areas, and provide primary care and community-based mental 
health services (as well as other health services) for those areas.  
Eighty to ninety percent of people with depression are managed entirely within 
primary care.25,26 The average practice size for general practices in Greater Glasgow & 
Clyde is 4,250 patients. A practice of this size will typically be staffed by three general 
practitioners and two practice nurses, with two attached district nurses and one 
attached health visitor. Eighty-nine percent of practice populations live within 2km of 
their practice.22  
There are on average 7 GPs per 10,000 population in Scotland. This ratio is not 
strongly influenced by deprivation, meaning that deprived areas have relatively fewer 
GPs in relation to need. There has been little change in the numbers of GPs working in 
Greater Glasgow and Clyde over the last 10 years.22 
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The organisation of secondary care mental health services varies across Health Boards 
in Scotland, but are based on services for adults (services for 18-65 year-olds are 
referred to as “General Adult Psychiatry”), older adults (65 years and older) and 
children and young people. Specialist services provide psychiatric services for 
mentally-ill offenders, people with learning disabilities, and people with substance 
misuse problems. 
General Adult mental health services are typically based on the Community Mental 
Health Team (CMHT). Access to such teams is usually by GP referral. The teams are 
multidisciplinary and usually include psychiatrists, community psychiatric nurses, 
psychologists, occupational therapists, social workers and support workers. 
Pharmacists often work in or alongside teams. The numbers of psychiatrists employed 
in General Adult Psychiatry increased by 40% between 1996 and 2006, from 725.7 to 
1,013 whole-time equivalents.27 Equivalent figures are not available for nursing and 
other staff, but there were 8,428 registered and 4,148 unregistered mental health 
nurses working in Scotland in 2005-6, and the number of nurses in all clinical 
specialities increased by 5% between 2003 and 2006.28  
Specialist teams have been developed in some areas to work more closely with 
primary care, to provide services to people experiencing acute mental health crises, to 
“assertively outreach” to people with the most severe mental illnesses like 
schizophrenia, and to provide early intervention for people experiencing the onset of 
psychotic illness.  
Most services “tier” their delivery of psychological therapies according to the general 
model set out in more detail in section 3.2.3. At the lowest tier, services are accessible 
to the public without a referral. For example, this level would include information 
26 Introduction 
 
leaflets available through GP surgeries and other health and social care locations, 
“bibliotherapy” reading schemes available through libraries or GPs, large-scale open-
access “psycho-educational” groups, and access to online therapeutic resources. 
A range of “low intensity” interventions are available in some areas at a primary care 
level by GP referral, including (for example) counselling, solution-focused problem 
solving, supported self help and structured anxiety management groups. These 
interventions are intended to support people with mild mental health problems, and 
typically take place over two to six sessions. Such services are often provided by 
secondary care practitioners working in “Primary Care Mental Health Teams”. Policy in 
the NHS in England has supported the development of specialist primary care mental 
health workers since 2000.29   
More intensive forms of treatment are usually based in secondary care, and involve 
the provision of psychiatric input and a range of psychological therapies, including 
cognitive behavioural therapy (CBT), interpersonal therapy and psychodynamic 
psychotherapy. This kind of care requires specialist input, and typically occupies six to 
sixteen sessions for “protocol-based” therapies like cognitive behavioural therapy and 
interpersonal therapy. Psychodynamic psychotherapy is often of far longer duration 
and is accessed by a relatively small number of people, in part because such 
treatments are resource-intensive.  
Specialist interventions may also be accessed through secondary care and have been 
developed to treat specific problems (e.g. eating and personality disorders, substance 
misuse) or to support individuals with very complex or treatment-resistant 
problems.30 
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A critical issue in the provision of psychological therapies at all levels of skill or 
intensity is the requirement for staff to be adequately trained, accredited and 
supervised in their practice. At the higher tiers of care, staff typically require specialist 
training and accreditation. At more basic levels of intervention, practitioners may 
need only minimal training, though usually still require some supervision.  
Voluntary sector organisations provide a range of support and treatment services for 
people with mental health problems. Many of these functions are directly 
commissioned and funded by the NHS, local authorities or Community Health 
Partnerships. For example, Renfrewshire Community Health Partnership funds the 
voluntary organisation Renfrewshire Association for Mental Health to provide a 
telephone-based crisis counselling service called “FIRST Crisis” and to deliver 
counselling services to local GP practices.   
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1.3 Policy context 
 The Scottish Government has responsibility for running the NHS in Scotland (the 
equivalent functions were carried out by the Scottish Office until 2000, and by the 
Scottish Executive until 2007).  
In 1997, a “Framework for Mental Health Services in Scotland”31 was published by the 
Scottish Office Health Department. The document described  detailed “service 
profiles” that sought to promote better coordination between health and social 
services in the planning, commissioning and provision of integrated mental health 
services. Building on this work, “Towards a Healthier Scotland - A White Paper on 
Health”32 proposed that mental health be a “a leading priority for the NHS in 
Scotland”.  
“Our National Health: a plan for action, a plan for change”33 included mental health as 
one of three clinical priorities in 2000.  It also made a commitment to a national anti-
stigma campaign, the promotion of mental wellbeing and a national framework to 
reduce suicides in Scotland.  
The Centre for Change and Innovation was established in November 2002 in the then 
Scottish Executive Health Department, in order to spread good practice and to 
increase the capacity of the NHS in Scotland for sustainable service improvement. In 
addition to  its depression care initiative (as part of the “Doing Well by People with 
Depression” programme), the Centre for Change and Innovation supported national 
improvement programmes for Outpatients, Primary Care, Cancer Services, 
Unscheduled Care, Eye Care and Diagnostics. The Centre sought to bring about 
improvement with the dissemination of quality improvement learning materials, 
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examples of national and international good practice in clinical and service redesign, 
and the encouragement of flexible and innovative ways of working.  
“Improving Health in Scotland: the Challenge”34 focussed on the public health 
dimension to mental and other health problems, and committed the Scottish 
Executive to establish four actions to promote public mental health. These included 
the establishment of a “National Programme for Improving Mental Health and Well-
being”, and ongoing support for programmes to reduce stigma and suicide between 
2003 and 2006. 
The Mental Health (Care and Treatment)(Scotland) Act 200335 came into effect in 
October 2005. The legislation was founded on a set of principles, including the 
importance of patient participation, non-discrimination and informed choice in 
treatment. Although most relevant to people with severe mental illness, the 2003 Act 
also emphasised the need for local authorities to provide “services which are designed 
to promote the well-being and social development” of people who have or have had a 
mental disorder. This provision includes services for people with depression. 
In 2005, “Delivering for Health”36 made a commitment to “accelerate improvements 
in mental health services”, building on the earlier Framework for Mental Health in 
Scotland. This initiative was followed in 2006 by a national Mental Health Delivery 
Plan called “Delivering for Mental Health”.37 The plan included three targets and 14 
commitments aimed at improving a range of services provided by the NHS and its 
partners. The plan committed Quality Improvement Scotland to preparing integrated 
care pathways for depression and four other conditions (schizophrenia, bipolar 
disorder, borderline personality disorder and dementia).  
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The Quality and Outcomes Framework is a system of paying practices for providing 
specified levels of quality that are measured using detailed, evidence-based indicators. 
In 2006, the framework was amended to include depression as a clinical indicator for 
the first time. Indicator DEP2 measures the “percentage of patients who have had an 
assessment of the severity [of depression] at the outset of treatment”.38  
The high prevalence of depression, the clinical burden of depressive symptoms, and 
the economic cost to the NHS and wider society were part of the rationale for 
introducing a quality measure related to depression treatment.38 The Quality and 
Outcomes Framework references the British Association for Psychopharmacology 
guidance about not prescribing for mild depression,39 and cites Kendrick40 in support 
of the use of an objective measure of depression severity to guide antidepressant and 
other treatment choices.  
In summary, the system of health care in Scotland is characterised by universality, 
democratic oversight, professional responsibility and a commitment to quality, to 
integration and to health promotion. Although financial incentives have been used to 
influence GP behaviour, overt commercial activity in the NHS is minimal, and perverse 
financial incentives are slight. However there may be a lack of coordination between 
primary and secondary care, who are “separated by budget, by organisation, by 
culture, by incentives and by disincentives”.23  
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1.4 Doing Well 
The “Centre for Change and Innovation” in the Scottish Executive Health Department 
established the “Doing Well by People with Depression” initiative in 2004 in response 
to strategic concerns about the rising use of antidepressant drugs, and a perceived 
need to ensure that an appropriate range of treatment strategies were available to 
people with depression. In May 2002, the Project Manager for the Improving Mental 
Health Information Project for the Information and Statistics Division presented data 
showing that the Scotland prescribed 20% more antidepressants per head than 
England, and at 40% greater cost.41 
In a joint letter to Health Boards in May 2003, June Andrews (Head of the Centre for 
Change and Innovation) and David Bolger (Head of the Mental Health Division in the 
Health Department of the Scottish Executive) outlined why the Health Department 
had chosen to “redesign services for people with depression”.42 
“Depression is common, costly and treatable, but in Scotland timely and local 
access to the full range of interventions and supports is not universal, even 
where there is good evidence of effectiveness. The issue is not just one of 
resources, but also the way we manage, communicate and share 
information.” 
The letter went on to describe a “Programme Proposal” which took “a whole systems 
approach to develop capacity” and sought to make best use of resources by the 
following actions: 
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 “Building increased capacity for self-help in order to meet the needs of those 
with mild depressive disorders and to provide support through the pathway of 
care. 
 Building increased capacity for psychological interventions in primary care 
thereby offering the potential to reduce some of the current pressures on 
secondary services. 
 Improving assessment of depressive symptoms and associated problems to 
ensure an agreed understanding of user need with users and carers, together 
with the sequence of treatments and supports that would be effective, 
including all of a user’s needs and for people with particular needs. 
 Improving access to a range of services and supports within local communities 
by the creation and active management of networked pathways of care.”  
These actions were intended to achieve the following benefits: “Improved wellbeing; 
improved access and waiting times; more efficient use of resources; improved 
integration of services across existing boundaries”. 
Local development projects were initially selected from seven NHS board areas (Argyll 
and Clyde, Dumfries and Galloway, Borders, Greater Glasgow, Ayrshire and Arran, 
Grampian and Lanarkshire). These projects examined approaches to learning and self 
help, access to psychological interventions, the assessment of depressive symptoms 
and associated problems and the development of pathways through services and 
supports.   
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A national evaluation team was established to monitor the outcomes of the 
programme and included input from the Universities of Glasgow and Edinburgh and 
the Scottish Development Centre for Mental Health. 
The programme described in this thesis was the project that was established in the 
NHS Argyll & Clyde area as part of the “Doing Well by People with Depression” 
initiative. The Renfrewshire project – which became known as the "Doing Well” 
programme – was set up to use the best available evidence to implement a major 
reform of service delivery systems and clinical practice. These changes were intended 
to: 
 provide cost-effective, evidence-based care of good quality for people with 
depression at all levels of severity who present to their GP 
 support psychological approaches to treatment, while rationalising 
antidepressant drug use 
 provide adequate clinical capacity to cope with the high need and demand for 
depression care in the catchment population 
A significant redesign was required to provide the new service. The following changes 
were particularly significant: 
 there was no “severity threshold” for referral to the new service 
 a paperless referral and record-keeping system was introduced, networked 
between primary and secondary care 
 all patients were seen in their local GP surgery, with clinicians trained, 
managed and supervised by secondary care 
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 depression severity was assessed at every contact using a standard depression 
measure; this measure was used to guide the type and intensity of treatment 
 the introduction of some form of psychological intervention for all 
participants, including guided self-help 
 an emphasis on brief interventions, with transfer to secondary care where 
more intensive or prolonged treatments were required 
 careful attention to the wellbeing and professional development of "Doing 
Well" staff 
These service changes are described in more detail in Chapter Four (“Methods”) and 
more details of the rationale for introducing them are provided in the Literature 
Review in Chapter Three. 
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2. Aims 
 
The aim of the work reported in this thesis was to conduct a limited evaluation of the 
Doing Well initiative for people with depression presenting to their general 
practitioner in Renfrewshire between July 2004 and October 2006. The overall 
hypothesis was that the implementation of Doing Well would lead to changes in 
prescribing practice and in other aspects of care.  
This thesis therefore has the following objectives: 
 To evaluate the capacity of the redesigned “service delivery system” to meet 
the needs of people with depression in a defined catchment population.  
 To evaluate clinical outcomes associated with Doing Well. The main clinical 
outcome measure was changes in score on the Personal Health Questionnaire 
(PHQ), a self-complete measure of depression.   
 To evaluate prescribing change associated with the programme. This included 
analysis of changes in the number (Defined Daily Doses), cost (Gross 
Ingredient Cost) and type (proportion of prescribing in keeping with local 
formulary recommendations) of antidepressants prescribed. Evaluation 
included comparisons over time as well as with local and national 
comparators.   
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3. Literature Review 
 
3.1 Introduction  
Section 3.2 examines the assumptions and definitions that underpin the organisation 
of depression care. Although these conceptual issues may not play a noticeable part in 
the day-to-day decisions made by clinicians and managers, they nonetheless set the 
context for routine practice, and will have a significant influence on the care that 
patients receive. To avoid duplication, this literature review includes material that 
influenced the development and implementation of Doing Well during the years 
reported in this study (2004-6). More recent work has been included in the discussion.  
Sections 3.2.1 (What is depression?) to 3.2.3 (How do services organise their response 
to depression?) set out some of the issues that arise when seeking to define 
depression. These include the natural history of depression, the health service 
response to it, and the consequences of a diagnosis of depression for patients.  
The chapter goes on to discuss the use of antidepressants (section 3.3), psychological 
therapies (section 3.4) and self-management (section 3.5) as components of the care 
for depression that is provided in the NHS.  
Section 3.6 (Depression: management in practice) steps back from everyday clinical 
practice to consider how service improvement might be able to tackle some of the 
problems in care delivery identified in Section 3.6.2 (Problems in current service 
provision). This is an important section, since it informs not only how we should seek 
to understand the question “did Doing Well improve clinical care?”, but also to shed 
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some light on the organisational mechanisms which may underlie the effective 
implementation of change in health systems.  
Some “generic” service improvement techniques are reviewed, before considering in 
Section 3.7.2 (Models of service redesign in depression) how these have been 
packaged together in mental health care to provide complex interventions for 
depression. This section will particularly focus on the need to acknowledge and 
respond to the “complexity” that characterises health systems. Some models of 
service redesign are described, before a summary of trials of that have evaluated 
different models of enhanced care for depression.  
  
38 Literature Review 
 
3.2 Depression: concepts and definitions  
3.2.1 What is depression? 
“Depressive” symptoms have been described with striking consistency for 2,500 
years.43 Since the first medical texts in ancient Greece, depression has been 
recognised as a syndrome characterised by low mood (including lack of pleasure, 
despair, anxiety, and suicidal thinking) and accompanied by bodily and behaviour 
changes (such as disturbance in appetite, sleep, self-care and social activity). Although 
successive generations of clinicians and scholars have struggled to define the 
boundaries of this condition, there has been near-unanimity in the recognition of two 
broad categories: “normal sadness” and “sadness without cause”.43 
This conceptual dichotomy was evident through much of the 20th Century, finding 
expression in distinctions between “endogenous and reactive” depression, “primary 
and secondary” depression or “depressive disease” and “depression spectrum 
disease”.44 
Until the mid-twentieth century, “anxiety” and “neurosis” were commonly described 
traits, but “depression” was diagnosed for only a tiny percentage of the population.45 
When antidepressants were first developed in the 1950s, initial estimates suggested 
that no more than 50 to 100 people per million suffered from the kind of depression 
that these new drugs would treat. These estimates wildly underestimated the growth 
in antidepressant use, which still continues to increase.  
What has caused this expansion in pharmacological treatment for depression? It may 
be that doctors are now better able to recognise and treat a valid clinical syndrome 
that has tended to be neglected in the past. Alternatively, we may have 
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inappropriately redrawn the boundaries of illness so that the clinical syndrome of 
“depression” has come to include the normal experience of sadness, worry and other 
forms of human distress.  
Some allege that doctors and the pharmaceutical industry created a “new” disease of 
depression to benefit from new drug treatments;46 or that a secular, fragmented and 
commercialised society has unrealistic expectations of happiness;47 or that 
antidepressants and other psychotropic drugs are used to make intolerable social 
conditions bearable. 
This thesis does not seek to answer such political and philosophical questions. 
Nonetheless, there is a consensus in the scientific literature (discussed later in this 
section) that our current diagnostic classification of mood disorder is unsatisfactory. 
Uncertainty about the boundaries of depression necessarily raises questions about the 
identification of appropriate forms of treatment, both psychological and 
pharmacological. This uncertainty and unease about our understanding of depression 
is shared by the general public, especially the large subset of the population who 
develop low mood each year.  
The Doing Well patients who were the subjects of this thesis sought help to 
understand why they had become distressed, because they had to decide how to 
respond to these problems. Should they take medicine, pursue a course of therapy, 
both of these options, or none at all? This section briefly outlines the changing context 
in which those decisions might be framed. 
A critical change in our conceptualisation of depression took place during the 
development of psychiatric classification systems from the mid-1970s. The current 
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versions of the International Classification of Diseases (ICD-10)48 and the Diagnostic 
and Statistical Manual (DSM IV)49 are based on a syndrome termed “depressive 
episode” in ICD-10 and “major depressive episode” in DSM IV. These syndromes are 
defined by a set of “depressive symptoms”, and a requirement that these should have 
been present for more than two weeks. Depression is further categorised in relation 
to mild, moderate and severe grades of illness, and between single and recurrent 
episodes. Both systems also identify a “somatic syndrome” (ICD-10), or depression 
“with melancholic features” (DSM IV) that is perhaps closest to older concepts of 
“endogenous” depression or “melancholia”.  
Crucially, contemporary classifications make a diagnosis on the basis of symptoms 
only, without reference to underlying theories of causation. There is, however, one 
important exception. Both ICD and DSM exempt a diagnosis of depression where, 
according to DSM, “the symptoms are not better accounted for by bereavement”. 
Horwitz and Wakefield point out43 that bereavement is a form of “sadness with 
cause”, and therefore that its exemption from a diagnosis of illness represents a tacit 
acknowledgement that “normal sadness” might otherwise be confused with a medical 
disorder. Should bereavement be the only form of loss to be so recognised, or should 
other life events (like unemployment, divorce or migration) not also be reasons to 
exclude the diagnosis of depression? 
Freud argued that melancholia might occur as the result of the death of a loved 
person, but could also be a response to the loss of an “an object of love”, even when 
“one cannot see clearly what has been lost”.50 Psychoanalysts in this tradition consider 
that the powerful emotions associated with depression and anxiety are, in fact, 
responses to loss. Rather than focus on specific symptoms, a psychoanalytic 
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perspective pays heed to (for example) dependence and neediness in relationships; to 
the re-enactment of earlier developmental difficulties; and to “identification” with the 
lost person and a range of other defence mechanisms.51 
Nonetheless, the decision to base psychiatric diagnoses solely on symptoms rather 
than presumed aetiology has sound practical and theoretical justifications. These were 
reinforced when an influential paper examining depression in primary care in the UK 
suggested that the distinction between “endogenous” and “reactive” depression was 
not relevant to drug treatment decisions.52  
Profound consequences have arisen from the use of a “symptom-based” classification 
that largely disregards context, and so does not distinguish between the symptoms of 
illness and the human expression of “normal” distress. It seems likely that this 
ontological blind spot has caused the  “boundaries of what constitutes depression 
being expanded relentlessly outward”.53 Sadness “with cause” is a common 
phenomenon, so such “diagnostic inflation”43 has ramifications beyond academia or 
the clinic.  
Clear evidence has emerged of the importance of social factors in the development of 
low mood. Depression is influenced by poverty,22,54,55 unemployment,54,56 separation, 
divorce,57 58and stressful life events, especially where these are perceived as 
threatening or humiliating.59-61 A large, prospective study of an Australian cohort with 
depression found a high prevalence of associated problems: 40% of subjects with 
depression reported childhood sexual abuse, 57% reported childhood physical abuse, 
42% had at some time been afraid of their partner, and 72% reported a chronic 
physical condition.62 Conversely, depressive symptoms remit when there is a fresh 
start or adjustment to the loss,58,63,64 especially for people with good social support.65 
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This critique was perhaps anticipated by the authors of ICD-10, in their tentative 
comments on the limitations of the classification: 
 “affective disorders are not yet sufficiently understood to allow their 
classification in a way that is likely to meet with universal approval… the 
classification presented here is put forward in the hope that it will at least be 
acceptable, since it was the result of widespread consultation”.  
The National Institute of Clinical Excellence guideline on depression summarises the 
difficulty as follows: 
 “the most significant limitation is with the concept of depression itself. The 
view of the Guideline Development Group is that it is too broad and 
heterogeneous a category, and has limited validity as a basis for effective 
treatment plans. A focus on symptoms alone is not sufficient because a wide 
range of biological, psychological and social factors have a significant impact 
on response to treatment and are not captured by the current diagnostic 
systems.”26 
 R Philip Snaith, one of the authors of the Hospital Anxiety and Depression Scale,66 
described with a more flamboyant scepticism the range of emotional states that a 
diagnosis of depression is supposed to encompass: "here are the states of grief at loss, 
frustration of failed aspiration, the gloom of despair, the accidie of disillusion, the 
demoralisation  of the long suffering and the cynical outlook of the pessimist".67 
If depression is “an over-inclusive term with a lack of conceptual clarity between 
symptom, syndrome, episode and illness”43, how could it be improved? Although 
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symptom-counting may be insufficient to distinguish an illness called “depression” 
from other forms of human distress, it is nonetheless necessary. Symptoms remain at 
the core of the psychiatric understanding of low mood: since they describe the 
patient’s current experience, they cannot be removed from a diagnostic assessment. 
However they may make more sense if complemented by consideration of the 
temporal and contextual relationship to loss events.  
Horowitz & Wakefield propose three characteristics of “normal” loss responses: they 
emerge after specific environmental triggers, they are proportionate in intensity to 
the loss, and they end either as the loss situation ends, or as natural coping 
mechanisms allow the individual to readjust to their new situation.43 
ICD-10 and DSMIV do recognise time course and context in relation to emotional 
distress, but relate them to “adjustment disorder” rather than “depression”. 
“Adjustment disorder” is defined in DSM as “the development of emotional or 
behavioural symptoms in response to an identifiable stressor occurring within three 
months of the onset of the stressor”. This causes “marked distress that is in excess of 
what would be expected from exposure to the stressor or significant impairment in 
social or occupational functioning”. 
Casey at al argue that adjustment disorder would be a better description for much of 
the low mood that presents to primary care.68 This diagnosis implicitly acknowledges 
the situational context for much distress, and that it tends to remit spontaneously. But 
both ICD-10 and DSM-IV state that this condition should only be made if criteria for 
other conditions are not met, meaning that in practice it will be subordinate to other 
diagnoses. There is a risk that this convention over-estimates the prevalence of 
depression at the expense of adjustment disorder. 
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The tension between a reductionist symptom-count and a more holistic appraisal of 
distress in a personal and social context will be returned to in the discussion. Doing 
Well sought to deal with the lack of conceptual clarity between symptom, syndrome, 
episode and illness in ways that are described in section 4.4, on page 133. Doing Well 
accepted referrals for depression, low mood and adjustment disorder, and responded 
to each with a careful case formulation and a pragmatic care plan. This will be 
discussed more fully later in this thesis.  
 
3.2.2 What happens to people who become depressed? 
Psychiatrists working in secondary care settings have long recognised that the 
depressive illnesses they see are often chronic conditions with a poor prognosis. 
Kraepelin speculated that left untreated, major depressive episodes would tend to last 
about 6 to 8 months in  most cases.69 Recent studies show that 12% to 40% of 
depressed inpatients never recover from their illness. Of those who do recover, 60%–
90% subsequently relapse over the next 5–10 years, and only 25% of patients never 
experience a recurrence.70,71  
By contrast, Posternak72 found relatively high rates of remission in a cohort of 130 
secondary care patients who had previously experienced one depressive episode and 
subsequently relapsed. Forty-six subjects went on to take drug treatment (with a 
median time to treatment of 62 weeks). Both groups were followed up six-monthly for 
five years and annually thereafter. The endpoint was considered to be remission from 
symptoms, the onset of antidepressant treatment, or the close of the study after 15 
years of follow-up. By three months, 38% of the drug-treated and 52% of the 
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untreated cohort had recovered. The recovery rate decreased rapidly after three 
months, though still stood at 67% at 6 months for the untreated group. It seems that 
non-treatment seeking individuals had a better prognosis than those who did seek 
treatment.  
Nonetheless, there is a consensus that people treated in secondary care often 
experience depression as a chronic disorder. Studies of the long-term outcome of 
depression in the community and primary care can be difficult to compare, but the 
natural history of depression in community samples is probably more benign: for this 
group,  depression is more typically a disorder that remits,73 with overall recurrence 
rates typically between 30% and 40%. The relationship between treatment and long-
term outcome remains unclear.71 
The findings of community-based studies relevant to the Doing Well programme are 
summarised below.   
Using a community survey, McLeod et al identified a sample of 119 married men and 
women with major depression according to the Diagnostic Interview Schedule.74 Forty 
percent of episodes recovered in less than 5 weeks, and 90% by one year.  
In an epidemiological study of 235 women meeting full DSM III-R criteria for major 
depression, Kendler75 found that for women whose depression began in the previous 
year, the median time to recovery was 42 days. One quarter and three quarters of the 
sample had recovered by 21 and 90 days respectively; 98% had recovered within a 
year. Seven percent of patients in the sample had experienced depression for more 
than a year prior to inclusion; including them in the analysis lengthened the time to 
recovery for the whole group from a median of 42 to 56 days, and more than tripled 
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the proportion unrecovered by the end of the year. The study did not collect 
information on treatment received. 
The Epidemiologic Catchment Area Program in Baltimore, USA followed up a 1981 
baseline cohort of 3,481 respondents with a second assessment 12-15 years later. The 
25th, 50th, and 75th percentiles for the duration of 71 first episodes were 4, 12, and 
30 weeks respectively. The duration of an episode, and time to an episode-free year, 
was longer in the first episode than in recurrent episodes.76 
A longitudinal cohort study of patients with depressive symptoms from 
30 metropolitan and rural general practices in Victoria, Australia, found that 22% of 
the cohort who satisfied criteria for “probable depression” at screening no longer did 
so around 2 weeks later.62 
A prospective psychiatric epidemiological survey in the Dutch adult general population 
found a median duration of major depression of three months, with 50% of patients 
recovered within three months, 76% within twelve months and 80% at 24 months.77   
In summary, most studies of depression have been conducted on patients recruited 
through secondary care, who tend to have low rates of remission and high rates of 
relapse. By contrast, epidemiological and community-based studies show relatively 
high rates of remission, including spontaneous remission without treatment.  Both the 
“secondary care” and the “community” cohorts were diagnosed as having depression 
using valid assessment tools, yet the prognosis for the two groups is markedly 
different.  
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This presents a problem for clinicians and service planners. One group (in secondary 
care) require intensive and sustained treatment to optimise remission and minimise 
the risk of relapse: while the other may do relatively well with no treatment at all. The 
effective design and delivery of an appropriate service would depend critically upon 
the ability to discriminate between these two groups. The following section reviews 
how services respond to people with depression in the British National Health Service. 
 
3.2.3 How do services organise their response to depression? 
Conventional descriptions of access to healthcare in the UK typically relate to the 
“tiered model” of care proposed by Goldberg and Huxley 78 (Figure 3-1). This model 
describes 5 “levels” of help-seeking, from relatively widespread psychological 
morbidity in the general population through to the small numbers of people who 
receive psychiatric inpatient care. These levels of care are mediated by 3 filters: of 
help-seeking by the patient, of recognition in primary care and referral to secondary 
care. 
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Level Type of care 
Level 5 Psychiatric inpatients 
Filter 4 Admission to psychiatric beds 
Level 4  Psychiatric patients 
Filter 3 Referral 
Level 3 Conspicuous psychiatric morbidity/ primary care 
visitors 
Filter 2 recognition 
Level 2 psychiatric morbidity/ primary care visitors 
Filter 1 Help-seeking 
Level 1 Psychiatric morbidity/population 
 
Figure 3-1: the tiered model of care 
 
If we accept that different forms of depression have different outcomes and may 
require different types of care, then the organisation of these “tiers” becomes crucial 
for effective service delivery.  Two aspects are especially important. Firstly, the type of 
care should be appropriate to the level of severity or complexity of the case. Secondly, 
the decisions taken at the level of the three filters need to be as well-informed and 
rational as possible. In fact, health systems have commonly failed to meet these two 
requirements. Severity and complexity are typically assessed using the subjective 
judgement of the clinician, rather than using formal measurement tools. The 
transition between one tier and another is often prolonged and bureaucratic, since 
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systems are usually constructed around service and professional structures, rather 
than the needs of the patient.  
For example, the 1997 Framework for Mental Health Services in Scotland31 was based 
on a 5-tier model that describes the type of help that people should access for mental 
health problems. It clearly borrows the structure of the Goldberg and Huxley model, 
with lower tiers of care covering more people, but requiring less skill or intensity in 
treatment than the higher tiers (Figure 3-2). The tiers are essentially defined by the 
setting and the input of professionals. Although there is a rough gradient of severity 
from mild to more severe problems, these are only vaguely defined. Tier one is for 
“less severe” problems, but severity is not mentioned in tier zero or tier two. The 
Framework document includes a two-page appendix that seeks to define “severe and 
enduring” mental illness, but it is difficult to distinguish between the “severe and 
enduring” problems associated with tier four, and the “severe, persistent and 
complex” disorders described in tier three. The indications for transition between tiers 
are therefore not well defined.  
  
50 Literature Review 
 
Tier  Description of services 
Tier 4 This tier is for those with severe and enduring mental health problems and 
services including day units and highly-specialised inpatient and outpatient 
care. 
Tier 3 A multi-disciplinary team, working in a community mental health team or 
psychiatry out-patient department. This is a specialised service for people 
with more severe, persistent and complex disorders. The team might include 
psychiatrists, community psychiatric nurses, clinical psychologists, 
occupational therapists and social workers, amongst others. 
Tier 2 At this level support and assessments would come from more specialist 
professionals such as counsellors, primary care mental health workers, and 
psychologists. Services may be based within primary care. Primary care 
mental health workers (who may or may not have a clinical background) are 
a relatively new support service within this tier. 
Tier 1 Help at this level would be provided by GPs, other primary care professionals, 
social workers, and voluntary sector agencies. General advice and treatment 
for less severe problems would be offered at this tier and referrals can be 
made to more specialist services as required. Self-help workers would also 
operate within this tier. 
Tier 0 At this level people would be accessing resources within the community to 
enable them to be able to cope better at home and avoid the need for 
professional or other interventions at Tier 1 
 
Figure 3-2: Tiers of care according to the "Framework for Mental Health Services 
in Scotland” 
 
The National Institute for Clinical Excellence (NICE) described a “stepped care” model 
for depression26, which has a similar hierarchical structure, but which makes more 
explicit reference to the need for assessment of severity. Five “steps” in care are 
proposed (Figure 3-3): step one represents recognition and assessment of depression 
in primary care. Mild depression (step two) and moderate to severe depression (step 
three) are managed by the primary care or primary care mental health team. 
Treatment resistant or complex depression at step four is managed by specialist teams 
in secondary care. Severe self-neglect or risk to life at step five is managed either by 
“intensive home treatment teams” or as an inpatient.  
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Step Who is responsible for 
care? 
What is the focus? What do they do? 
Step 5 Inpatient care, 
intensive home 
treatment teams 
Risk to life, severe self-
neglect 
Medication, combined 
treatment, ECT 
Step 4 Mental health 
specialists, including 
intensive home 
treatment  teams 
Treatment-resistant, 
recurrent, atypical and 
psychotic depression, 
and those at significant 
risk 
Medication, complex 
psychological 
interventions, 
combined treatments 
Step 3 Primary care team, 
primary care mental 
health worker 
Moderate or severe 
depression 
Medication, 
psychological 
interventions, social 
support 
Step 2 Primary care team, 
primary care mental 
health worker 
Mild depression Watchful waiting, 
guided self-help, 
computerised CBT, 
exercise, brief 
psychological 
interventions 
Step 1 GP, practice nurse Recognition Assessment 
 
Figure 3-3: National Institute for Clinical Excellence "stepped care" model for 
depression 
 
This model therefore defines the levels of care in three ways: by the severity of illness, 
the type of treatment and by the teams or clinicians who could deliver those 
treatments. The guidance refers to this as a “stepped care” model: 
“The stepped-care model of depression draws attention to the different needs 
that depressed people have – depending on the characteristics of their 
depression and their personal and social circumstances – and the responses 
that are required from services. It provides a framework in which to organise 
the provision of services supporting both patients and carers, and healthcare 
professionals in identifying and accessing the most effective interventions.”26  
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It goes on to say: 
“Each step introduces additional interventions; the higher steps assume 
interventions in the previous step.” 
This interpretation of the stepped care model differs significantly from the more 
sophisticated interpretation of stepped care described by Bower and Gilbody79: 
“Stepped care is a model of healthcare delivery with two 
fundamental features. First, the recommended treatment within a 
stepped care model should be the least restrictive of those currently available, 
but still likely to provide significant health gain. Second, the stepped care 
model is self-correcting.”  
To “assume interventions in the previous step” contradicts the first feature of the 
Bower & Gilbody model, in that the “least restrictive” intervention likely to work 
should be the first to be tried (and not the most basic, as NICE guidance suggests). 
Secondly, the NICE model does not take account of the critical role played by 
monitoring and feedback as part of the “self-correcting” requirement to determine 
the right level of care. For example, non-response needs to be identified promptly if 
treatments are to be “stepped up”, but the NICE model does not incorporate this 
critical element in its description. 
An alternative to the “tiered” care model can be represented by a more linear model 
of patient “flow”, which uses feedback about progress to influence treatment 
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decisions (Figure 3-4).
 
Figure 3-4: flow in stepped care (adapted from Bower & Gilbody, 2005) 
 
Depression severity will typically vary within any one episode of illness. For example, 
although a patient may present to their GP with mild depression, this may become 
more severe over time, before remitting in response to treatment. That individual 
might therefore benefit from intervention at steps one, two, three and four, rather 
than remaining within one category.  
Defining care according to categories (of illness severity, staff role and therapeutic 
intervention) as the NICE model does is therefore problematic. There are extensive 
areas of overlap between “steps” and the optimal combination of interventions at any 
given level is unknown.80 The kind of “stepped care” model outlined above seeks to 
overcome these limitations by acknowledging the potential for change within a 
patient’s experience of an episode of depression. The use of dynamic models of “flow” 
within healthcare systems influenced the design of the Doing Well service, and will be 
GP: refers to most 
appropriate step
•NB referral influenced 
by depression severity, 
past history, patient 
preference
step 1
eg guided self-help
•assess outcome: 
if improved, discharge; 
if not then step 2
step 2
eg brief CBT plus 
antidepressant
•assess outcome: 
if improved, discharge; 
if not then step 3
step 3
eg long-term therapy, 
2nd-line antidepressants
•assess outcome: 
if improved, discharge; 
if not then continue or 
review
discharge after successful treatment 
increasing treatment intensity 
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discussed in more detail in section 3.7.1, (Components of health service redesign). A 
key component in the successful implementation of such models is to ease the 
transfer between one part of a service and another. This may be particularly 
challenging when organising care delivery between primary and secondary care 
services.  
 “Collaborative” care aims to support these transitions, “with active collaboration 
from primary and secondary care in devising a common pathway or ‘ladder’ they can 
each welcome and work with easily.”81 
 
3.2.4 Mental health literacy, stigma and public attitudes  
Patients with acute and chronic health problems benefit when they are involved in 
their care, and there is some evidence to suggest that this can lead to better use of 
resources.82 This section considers some of the factors that may act as barriers not 
only to seeking professional help, but also to being able to recognise and understand 
problems with mood when they arise.  
This type of knowledge and skill has been termed “health literacy”: the ability to 
access, understand and use information in ways which promote and maintain good 
health. Although depression is a very common condition, some members of the public 
may not share clinical concepts, or have a limited understanding of it when they do. 
When an Australian sample was asked to identify case vignettes designed to represent 
depression, only 39% correctly identified depression, with a further 22% of 
respondents mentioning stress.83 In a similar exercise conducted in Scotland a decade 
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later, about three-quarters of a representative sample of the population were able to 
correctly identify a “depression” case vignette.84  
Health care professionals are rarely a source of information about mental health 
problems for the general public. Asked which single source of information had been 
most influential in forming their impressions of mental health problems, the majority 
of respondents in a large-scale Scottish survey mentioned either personal contact and 
experience, or television news and current affairs programmes, with only a small 
minority (nine percent) mentioning information from clinicians.84 Nonetheless, when 
asked who would be the most appropriate source of support for someone with 
depression, respondents in the Scottish survey suggested a family doctor (63%), a 
qualified counsellor (43%) or “someone in the family” (53%). Twenty-nine percent of 
respondents thought a psychiatrist was the most appropriate source of support.  
Poor information and a lack of a shared understanding about depression may not 
prevent help-seeking, so much as redirect it to less conventional sources of help. 
About one half of the population of European countries have consulted 
“complementary” or “alternative” medical practitioners (seeking remedies such as 
homeopathy, Chinese medicines, and reflexology), and many of these people seek 
help with depression, stress, insomnia and anxiety. In 2005, there were 47,000 
complementary and alternative practitioners in the UK, compared with 35,000 GPs.85   
Evidence suggests that interventions designed to mitigate the effects of low health 
literacy in general health settings (such as providing information leaflets or patient-
focussed websites) can improve knowledge and health behaviour, but work best when 
used to complement or augment communication with clinicians.82  
56 Literature Review 
 
Critics of psychiatric attempts to reduce stigma or “educate” the public have pointed 
out that the “medical model” of mental illness is not only unproven but contested; 
furthermore that “the prospect of psychiatrists successfully simply offering ‘the facts’, 
relies on audiences who will trust them.86 An historically fraught relationship between 
psychiatry and the public means that this trust may not be present.87 
However the evaluation of a large-scale, multifaceted Australian campaign 
(“beyondblue”) to improve understanding of depression suggests that people living in 
the States and Territories that received the programme were more likely to recognise 
symptoms, to seek help and to accept treatment for depression than people in areas 
who were not exposed to the campaign.88 
The problem is not merely a lack of knowledge, but also a question of attitudes. 
Depression is less stigmatised than other conditions, but a significant minority of 
respondents in UK surveys nonetheless agree with discriminatory or inaccurate 
statements about people with depression.89 For example, a common myth in relation 
to depression is that it “results from a personality weakness or character flaw, and 
people who are depressed could just snap out of it if they tried hard enough”.90 
Members of the public may therefore not share professional concepts of what 
constitutes a mild to moderate psychiatric problem. Many people do not regard the 
experience of psychosocial distress associated with a range of conditions as an 
appropriate topic for medical consultation or scrutiny.91 
In order to seek help, therefore, someone with depression needs to be able to 
recognise and understand their problems, while resisting stigmatising pressures which 
militate against disclosure. There is a final step that must be negotiated. Since clinical 
interactions are governed by social etiquette, consultations can be difficult 
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encounters for patients. A reluctance to divulge personal information may be an effort 
to protect their privacy and personal integrity,92 and therefore act as a final barrier to 
accessing appropriate care. (The interaction between patient and doctor during 
consultations about depression is discussed further in section 3.6.1.)  
Negotiation through the “tiers” of care is therefore determined not simply by the 
service response to a “case” of low mood, but instead reflects a more complex 
relationship between the concerns, information and expectations of the individual in a 
dynamic interaction with staff working in the health system.  
To be effective, services therefore need to take account of the concerns and 
expectations held not only by individuals, but also by the social context in which they 
live and work. The diversity of perspectives about low mood and emotional distress 
mean this is a particular challenge for depression care.   
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3.3 Antidepressants 
3.3.1 The rise in antidepressant use 
 Marked increases in antidepressant use have been reported in many Western 
countries since the early 1990s. Rises in antidepressant use have been reported in  
Scotland,17 England,93 France,94 Germany,94  Italy,95 Holland,96 Scandinavia,97 Iceland,98, 
Canada,15,99 the United States 14 and Australia.100  
It is difficult to draw clear conclusions from international comparisons, since the 
situation in each country can be quite distinct. For example, in  2002 more than twice 
as many Defined Daily Doses (DDDs) of antidepressants per 1,000 inhabitants were 
consumed in the United Kingdom and France than in  Germany.94 There are several 
reasons why antidepressant drug use should be lower amongst German people. The 
prevalence of depression is recognised to be lower (4% in Germany, compared with 
9% in France and 10% in the UK). But there is also a high level of herbal antidepressant 
use in Germany,94 and people in that country have relatively easy access to 
psychological therapies.101 Concerns about adverse effects of SSRIs (suicidality and 
haemorrhage) by the German regulatory authorities seem to have slowed the uptake 
of these drugs until recently.94 By contrast, most of the rise in antidepressant drugs in 
the UK,94 the USA,102 Nordic countries97 and Iceland98 relates to an increase in the use 
of SSRI drugs.  
In Canada, antidepressant prescriptions rose 238% between 1981 and 2000,15 a rise 
which may have been largely accounted for by a rise in the prevalence (but not 
incidence) of depression.99 In the USA, consultations for depression rose by 70% 
between 1987 and 2001 (representing a relative increase in the number of primary 
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care rather than psychiatry visits), and over the same period the total antidepressants 
prescribed increased by 116%.102 Antidepressant use increased in Iceland by as much 
as 8.6 times between 1975 and 2000 and 3.9 times between 1989 and 2000. This 
increase was associated with modest rises (2% per annum) in outpatient service use 
for depressive disorders.98 
The number of prescriptions for antidepressants almost trebled in Scotland over the 
decade to March 2003,103 yet there was no association between this rise and the 
incidence or prevalence of depression, consultation rates for depression or levels of 
psychological morbidity (as measured by the GHQ12) in Scotland between 1995 and 
2001.17,104  
Variation in prescribing rates is recognised in other areas of medicine. For example, in 
a comparison of 500 GP practices in England, some prescribed as much as 50 times 
more cholesterol reducing drugs than others,105 even though the use of such drugs 
does not involve the kind of socio-cultural or diagnostic complexities influencing 
practice in depression care.  
Antidepressant prescribing varied up to 25-fold in one study in East London.106 Some 
of this variation will relate to differences in the prevalence of depression in different 
areas, and some will relate to the use of “antidepressant” drugs for indications other 
than depression. Nonetheless, these factors alone do not adequately explain the 
entire rise in antidepressant prescriptions.  
In a large Scottish study of 983 practices by our group, Morrison et al.21 found a 4.6-
fold difference between the first and ninth deciles of antidepressant prescribing, 
standardised for registered patients’ age and sex composition. A multivariate model 
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was used to examine factors associated with prescribing. The age–sex standardised 
rate of limiting long-term illness, practice location in an urban area, and the 
proportion of female GPs were positively associated with prescribing levels of 
antidepressants. A higher proportion of patients from minority ethnic groups in the 
practice, single-handed practices, higher practice list size, practice location in very 
remote areas, higher GP age, and a higher proportion of GPs born outside the UK 
were associated with lower antidepressant prescribing levels. These nine factors 
accounted for half of the observed variation in prescribing rates. No association was 
found between markers of quality care and antidepressant prescribing. In this study, 
limiting long-term illness was the most influential factor on variation in antidepressant 
prescribing levels, and represented a proxy indicator of deprivation. 
Significant associations between raised prescribing levels, socio-economic deprivation 
and limiting long-term illness has been noted for all prescribed drugs107 and also for 
antidepressants.108 A study of 3,044 National Health Service (NHS) patients attending 
26 general practitioners in the West of Scotland examined the interactions between 
deprivation, morbidity, access and consultation behaviour in primary care.109 The 
authors found a close association between low socioeconomic status, 
“multimorbidity” (the number of long-term conditions) and psychological distress. 
Patients in deprived areas consulted more often for psychological and social problems 
compared with patients from affluent areas. Consultations for psychosocial problems 
with patients from deprived areas were more likely to be longer, to be associated with 
lower patient enablement, and to be more stressful for GPs. 
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Nobody can say with certainty what the “right” level of antidepressant use for any 
given population might be. However the following factors could be expected to have 
an influence on prescribing rates in any given population:  
 The incidence and prevalence of depression  
 The concepts of depression and psychosocial distress understood by patients  
 The proportion of people with depression seeking professional help 
 The concepts of depression and psychosocial distress understood by 
prescribers  
 How clinicians recognise and respond to depression in the consultation 
 The proportion of people with a diagnosis of depression offered drug 
treatment 
 The dose of antidepressants prescribed 
 Acceptance of antidepressant treatment by patients, and concordance with 
that drug treatment 
 The duration of drug treatment 
 The proportion of antidepressant drugs used for non-depression indications 
(such as anxiety, obsessive-compulsive disorder, insomnia, chronic pain, 
eneuresis etc.) 
 The availability of non-pharmacological methods of treatment 
 The attitude of the GP towards the effectiveness of antidepressants 
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A recent UK study of 189,851 patients in the UK who experienced their first episode of 
depression between 1993 and 2005 has shed some light on this issue. The study 
examined the GP research database, which contains linked anonymised records of 
over 3 million patients registered in the UK. The majority of antidepressant 
prescriptions were given as long term treatment or to patients with multiple episodes 
of depression. Small increases both in the proportion of patients in these groups and in 
the duration of prescriptions made to such individuals accounted for a near doubling 
of the total volume of antidepressant prescribing between 1993 and 2005.110  
This is clearly a complex area, and information is limited. Nonetheless, the extent of 
the rise in antidepressant use has not prevented some influential observers from 
drawing broad conclusions relating to the influence of pharmaceutical companies and 
the readiness of the population and their doctors to “medicalise” problems in 
everyday living. The UK Parliament Select Committee on Health reported in 2005111 
that: 
“The belief that every problem may be solved with medication seems 
particularly relevant in the context of antidepressants. While we readily 
accept that antidepressants can be effective medicines and have been 
successfully used by many patients, it is also clear that SSRIs, in particular, 
have been over-prescribed to individuals, often with mild forms of depression, 
who may be distressed by difficult life circumstances. Unhappiness is part of 
the spectrum of human experience, not a medical condition.  
This trend has not been created by the pharmaceutical industry but it has 
been encouraged by it. The industry has acted, in the words of some 
witnesses, as a "disease-monger", with the aim of categorising an increasing 
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number of individuals as 'abnormal' and thereby requiring [drug] treatment. 
This process has led to an unhealthy over-reliance on, and an over-use of, 
medicines. It also diverts resources and priorities from more significant 
diseases and health problems.”  
This Parliamentary Report is quoted here to emphasise that although clinical research 
into prescribing practice suggests a complex issue that is only partly understood, 
politicians may nonetheless come to firm views and express them in strong language. 
As a Government-funded initiative, visited and reviewed by Ministers from the 
Scottish Government, Doing Well was careful to acknowledge with policymakers that 
clinical evidence in this area is often partial or inconclusive.  
 
3.3.2 Pharmacological efficacy of antidepressant drugs  
A full review of antidepressant efficacy is beyond the scope of this literature review. 
Instead, the 2004 NICE good practice guideline on the treatment of depression26 will 
be taken as the baseline. Evidence published after the NICE guideline is then briefly 
reviewed.  
3.3.2.1 NICE guidance 
NICE identified 103 studies relating to the drug treatment of depression published 
between 1983 and 2003, of which 48 were considered to be suitable for inclusion in 
the review (including a total of 7,460 patients). The guidance acknowledged some 
significant limitations to the analysis. The trials included were typically short-term, 
with only 16 trials of eight weeks or longer (range between four and 24 weeks long, 
with a mean of 6.75 weeks). Thirty-one studies were of outpatients, one was located 
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in primary care, three were in inpatient populations and 13 in either mixed or 
unspecified settings. It was possible to determine baseline severity in 19 studies, with 
depression being classified in four studies as moderate, in six as severe and in nine as 
very severe. Meta-analysis indicated the possibility of publication bias.  
NICE concluded that there is strong evidence that antidepressants have greater 
efficacy than placebo on achieving a 50% reduction in depression scores (“response”) 
in both severe and very severe depression. There was some evidence for a similar 
effect in moderate depression. The effect was similar in longer trials. However there 
was insufficient evidence to determine whether there was a clinically significant 
difference between SSRIs and placebo on increasing the likelihood of achieving 
remission. There was evidence to suggest that antidepressants were effective in the 
prevention of relapse in depression.  
The guideline did not recommend the use of antidepressants in mild depression (four 
to six depressive symptoms according to ICD-10) “because the risk–benefit ratio is 
poor”.26  
NICE concluded that all antidepressant drugs were of equivalent efficacy. The 
guidance noted that there was little evidence to support the dosing of tricyclic 
antidepressants above 100mg, nor the use of SSRI drugs above their “licensed dose”.  
3.3.2.2 NICE guidance and clinical practice in relation to antidepressants 
There is evidence to suggest that patients with minor depression and adjustment 
disorder are frequently treated with antidepressant drugs, even though there is little 
or no evidence of pharmacological effectiveness for such conditions.112-114  
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A review of studies examining antidepressant prescribing found that almost all drugs 
in the SSRI class were prescribed at an effective dose, whereas only 15% of tricyclic 
prescriptions  were prescribed at 125mg of more.115 In a Scottish study of 20,195 
patients taking antidepressants, 72% of tricyclic and 8% of SSRI prescribing was at a 
sub-therapeutic dose.116  
Endorsing a prior review by Geddes,117 NICE made a strong recommendation that drug 
treatment should be continued for at least six months after evidence of effectiveness. 
Many patients do not experience a full recovery when treated with antidepressant 
drugs alone: in clinical studies, about one-third of patients achieve a full remission, 
one-third experience a response and one-third are non-responders.119 Partial response 
is therefore a common problem with drug treatment. Psychotherapy may have a role 
to play in improving outcomes for patients.120  
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3.3.2.3 Summary 
Trials of antidepressant treatment are complicated by high rates of placebo response 
and natural remission. Research in this area is particularly affected by publication bias, 
and research trials may have limited applicability to “real world” settings. 
Nonetheless, NICE guidance and other work could be summarised as follows: 
 Antidepressant use for people with moderate to severe disorder was likely to 
be beneficial, though the effect size is small  
 There was no evidence to suggest clinically significant benefit from 
antidepressants in mild depression, though one study in UK primary care has 
detected small but statistically significant treatment effects.121 
 Outcomes were best for patients with no previous history of depression, with 
milder symptoms, and with a shorter duration of illness 
 Full remission of symptoms may correlate with reduced longer-term risk of 
relapse 
 Treatment trials with antidepressants need to be continued beyond six weeks 
to establish full benefit 
 Switching and augmentation strategies may improve clinical outcomes  
 Clinical interventions might benefit from attention to benefits conferred by 
the “placebo” components of treatment. This will relate to all aspects of 
participation in a trial apart from the active drug, and includes the motivation 
to participate, regular monitoring and follow-up, and a structured approach to 
care.  
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 Research subjects are clearly motivated to make choices about treatment, and 
compliance (and possibly outcomes) are better in those who could access 
their preferred forms of treatment. 
 
3.3.3 Effectiveness of antidepressants in routine practice 
The following section outlines the evidence relating to the effectiveness of 
antidepressant drugs in the acute treatment of depression. This topic relates not only 
to the technical “efficacy” of antidepressants as measured in clinical trials, but to the 
more complex concept of “effectiveness” in routine practice. 
Research seeking to establish the response to drug treatments for depression faces a 
number of methodological challenges. As discussed above, depression is difficult to 
define (section 3.2.1), and measuring outcomes in people with low mood may not 
always be straightforward (section 3.4.1). Given the complexities of clinical practice, 
randomised controlled trials may therefore overestimate the “real-world” 
effectiveness of antidepressants.122 Statistically-significant changes in depression 
scores may not represent clinical significance for patients. NICE defined clinical 
significance in relation to the Hamilton Rating Scale for Depression123 as a three-point 
difference in scores. Notwithstanding concerns that the scale itself may be 
“psychometrically and conceptually flawed”,124 this represents a relatively small 
change (6%) in a scale that has a maximum score of 52 points.  
Nonetheless, trials do report “significant” clinical effects of smaller size. For example, 
the Threshhold for Antidepressant response study—while acknowledging the effect 
was small—concluded that “treatment with an SSRI plus supportive care is more 
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effective than supportive care alone for patients with mild to moderate depression”. 
Yet the mean differences in HDRS scores between drug-treated and control groups 
were just 2.3 points at 12 weeks and 1.7 at 26 weeks.121  
Two issues particularly complicate the assessment of trials of antidepressant efficacy: 
the placebo effect and publication bias. 
3.3.3.1 The placebo effect 
The “placebo” effect in antidepressant trials is unusually large compared with that 
observed for other conditions.125 In a review of 19 placebo-controlled trials of 
antidepressants, Kirsch and Sapirstein126 found that three-quarters of the 
improvement shown in the drug-treatment groups was attributable to placebo. The 
influence of “placebo” arises due to the placebo effect proper (the 
sensitivity of patients to the non-drug therapeutic aspects of the trial), but is amplified 
by the natural history of depression. As discussed in section 3.2.2, there is a high 
spontaneous remission rate in the first three to six months of a depressive episode. 
Kirsch and Sapirstein126 estimated that improvements in the drug-treatment group 
could be attributed as follows: 25% to the active drug ingredient, 25% to natural 
improvement over time, and 50% to the placebo effect. Since most spontaneous 
remission occurred within 3 months, some authors suggest that studies should only 
include subjects who had been depressed for at least this period of time.127 
Placebo-controlled antidepressant trials have shown that patients with a shorter 
duration of depressive illness (one to six months) failed to show benefits of drug 
treatment over placebo, whereas those with longer durations did.128 Placebo effects 
above 40% may make smaller studies (under 300 patients per cell) underpowered.129 
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Patients given their preferred treatment in clinical trials are probably more likely to 
comply and to have better overall outcomes;130 patients with a strong preference for 
psychotherapy are unlikely to join or comply with antidepressant trials, which may 
distort their findings.131  
It should be noted that most depression rating scales such as the Hamilton Rating 
Scale for Depression123 contain items—such as sleeping difficulties, anxiety, and 
agitation—that are not specific to depression, and which may respond to nonspecific 
sedative effects associated with many antidepressants.132 Such a non-specific 
“antidepressant” action has been noted in trials of agents as diverse as 
methylphenidate, benzodiazepines, and antipsychotics.133  
A review of 75 placebo-controlled trials for depression conducted between 1981 and 
2000 found that the placebo effect was not only significant, but rising: the proportion 
of patients responding to placebo increased at the rate of approximately 7% per 
decade.134 The reasons for such an increase are unknown, though may have been 
influenced by a trend towards conducting trials in patients with less severe depression 
because of ethical concerns regarding appropriate treatment for very ill or suicidal 
patients.135 Early efficacy trials often use symptomatic volunteers, recruited through 
media advertising. Such subjects are not typical of self-declared patients seen in 
practice settings: they are less likely to have significant medical or psychiatric 
complications, or to have chronic depression.26 Efficacy trials may therefore generalise 
poorly to actual practice.122,136 
A meta-analysis of all the clinical trials submitted to the Federal Drug Administration 
for the licensing of fluoxetine, venlafaxine, nefazodone and paroxetine illustrates how 
these issues may interact in practice.137 The study found that antidepressants were 
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effective only in the most severely depressed patients, and that this was mediated 
principally by a reduction in placebo effect for this group, rather than a specific 
increase in pharmacological effect.  
Although clearly a complicating factor in the design of drug trials, the fact that many 
people recover without active treatment should not be considered a “negative”. In 
fact, the strength of the placebo effect should perhaps guide us towards emphasising 
other aspects of patient care. 
“Perhaps we should actively strive to potentiate the placebo effect when 
treating people with depression. The prescription of drugs alone is not 
enough to get people fully better, whereas drugs, good clinical care, and 
elements of cognitive-behavioural therapy like structured problem-solving and 
pleasant event scheduling, may well be.”125 
There may be potential, therefore, for services to improve outcomes for patients by 
optimising the factors that enhance the “placebo” and non-specific therapeutic 
components of treatment.  
3.3.3.2 Publication bias 
There are indications that antidepressant trials are affected by substantial publication 
bias. A review of 74 antidepressant trials registered with the American Federal Drug 
Administration revealed that 31% of these were not published. The published record 
suggests that 94% of the trials conducted were positive. In fact, only 51% were 
positive when unpublished trials were taken into account.138 It is not known whether 
this publication bias relates to a failure to submit or publish manuscripts with 
“negative” findings, but the potential to distort the research base is clear. Some have 
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advocated that licensing authorities should insist on publication of data from all 
registered trials.139 
 
3.3.4 Influences on antidepressant prescribing 
Once a diagnosis of depression is made, most patients are given a prescription for an 
antidepressant. Eighty-one percent of all patients diagnosed with depression received 
at least one prescription for antidepressants in a large UK study of primary care 
prescribing.110 Seventy-three percent of New Zealand primary care attenders140  and 
94% of Australian primary care patients141  received an antidepressant when they had 
a diagnosis of depression. The proportion of American patients receiving a 
prescription for depression increased from 70% to 89% between 1987 and 2001.102  
The greater the severity of symptoms, the more likely GPs are to “medicalise” low 
mood and treat with antidepressant medicines.140  
Doctors'  perceptions of patients' expectations strongly predict the decision to 
prescribe, yet doctors may be making inappropriate decisions “without checking 
whether their assumptions about patients’ preferences are correct.”142  In one study, 
7% of prescriptions had not been wanted or expected by patients beforehand, and 
doctors recorded that one in five prescriptions they wrote were not strictly 
indicated.143 Patient pressure does have an influence on prescribing, but doctors may 
overestimate “direct pressure” from patients, or even how sure they are about what 
patients want from the consultation.142,144  
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Patients and doctors have moderate differences in the priorities they attach to a 
choice of drug. Although doctors and patients agreed that common side effects were 
the most important factor, patients were more concerned about uncommon side 
effects than doctors, and doctors more concerned about cost than patients.145 Not 
surprisingly, GP attitudes towards the effectiveness of drugs does influence their 
prescribing decisions.146 
There is evidence to suggest substantial public resistance to the use of antidepressant 
drugs to treat low mood. Even after a 5-year campaign run by the Royal College of 
Psychiatrists and Royal College of General Practitioners to “defeat depression”,  only 
24% of the public thought that someone with depression should be offered 
antidepressants, and 74% thought that they were addictive.147 A review of sixteen 
studies of preference for talking treatments or medicines in the treatment of 
depression found unanimously in favour of psychotherapies.131  
Van Schaik and colleagues conclude from their review that when clinicians supported 
patients’ preferences, patients could be encouraged to use the treatment that was 
most suitable for them. In addition, it was found that patients who strongly preferred 
counselling but did not receive it were likely to go without treatment altogether.131  
A service that can offer both psychotherapy and pharmacotherapy is therefore more 
likely to be able to attract people into treatment, and to encourage their concordance 
with that treatment. Careful attention to actual, rather than inferred, patient 
preferences could align clinician and patient perspectives and improve outcomes 
overall.  
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The influence of pharmaceutical marketing on prescribing decisions is difficult to 
measure directly, but evidence suggests that it is likely to be substantial,148 and not 
always in the best interests of the patient or the health system.149,150  
 
3.3.5 Concordance with treatment 
Far fewer people take antidepressants than are prescribed them, and rates of drop-
out from treatment are high.151 Non-compliance rises from about 30% within a month 
of treatment to 50-70% by 3 months of treatment.152,153 Overall perhaps only about 
50% of all prescriptions are taken as prescribed.153  
Drop-out rates in primary care may be higher for tricyclic than SSRI drugs, though any 
effect is less marked in studies in secondary care settings.153,154 A positive attitude 
towards medicines was the most important predictor of adherence in one study, 
which also found that experience of adverse effects, early treatment response, longer 
onset of depression, and a higher educational level predicted better concordance.155  
Mismatch between treatments preferred and treatment actually received acts as a 
significant barrier to sustained adherence. Patient concerns about antidepressant side 
effects and general worry about taking antidepressants were independent predictors 
of antidepressant non-use. 156 
An American study evaluated the effect of a programme designed to improve 
concordance and outcomes for primary care patients who had experienced multiple 
episodes of depression. Provision of two additional primary care visits and three 
telephone calls by a depression specialist improved compliance with antidepressant 
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treatment from 58% to 72% at 3-6 months and 50% to 63% at 12 months follow-up. 
The intervention group had significantly improved depression scores compared to the 
usual care group, but relapse rates were not different.157 
 
Provision of psychotherapy and the selection of an appropriate antidepressant 
medication may reduce the risk of discontinuation during the first 3 months.158 A 
systematic review of 16 studies comparing outcomes and adherence for people taking 
antidepressants alone or in combination with psychotherapy159  found that 
combination treatment was associated with greater improvement. Longer 
psychotherapies were associated with a lower drop-out rate. It was not clear to what 
extent the improved outcomes related to a direct effect of psychotherapy, as opposed 
to a consequence of improved medicines compliance. Provision of combined 
psychotherapy and pharmacotherapy for depression provided lower cost care per 
quality-adjusted life year than both usual care and psychotherapy alone.160 
However some authors assert that there “is an uncritical assumption that improved 
adherence is always a desirable goal, and that the clinical task is to overcome the 
barriers in its way”.161  Qualitative work emphasises that the decision to stop taking 
psychotropic drugs is often not a form of “patient shortcoming” associated with 
forgetfulness or lack of insight, but instead a thoughtful, personal decision. Such 
decisions took into account the “attribution” of depression to a medical problem, and 
weighed up the benefits and disbenefits of medical treatment (especially adverse 
effects). “Stopping and seeing what happens” was a common strategy used by 
patients.161  
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Concerns about dependency and being reliant on a chemical played a key factor in 
people’s assessment of their SSRIs. While individuals felt normal with medicines, they 
also perceived they would only be able to feel completely normal without them. The 
quest for normality and desire to manage their emotional state without the need for 
medication led respondents to want to quit their treatment.161 
 
3.3.6 Measures of antidepressant prescribing  
Technical issues relating to the measurement of antidepressant use will be dealt with 
in some detail in this section, since this has a direct bearing on the reporting and 
interpretation of prescribing information in the Results section. The Defined Daily 
Dose (DDD) of a drug is a theoretical unit of measurement defined by the World 
Health Organisation as the “assumed average maintenance dose per day for a drug 
used for its main indication in adults.”  
The level at which the daily dose is "defined" is a reference unit that may not reflect 
the recommended or typical use of that drug in particular countries or clinical settings.  
Table 3-1 compares these Defined Daily Doses for some commonly-prescribed 
antidepressants with the standard and maximum doses recommended by the British 
National Formulary.162  
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Drug Defined Daily 
Dose163 
Standard 
treatment dose162 
DDD as %  of maximum 
British National Formulary 
fluoxetine 20mg 20mg 33% (60mg) 
citalopram 20mg 20mg 33% (60mg) 
venlafaxine 100mg 150mg 27% (375mg) 
amitryptiline 75mg 75- 150mg 38% (200mg) 
lofepramine 105mg 140- 210mg 67% (210mg) 
 
Table 3-1: Defined Daily Doses (DDD) and percentage of maximum British National 
Formulary doses for commonly-used antidepressants 
 
It can be seen that most Defined Daily Doses and formulary doses are equivalent (with 
the exception of lofepramine) but that Defined Daily Doses are typically only a fraction 
of the maximum British National Formulary dose, and in the cases of venlafaxine, 
lofepramine  and amitryptiline are also lower than the standard recommended British 
National Formulary dose. 
3.3.6.1  Interpreting doses and clinical use 
Routinely-collected prescribing information in Scotland only counts the amount of 
drug dispensed; it does not record the dose to be taken or the duration of treatment. 
This means, for example, that prescribing “three Defined Daily Doses of fluoxetine” 
could mean three people receiving a standard dose of 20mg, or one person receiving 
the maximum British National Formulary dose of 60mg.  
Scottish data does not yet allow for a comprehensive linkage to be made between 
drug use and the condition for which it was prescribed. For example, it is not possible 
to know what proportion of amitryptilline use relates to depression and what 
proportion is prescribed for other indications (such as enuresis or neuropathic pain). 
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3.3.6.2 Artefact and national recording of Defined Daily Doses 
Information about antidepressants is collected by the Information Services Division of 
the Scottish Government, and is based not on prescriptions written, but on drugs 
dispensed.  Defined Daily Doses vary by about 10% between months, following a 
consistent pattern from year to year. This variation is mainly caused by the different 
number of days in each calendar month, but is also influenced by increased GP 
prescribing before the Christmas and Easter public holidays. Analysis of prescribing 
trends therefore needs to be averaged over a period of months, or to use comparisons 
for the same periods each year in order to take account of artefactual variation.  
The Scottish population is not static, so the calculation of Defined Daily Doses 
dispensed per head of population needs to be adjusted for any chances in the 
denominator. In practice, this can only be done once per year, when the General 
Register Office of Scotland publishes the national population estimate.  
For these reasons, analysis of prescribing in this study: 
 Used World Health Organisation definitions of Defined Daily Doses, since 
other more accurate measures are not routinely available in Scotland 
 Makes year-to-year comparisons against equivalent time periods 
Calculates antidepressant use at practice level using monthly practice populations 
and at national level using annual population estimates (the most detailed data 
available in both instances).  
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3.4 Psychological therapies 
3.4.1 What types of therapy are effective for depression? 
A range of different psychological models have been applied to mental health 
problems, and different ‘schools’ or modalities of therapy have grown up around 
them. A review of brief psychological therapies for depression found trials 
investigating 32 distinct psychological models or techniques.164 A detailed discussion 
of the rationale, effectiveness and availability of the full range of talking treatments is 
beyond the scope of this thesis. The purpose of the following section is to set out 
briefly the current clinical consensus.  
The term ‘Psychological Therapies’ as used in this section is consistent with the 
following definition: 
 “A range of interventions, based on psychological concepts and theory, which 
are designed to help people understand and make changes to their thinking, 
behaviour and relationships in order to relieve distress and to improve 
functioning. The skills and competencies required to deliver these 
interventions effectively are acquired through training, and maintained 
through clinical supervision and practice.”30 
Several forms of psychological therapy are available and recommended by the 
National Institute for Clinical Excellence for use in depression care.26 Generally 
speaking, psychological treatments (including guided self-help) are considered the 
treatments of choice in mild depression; are an alternative to antidepressant use in 
moderate depression; and cognitive therapy with antidepressant drugs is the 
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treatment of choice in severe depressive episodes. Cognitive therapy is also 
established as a treatment to reduce the risk of relapse of depression.165 
A critique from a psychoanalytic psychotherapy perspective argues that the studies 
upon which such reviews are based are fundamentally flawed. Perhaps most 
importantly, “patients complain of problems of functioning and of life not captured by 
measures of symptoms or categorical diagnoses”, and that “apparently exact rates of 
diagnosis lend pseudo-objectivity to the familiar taxonomy”, meaning that anxiety, 
depression and obsessive-compulsive symptoms are considered as separate disorders- 
a “dismemberment” of related difficulties that analysts consider unjustified and 
inappropriate.51   
The validity of clinical trials comparing one form of psychotherapy against another has 
also been called into question, since the common features described above mean that 
the therapies may not represent “distinct treatments”.166  
While acknowledging these critiques, the Doing Well programme was based on a 
conventional reading of the literature in this area. 
There is no evidence to suggest that there is a “specific” form of psychological 
treatment for depression.167 In fact, while therapies may begin from very different 
theoretical standpoints, independent coding of the content of therapies suggests that 
there is considerable overlap in their functioning in practice.166 Effective therapies for 
depression typically have the following characteristics:165  
 The therapy offers a specific formulation of the individual’s problems 
 The model of therapy is shared openly with the patient 
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 There is rational use of techniques in a logical sequence 
 There is an emphasis on skill development and transfer of learning to the 
patient outside of therapy sessions 
 Change is attributed to the patient’s rather than the therapist’s efforts 
In all psychological interventions, an appropriate therapeutic alliance is associated 
with a positive outcome, regardless of the modality of therapy offered.26 This refers to 
the patient’s capacity to work productively with the therapist because the therapist is 
perceived to be a “helping professional with good intentions”. The nature of the 
therapeutic alliance in the opening sessions of therapy may be predictive of the 
eventual outcome.168 Despite the importance of the therapist-patient interaction, a 
systematic review did not consider that any of the 83 available measures of this 
interaction were of sufficient quality to guide practice.169  
In summary, most therapeutic models show considerable overlap, the principal 
common factors can be identified, and our current knowledge does not permit us to 
assess reliably patient-therapist interaction.   
There are three contemporary UK reviews of the evidence in relation to psychological 
treatments for depression: the National Clinical Practice Guideline for depression 
prepared by the National Institute for Clinical Excellence,26 the Scottish Intercollegiate 
Guideline Network Guideline on Non-Pharmacological Management of Depression in 
Adults170 and the Scottish Government’s “Guide to delivering evidence-based 
Psychological Therapies in Scotland: the Matrix”.30 The NICE and SIGN guidelines are 
based on systematic reviews of the evidence; the “Matrix” report is a “summary of 
information” about psychological therapies intended to support NHS Boards to 
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commission appropriate services. It is included here because it represents official 
policy on the commissioning of psychological therapies in Scotland (though it was not 
available at the time when the Doing Well intervention was set up). 
Table 3-2 sets out the recommendations made by these bodies for depression care.  
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Therapy Description, rationale NICE graded 
evidence of 
efficacy26 
 
SIGN-graded  
evidence of 
efficacy170 
“Matrix” 
evidence of 
efficacy30 
Notes  
Cognitive–
behavioural 
therapy (CBT) 
a structured, problem-focused, 
goal-orientated  approach based 
on a model that changing 
cognitive biases in depressive 
thinking mediates changes in 
mood and behaviour  
B; A when 
used with 
antidepressa
nt  in chronic 
depression 
A A Good evidence of effectiveness for individuals 
with mild to moderate depression and in 
combination with antidepressants for severe 
and resistant depression. Good evidence lacking 
in treatment of severe depression without 
concomitant antidepressant use.  
“Treatment of choice” in moderate, severe & 
treatment-resistant depression26 
Interpersonal 
therapy 
Intended as a short-term 
treatment for depression, 
targeting areas of interpersonal 
functioning, eg role transitions, 
disputes, unresolved grief, 
isolation and withdrawal 
B A A Superior to placebo and equivalent to 
antidepressant drugs for individual therapy in 
mild/moderate depression; not as effective as 
antidepressant drugs in severe depression. 
Psychodynamic 
therapy 
a relatively intensive therapeutic 
approach aimed at reducing inner 
tensions and relational conflicts 
through the exploration of 
unconscious meanings and  
motivations, often with reference 
to past formative experiences and 
current care relationships 
n/a B n/a Uncertain evidence of efficacy in one trial for 
moderate depression. “Psychodynamic 
psychotherapy may be of value in the treatment 
of the complex comorbidities 
that may be present along with depression”26 
Behavioural 
activation 
A re-engagement in meaningful 
and necessary activities, without 
considering possible cognitive 
distortions 
n/a A A “No evidence” with which to compare efficacy 
with other forms of psychotherapy.26 Effects 
may be similar to cognitive therapy and 
medication, though needs to take place in a 
“skilled therapeutic context”.  
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Family and 
couple 
interventions 
 B n/a n/a “Insufficient evidence on which to base a 
recommendation”170; “consider for people who 
have a regular partner and who have not 
benefitted from brief individual intervention”26 
Problem-
solving therapy 
shifts the focus of therapy from 
the client to the framework of the 
family unit, emphasising the social 
context of problems  
B (mild 
depression) 
B n/a “may be considered a treatment option”;170 
may be no more effective than usual care.171   
Counselling typically brief interventions that 
offers empathic and non-directive 
support for challenging 
circumstances  
B (mild 
depression) 
B n/a “may be considered as a treatment option” but 
effects inconsistent and probably no additional 
benefit after 12 months 
Self-help 
guided by 
therapist 
A self-administered intervention 
designed to treat depression, 
which makes use of a range of 
books or a self-help manual that is 
based on an evidence-based 
intervention and is designed 
specifically for the purpose. 
C (mild 
depression) 
A (mild to 
moderate 
depression) 
A  
 
Table 3-2: types of psychological intervention available in Scotland and evidence for their efficacy for depression in adults. Grading of evidence 
generally from A (strongest) to C (weaker). Details in Appendix 10.1, page 280 
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There are clearly some differences in the conclusions drawn from these reviews of evidence. 
It is beyond the scope of this chapter to investigate or explain all these differences. 
Nonetheless, it is relevant to acknowledge that: 
1. This is an active field for research, with a rapidly expanding evidence base.172 
Decisions about what to include in the Doing Well intervention were made prior to 
the publication of NICE guidance in 2004, but were based on the same evidence and 
were consistent with that guidance. A significant number of new studies have added 
to the body of knowledge since NICE guidance on the management of depression 
was first published.  
2.  “Objective” appraisal of the evidence will nonetheless depend on some subjective 
judgements on the behalf of the reviewer, and there are some subtle differences in 
the standards used to grade evidence. 
3. The implementation of psychological therapies at a service level will be influenced 
by policy and resources as well as the available “evidence base”. 
4. There may be doubts about the “fidelity” to theoretical models when care is 
delivered in practice.   
 
3.4.2 Issues in the delivery of psychological therapies 
3.4.2.1 Which patient?  
The selection of a particular therapeutic modality for a patient will depend not only on the 
availability of that therapy, but on the patient’s own preferences and experience, on the 
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GP’s awareness of the available options and the access to other services that may also be 
available.  
A Healthcare Commission survey of over 18,000 people in secondary care mental health 
services in England in 2006 found that 39% of patients received “talking therapy”, though 
57% would have liked such treatment. However only 52% of those who did access “talking 
therapy” found it helpful.173  
It would clearly be beneficial to be able to predict and select which patients might benefit 
from psychological approaches to managing depression. A systematic review of the clinical 
effectiveness of psychological treatments174 found that outcomes were not greatly affected 
by the gender or age of patients. There was some evidence to suggest that patients from 
ethnic minority backgrounds had better outcomes in short-term psychodynamic therapy 
when their ethnicity was matched to that of the therapist. Other reviews did not find any 
association between ethnicity and outcome. Three studies found no evidence of an effect of 
intelligence on outcome. One study suggests that low socioeconomic and educational status 
is associated with poorer outcomes, but three studies suggested no effect. Not surprisingly, 
people who have difficulties in interpersonal relationships tend to have poorer outcomes in 
therapy.  
3.4.2.2 Mode of treatment 
Group and individual therapy were generally found to be of equivalent efficacy, except for 
brief therapies, which generally had better outcomes in individual rather than group work.174 
3.4.2.3 Duration of treatment  
A range of short-term psychological therapies have been developed that are based on the 
principles of counselling, problem-solving therapy, psychodynamic psychotherapy and 
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cognitive behavioural therapy, but which cover the same material much more quickly. Such 
“brief” therapies typically take place over six to eight sessions (although “brief” 
psychodynamic psychotherapy usually means up to 20 sessions,51,168 some have advocated 
that interventions can be as brief as ten minutes175). They require patients to be able to 
understand the rationale of therapy, to articulate their difficulties, to quickly form a 
therapeutic alliance with the therapist, and to be able and motivated to work on problems 
outside the therapy session. Patient and therapist need to be able to identify the focus of 
treatment in the first one or two sessions.168  
Two systematic reviews suggest that brief therapies are more effective and more acceptable 
to patients than either placebo or wait list control. Short-term therapies seem to work at 
least as well as GP care and antidepressant treatment, but the evidence in relation to short- 
versus longer-term therapy is less clear cut.26,164 In general , treatments based on cognitive 
behavioural therapy had similar outcomes to those achieved by interpersonal therapy, and 
better outcomes than psychodynamic or supportive therapies.164 Psychoanalytic 
psychotherapy is much longer than any other form of psychological treatment (often 45-300 
sessions).51 
No effect of treatment length on outcomes for therapy in depression was found in two 
studies, but there was some evidence that 16 weeks of CBT or IPT may be insufficient for 
people recovering from major depressive disorder.174 
A “stepped care” model providing psychological therapies should be able to broadly match 
the appropriate duration of therapy to patient needs. This will partly be determined by the 
formulation generated after assessment. For example, a patient who experienced prolonged 
childhood adversity and who describes longstanding mood problems is unlikely to gain 
adequate benefit from a brief intervention: they would best be referred directly for longer-
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term treatment. Other cases are less clear-cut, and the appropriate duration best 
established by monitoring their response to treatment. Those showing adequate benefit 
from a few sessions of therapy could safely be discharged; those showing a partial or absent 
response would require longer-term intervention. 
3.4.2.4 Access 
The National Institute for Health and Clinical Excellence (NICE) has recommended that a 
range of psychological therapies be made available on the NHS.26 Only one quarter of the 
estimated 6 million people in England with anxiety and depression receive psychological 
treatment, which led to the development of the “Improving Access to Psychological 
Therapies” (IAPT) programme. The objective of the programme is to support Primary Care 
Trusts in England to implement NICE guidance.176  
A similar commitment (to “increase the availability of evidence-based psychological 
therapies for all age-groups in a range of settings and through a range of providers”) was 
made in the Scottish Mental Health Delivery Plan.37  
There is considerable unmet need for treatment with psychological therapies in both 
primary and secondary healthcare in the UK.81 The difficulty in accessing appropriate  
psychological therapies was cogently expressed by Layard7: 
“If you have schizophrenia or bipolar depression in Britain, you will generally get 
specialist help from the NHS. But only about 1% of the British population have these 
terrible conditions. Many more (some 15% of us) have unipolar depression or 
anxiety disorders, yet if you have one of these, often crippling, conditions you are 
unlikely to get any specialist help at all. You can see your general practitioner, but he 
or she is unlikely to prescribe any treatment other than drugs.” 
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This position is supported by surveys of GPs. A nationally representative sample of 200 GPs 
in England were asked their views about forms of depression care in self-completed online 
questionnaire.177 Fifty-five percent of respondents believed that some form of 
psychotherapy or counselling was the most effective response to mild or moderate 
depression (35% believed that antidepressants were the most effective response for this 
group). Seventy-eight percent of doctors reported that they had prescribed an 
antidepressant while believing an alternative would have been preferable. The commonest 
reasons for prescribing were either that a suitable alternative was not available (66%), or 
involved too long a wait (62%). 
Layard7 estimates that 10,000 additional therapists will be required to meet the need for 
therapies, but others predict that the cost may be even higher.178 It is relevant to note that 
the £338,546,700 spent on antidepressants in England in 2005 was more than double the 
“planned spending on psychological therapies” (excluding primary care) of £142,047,000 for 
the same year.179 However Priebe101 cautions that increasing psychotherapy provision in the 
UK “will absorb large amounts of funding and that the demand will not stop increasing once 
a certain level of provision has been reached.” 
A number of issues are thought to have impeded the development of appropriate 
psychological therapies in Britain.81 These include a perceived lack of efficacy of 
psychological therapies (despite the evidence referenced above), the relative cost of 
psychological therapies and “few distinct models of service delivery”. The report also 
identified a lack of suitably trained staff, limited access to appropriate training, and difficulty 
in using specialist skills in everyday practice. The view of the Royal Colleges was that poor 
integration between secondary and primary care was also thought to hinder access for 
patients.  
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In summary, services seeking to address these problems might provide brief interventions to 
manage cost and resource restraints. Longer or more intensive treatments would be 
reserved for those with clear indications for such approaches, or who had failed to show an 
adequate response to less intensive treatments. Psychological approaches should be based 
on validated models, with a particular focus on the “common factors”. A significant 
investment would require to be made in staff training and supervision. Finally, care should 
be taken to enhance integration between primary and secondary care.  
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3.5 Self-help for depression 
The term “self-help” is used here to refer to a range of interventions (including interactive 
internet or paper-based packages), which patients may work through alone:  
“the patient receives a standardised treatment method with which he can help 
himself without major help from the therapist. It is necessary that treatment be 
described in sufficient detail, so that the patient can work through it independently. 
Books, in which only information about depression is given to patients and their 
families, cannot be used”.180 
“Guided self-help” refers to the use of these materials with limited support from a health 
care professional (or para-professional) who typically introduces the self-help programme 
and reviews progress and outcome. Such an intervention usually takes place over 6 to 8 
weeks”26  
The use of self-administered treatment manuals has been available since the 1960’s.181  
Originally developed as a technique for personal “self-improvement”, self-help now has an 
established place in the treatment of illness. This development has been viewed with 
scepticism by some authors: is it a “philosophical approach” that supports individual 
responsibility and self-efficacy, or a resource-driven “health technology solution to volume 
and demand”, improving nominal access to psychological therapies by providing a cut-down 
version of what professionals do?182 It may, of course, be both: and even a “cut-down” 
version of therapy may be preferable to nothing at all. 
Self-help has several potential advantages over conventional face-to-face psychotherapy. It 
is more accessible, less constrained by capacity issues, is private and has been argued to be 
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an “empowering” tool that may help to prevent the deterioration of depressive 
symptoms.181  
As described in section 3.4.1, several systematic reviews have supported the effectiveness of 
self-help techniques in depression. Guided self-help has been recommended both by NICE26 
and the Scottish Intercollegiate Guidelines Network183 for patients with mild (NICE) or mild 
to moderate (SIGN) depression. Computerised self-help is also supported by research 
evidence.183  
However NICE recommendations are based on only nine randomised controlled trials 
including 453 participants. SIGN guidance was itself based on NICE, with the addition of a 
more recent meta-analysis involving 34 studies.184 This latter report noted some significant 
methodological limitations in the studies examined, and suggested that outcomes may be 
less positive in symptomatic primary care patients or waiting list controls, rather than 
volunteer subjects recruited through advert.185 Outcomes were better for “guided” rather 
than self-directed self-help, for people with established symptoms rather than those at risk 
of depression, and for interventions based on cognitive behavioural therapy techniques.  
There are no direct comparisons of the self-help materials available, and a meta-analysis of 
11 studies assessing three self-help books found evidence of effectiveness in only one (a US 
resource called “Feeling Good”).186  
Guided self-help has been proposed as “step one” in a stepped care system in the UK, and 
seems to be capable of increasing the number of people supported in primary care with no 
loss of effectiveness compared to traditional services.187 In this sense self-help is considered 
an adjunct to “conventional” health services, particularly used in mild problems and in 
health promotion. 
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Advocates of self-help envisage a more ambitious or radical “consumerist” model, which 
represents a confident vision of patient-focussed care, rather than being relegated to the 
margins of the system. This alternative vision would enable patients to access care directly in 
a “graduated, non-linear way titrated to their needs”. Reform of this kind, it is argued, would 
empower patients to find the right help while avoiding the delay and bureaucracy associated 
with conventional referrals, consultations and discharges: “a knowledgeable, informed 
public may be better able to improve its own health and manage its progress through the 
whole system without necessarily overwhelming the system.”188 
 Papworth181 suggests that individuals should be offered an intervention based on their 
presenting difficulties, personal preferences and their individual characteristics, perhaps 
within a flexible stepped care model.189  Such an approach might extend to population-based 
initiatives seeking to reach people who might never otherwise come into contact with health 
services.182 There is some limited evidence to support the effectiveness of self-management 
programmes by lay leaders for people with depression.190 
“The response of primary care professionals to patients with common, minor 
illnesses is itself a determinant of subsequent patterns of healthcare seeking 
behaviour. More research is needed to guide practitioners towards the optimum 
ways of configuring services, interacting with patients, and providing drug and non-
drug solutions to illness.”191 
Self-help is not, however, suitable for all patients. Subjects with high levels of “self-efficacy” 
and “realistic” personality traits may do better than others when using such materials,181 
whereas those with poor functional literacy are unlikely to benefit. Self-help is considered 
unsuitable for people with suicidal thoughts or impaired attention and motivation, even 
though these are difficulties commonly associated with depression.192 A small proportion of 
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patients may experience harm when using self-help without professional support.181 Some 
authors have questioned GP’s readiness to provide such support for patients seeking self-
help for depression in primary care.193  
In summary, a self-help approach may exclude some people who find the materials too hard 
to read or absorb; may have significant drop-out rates; and difficulties experienced while 
using the material may exacerbate feelings of hopelessness. Nonetheless, the benefits of 
self-help (ease of delivery, low cost, reduced referrals to specialist services, acceptability to 
patients) offer clear potential for those who can engage. A move towards strategies to 
improve patient information, participation and engagement in treatment would be 
consistent with similar trends in general health care settings.82  
3.5.1.1  Self help in practice 
About 2,000 self-help books are thought to be published each year,26 and a large number of 
these relate to depression. However in 2003, when the Doing Well intervention was being 
planned, there was limited information available to guide the choice of self-help materials.  
Nonetheless the local health system had participated for some years in the SPIRIT 
(Structured Psychosocial InteRventions In Teams) course, which trained practitioners to 
work effectively at a basic level of cognitive behavioural therapy delivery. These skills 
included being able to formulate a management plan using a cognitive behavioural model to 
identify areas for change, to help the patient to identify and overcome unhelpful thinking 
and behaviours, and use the self-help materials based on the “Five Areas” approach and 
associated “Overcoming Depression” text194 effectively and safely.195 Since these self-help 
materials were available without charge, considerable local expertise had built up in their 
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use, and no comparative evaluations had been published at that time, a pragmatic decision 
was taken in 2003 to use the “Five Areas” approach as part of the Doing Well intervention.   
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3.6 Depression: management in practice 
3.6.1 Detection in primary care 
Doctors stand “at the gateway between illness and non-illness”:196 the GP must interpret a 
patient’s description of distress, and seek to make sense of their problems in the social, 
physiological and personal context in which the patient finds themselves.  The traditional 
“rule of halves” suggests that “approximately half of most common chronic disorders are 
undetected, that half of those detected are not treated, and that half of those treated are 
not controlled.”197  
Unlike other common conditions presenting to primary care, a diagnosis of low mood cannot 
be established with physical tests, and the distinction between “illness” and “non-illness” 
can be particularly hard to distinguish.  
Studies commonly assert that that “up to half”,198 “at least half”199 or “about half”200 of cases 
of depression amongst primary care attenders are not detected by general practitioners. A 
consensus statement by the “Defeat Depression” campaign stated that “at any consultation 
about half the patients consulting with depression  are not recognised”.201. These authors 
either cite studies from the 1970s reported by Goldberg & Huxley,78 or more recent work by 
Simon202 (where GPs actually identified about 64% of major depression).  
But these figures may underestimate the true detection rate in practice. Studies examining 
this issue typically use dichotomous categories for “depressed” and “not depressed”.203 
More recent work has shown that GPs respond in a more “dimensional” way in practice. A 
study in of 18,414 primary care consultations in Hampshire, UK,204 showed that there was a 
close association between the severity of presenting depressive symptoms and the 
likelihood of illness being detected by GPs. The proportion of missed cases reduced 
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markedly when the threshold for a diagnosis was raised. Fifty-nine percent cases scoring 8 
on the depression subscale of the Hospital Anxiety and Depression Scale were “missed” by 
GPs, but this proportion fell to 20% for people with a score of 17.  The authors estimated 
that only one probable new case of depression would be missed in every 29 consultations.  
An observational study in a Scottish primary care setting reported rates of depression 
diagnosis for three levels of score on the Hospital Anxiety and Depression Scale. Eight 
percent of patients with a score below eight were diagnosed as depressed, rising to 24% of 
patients with a score between eight and ten, and 52% of patients with a score above ten.205 
An American study in primary care had similar findings: subjects reaching a “caseness” 
threshold for major depression were nearly three times more likely (56%) to be recognised 
than “sub-threshold” cases (20%).206 
“Cross-sectional” studies may also give misleadingly low detection rates in primary care 
when they assess the proportion of cases “missed” at a single appointment.  Studies with a 
longitudinal design suggest that unidentified cases are often picked up at subsequent visits, 
with one study suggesting that the rate of non-detection is “closer to one in seven than one 
in two”.207  
Nonetheless, it seems likely that a significant proportion of presentations of depression are 
not picked up by GPs. A number of factors will influence detection rates. Doctors are less 
likely to detect new cases of depression when they face significant time pressures,208 have 
knowledge and skill deficits198 or have a consultation style that  is less likely to enquire about 
“feelings and affect”.209 Increasing consultation length was associated with better 
recognition of psychological distress in a Scottish study of 1,075 consultations: a 50% 
increase in consultation length was associated with a 32% increase in identification.210   
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Doctors’ confidence in their own ability to identify depression was not associated with 
detection rates in a British study in primary care. However a “sense of ease” in managing 
depression and a belief in the possibility of successful treatment within primary care were 
both associated with increased detection rates.146  
Patients are less likely to have their emotional needs recognised if they present with physical 
rather than psychological complaints,211-213 have cultural beliefs about depression that 
prevent them from seeking help214,215 or make them reluctant to take antidepressants.216 
Determining an appropriate threshold for diagnosis may be problematic where patients are 
experiencing stressful life experiences, a problem that is particularly common in deprived 
practice populations.217  
The American Preventive Services Taskforce218 recommended screening for depression in 
primary care, and the UK National Institute for Clinical Excellence recommended screening 
for at-risk patients.26 But the instruments in use have low positive predictive value in primary 
care,219 and a recent meta-analysis showed that the introduction of screening instruments 
for depression had no effect on the detection or management of depression (in non-
specialist settings without adding other enhancements in care).220 However it is possible that 
GP detection of symptomatic cases of depression may be improved by the use of objective 
scoring measures.199  
There is little evidence to support a view that improved detection of depression improves 
clinical outcomes,206,221  which may be in part because GPs and patients often choose not to 
treat cases identified in this way.222,223 The conventional biomedical view that stresses the 
importance of managing symptoms may not be shared by patients, who are also concerned 
with issues of control and social functioning when they decide to seek help and assess their 
own progress.224 Even where doctor and patient agree on the need for treatment, 
98 Literature Review 
 
concordance will vary, therapies may be ineffective – and many patients would have 
recovered without intervention anyway.  
3.6.1.1 Clinician education 
The Doing Well programme was predicated on an assumption that there was scope to 
improve the management of depression in primary and secondary care, and that clinical 
behaviour in these settings was amenable to change. Yet optimism about the potential of 
educational initiatives to change clinical behaviour is often misplaced. (Section 3.7 reviews 
the literature on quality improvement in healthcare more generally).  
In 1983 and 1984, the Swedish Committee for the Prevention and Treatment of Depression 
(PTD) organised a training programme on the diagnosis and treatment of depression to all 
the general practitioners on the island of Gotland in Sweden (population 58,000). In the 
following years, the suicide rate fell by 60%, and there were significant reductions in 
inpatient care and the frequency of sick leave for depression and rates of antidepressant use 
increased.225,226  
The Gotland experience generated significant optimism that GP education could have a 
significant impact on the management and outcome of depression. Unfortunately this early 
optimism has not been supported by subsequent findings, in Gotland or elsewhere.  
The maximum benefit in Gotland was seen in 1986, and by 1988 the effect had begun to 
fade, with suicide only slightly lower than baseline values. The study had significant 
limitations (for example, the small population size, significant cultural change over the 
period of the intervention, and a lack of effect on male suicides).  
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A review of 50 years of “education” of primary care physicians found equivocal evidence of 
efficacy.227 Some studies seemed to increase knowledge and skill (as tested by multiple 
choice tests, video reviews and objective structured clinical examinations). However, other 
studies showed no effect on these parameters. Evaluation of a German intervention to 
implement depression guidelines in 29 primary care practices showed no change in patient 
outcomes.228 
British studies suggest that training for GPs does not improve depression outcomes for 
patients,229-231 though it may improve their confidence, communication skills and patient 
satisfaction.232 Providing information leaflets about depression to primary care patients in 
the waiting room made no difference to the care they subsequently received.233 
Even where GPs are aware of appropriate depression management strategies, they do not 
always practise in accordance with that knowledge. For example, although two thirds of GPs 
were aware of the “Defeat Depression” campaign, only 40% said that they had made 
changes in their practice as a result.234 This applies both to delivery of care by GPs221 and by 
other members of the practice team.235   
Scepticism was expressed in the past about the authority of those doing the “educating” 
about depression,203 and the validity of the guidelines themselves,236 but the clinical 
consensus generally supporting subsequent NICE guidance went some way to resolving 
these issues.  
In summary, GP behaviour in response to a patient presenting with depression often differs 
from what is considered to be “best practice”, even when they seem to be aware of the 
guidance and accept that it should influence their clinical care. This is a complex area, but it 
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seems likely that understanding clinical behaviour in real-life settings requires an approach 
that extends beyond knowing the “facts”. 
The consultation is a two-way process between patient and doctor, and patient views about 
the appropriate response to depressive symptoms may differ significantly from those of 
their GP. A qualitative study of patient views about depression care in the north of England 
found that patients hold varied and complex views about the aetiology of their 
depression.237  Causative factors identified by patients included biochemical causes, 
hereditary influences, personality traits, multiple demands and social problems. The 
attribution of their difficulties to life events was a prominent feature. There was a resistance 
to “disease management” strategies,238 with many people considering such “medical” 
approaches as only one therapeutic option amongst many.  
GPs share many of these views,9 and may place a high value on “tacit knowledge” based on 
their personal qualities and experience. These factors may be considered more important 
than formal education when interacting with depressed patients,239 not least because the 
distribution of educational materials generally has little effect.240 Difficulty integrating a 
medical understanding of depression with a recognition of the social context of depression 
may lead to “dissonant descriptions of depression” from doctors.241   
Taking these complexities into account, interventions to change GP behaviour might be 
expected to benefit from an individualised, tailored approach.242 However a more recent 
review of 15 studies to tailor interventions to change behaviour in health care professionals 
showed mixed results. It therefore remains unclear whether “tailored” or “untailored” 
strategies show any benefit over each other- or no strategy at all.243 
Literature Review 101 
 
    p
Reviews of methods for changing professional practice concluded that most interventions 
work to some degree, and that the use of multiple approaches in parallel was perhaps most 
effective.244,245 There are few studies of different interventions compared against each other, 
and no controlled studies that have evaluated system-wide approaches to organisational 
development.240  
However, the following interventions have been shown to have had some effect.  
“Educational outreach visits” (also known as “academic detailing”) have a range of effects, 
from “non-significant to substantial”.246 Outcomes are generally better where a small, 
specific change is targeted, e.g. in relation to prescribing, and where visits were combined 
with other interventions,247 such as direct mailings to patients, patient counselling delivered 
by others, or clinical information collected directly from patients and given to the 
provider.246,247 Expert opinion leaders are thought to influence through their authority and 
status; peer opinion leaders influence by virtue of representativeness and credibility.248 
“Social marketing” approaches assess the motivation for current practice and barriers to 
change; educational interventions are then designed to respond to those needs. Some social 
marketing programmes target physicians and their “opinion leaders”, emphasising physician 
participation, the use of concise educational materials, the repetition of key messages and 
reinforcement through subsequent visits.247   
This approach is very close to the marketing strategies of pharmaceutical companies, who 
have proved to be effective in influencing clinical behaviour (even though doctors tend to 
underestimate the influence of pharmaceutical marketing strategies).249 This knowledge 
influenced the “marketing” strategy for Doing Well, which sought to bring about change in 
GPs by peer influence, group educational sessions, and the repetition of simple messages 
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with a consistent “brand”. This included the use of branded pens and mugs, as described in 
section 4.7.  
 
3.6.2 Clinical outcome measures 
The implementation of a stepped care model requires the continuous assessment and 
feedback of response to treatment, so as to be able to influence the type and intensity of 
care that is provided. Doing Well required to choose an appropriate measure before this 
became a requirement of the Quality and Outcomes Framework (QOF) in primary care in 
2006, 38 or the  Integrated Care Pathway for Depression in 2007. 250   
Recent work has found that both patients and GPs support the use of depression scoring 
tools, considering them to be a useful component of holistic care. Despite some initial 
scepticism, doctors were sometimes surprised by the score results, and did use this to 
change their behaviour.251  Research also confirms that itemised symptom measures are 
more effective than “global judgment” in detecting modest change in symptoms that might 
otherwise not be reported.136 
A depression measure was sought that would: 
 Accurately assess depression severity at referral, so as to guide the type of clinician 
who would be allocated to a new case 
 Be suitable for monitoring change during the course of treatment 
 Allow for self-completion by the patient 
 Be simple to understand and quick to complete 
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 Be cheap or free  to use 
There is a wide range of depression scoring measures, including several in common use, but 
a review of all these instruments falls without the scope of this chapter. Four established 
depression measures were considered, but two failed to meet the requirements set out 
above.  
The accepted “gold standard” rating scale in clinical trials of antidepressants is the Hamilton 
Depression Rating Scale (HDRS).123 Although used to assess outcomes since the late 1960s, 
the scale has been criticised for poor content validity and inter-rater and test-retest 
reliability.124 Since the measure is not suitable for self-completion by patients, it was not 
considered further. The Beck Depression Inventory (BDI),252 is a well-established scale and 
suitable for self-completion, but it was too costly for widespread use in this intervention.  
Two further rating scales were considered: the Hospital Anxiety and Depression Scale 
(HADS),66 and the Patient Health Questionnaire (PHQ)253. Their characteristics are discussed 
below. 
3.6.2.1 Hospital and Anxiety Depression Scale 
The HADS was introduced in 1983 to support the identification of depression and anxiety in 
hospital-based medical outpatient clinics,66 although it has subsequently been validated for 
use in primary care and community settings. An important consideration in the development 
of the scale was the avoidance of a large proportion of items relating to “somatic disorder”. 
Accordingly, five out of the seven items relating to low mood enquire about “pleasure 
response”.  The scale deliberately excludes such “obvious implications of psychiatric disorder 
as suicidal inclinations” in case this might lead to suppression of self-report by the patient.254 
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The HADS takes two to five minutes to complete 14 questions such as “Do you take as much 
interest in things as you used to? Do you laugh as readily? Do you feel cheerful? Do you feel 
optimistic about the future?” Respondents are requested to give their answers in relation to 
the preceding week. Each item can be scored 0-3. Scores greater than 8 on either subscale 
suggest the possible presence of anxiety or depression, with scores above 11 suggesting 
“caseness” for these conditions.254 The scale is available from a commercial publisher at a 
cost of 5-50p per item, but a block license was purchased by NHS Greater Glasgow and 
Clyde, so the scale could have been used by Doing Well without cost. 
A review of 747 papers that used HADs supported the two-factor structure of the measure, 
which has strong correlations between the depression and anxiety subscales.254 The HADs 
was found to be internally consistent, to have a good balance between sensitivity and 
specificity at a threshold of 8+ for both subscales (range between 0.70 and 0.90). In general 
practice populations, the areas under the curve were found to be 0.84 to 0.96, indicating 
very good case-finding abilities.255  
3.6.2.2 The Personal Health Questionnaire  
The clinician-administered Primary Care Evaluation of Mental Disorders (PRIME-MD) was 
developed as a screening instrument for depression, but was found to take too long to 
administer. A nine-item shorter form suitable for self-completion was evaluated in primary 
care and found to have equivalent diagnostic validity to the PRIME-MD, but to be easier to 
use. This measure became known as the Patient Health Questionnaire (PHQ, or PHQ-9).256 
Although the measure does not assess anxiety symptoms, it is compatible with a 7-item 
scale called the “GAD-7” used to assess generalised anxiety disorder.257 
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The 9 questions are rated from one to three, based on the frequency of symptoms 
experienced in the previous two weeks. Unlike the HADS, the PHQ asks about physical 
symptoms of depression and suicidal thoughts, and is consistent with DSM IV definitions of 
depression. However, like other scales, definitive diagnosis should be established by clinical 
assessment. The scale can be self-completed, or administered with a clinician; it takes less 
than 3 minutes to answer for 85% of patients.253  
In a sample of 3,000 adults in an American primary care setting, the PHQ had internal 
reliability of 0.89 and test-retest reliability of 0.84. ROC analysis showed an area under the 
curve of 0.95, suggesting that it discriminates well between people with and without major 
depression.253 
3.6.2.3 Comparison of HADS and PHQ-9 
A summary of the characteristics of the HADS and the PHQ-9 is set out in Table 3-3.  
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 PHQ HADS comments 
Original paper 
 
256 Zigmond & Snaith 66  
Original setting Primary care (US) Medical outpatient 
clinic (UK) 
 
Subsequent 
evaluation 
Medical, psychiatric 
and primary care (UK) 
populations 
Telephone 
completion258 & 
epidemiological use 
(US) 
Medical, psychiatric 
and primary care 
populations 
 
NB Direct PHQ-HADS 
comparison in 
primary care in 
Scotland 259 
Scope Depression only Depression and 
anxiety 
PHQ-anxiety also 
available 
Time taken 2-3 minutes 2-5 minutes  
Criteria for  illness Yes (DSM IV criteria) No 
‘within the normal 
range’, or in a 
‘mildly’, ‘moderately’ 
or ‘severely’ 
disordered state 
Normative data for 
HADs from general 
population is 
available 260 
Number of items 9  
(16 including GAD-7 
for anxiety) 
14  
Self complete Yes Yes  
Scoring Items rated 0-3.  
Add items to generate 
summary score for 
diagnosis and/or 
assessment of 
severity 
Items rated 0-3.  
Reverse scoring for 8 
items then add to 
generate summary 
scores for depression 
and anxiety 
 
Cost Free for clinical use 5- 50p/sheet  
Severity of illness Yes  
(frequency of 
symptoms in previous 
2 weeks) 
Yes  
(assessment of 
symptom severity) 
 
Validity Good Good  Both measures have 
been extensively 
evaluated and have 
equivalent 
reliability, 
specificity, 
sensitivity 
259,261 
Sensitive to change Yes259,262 
 
Yes259  
 
Table 3-3: characteristics of PHQ-9 and HADS  
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Comparison of the psychometric properties of the HADS-D and PHQ-9 was conducted in a 
Scottish sample of 1063 patients referred by their GPs to mental health workers with “mild 
to moderate mental health problems”. Both scales had satisfactory reliability, 
convergent/discriminant validity, robustness of factor structure, and were equivalent in their 
responsiveness to change.259  
However there were significant differences between the scales in their thresholds for 
“caseness”, with the PHQ suggesting that patients had higher levels of depression than did 
the HADS. It is worth noting that the cut points used in the PHQ (depression rated as 
“minimal” (1-4), “mild” (5-9), “moderate” (10-14), “moderately severe” (15-19) and “severe” 
(20-27)) were chosen partly on the pragmatic basis that “they are simple for clinicians to 
remember and apply”, as well as the observation that changing cut points did not 
significantly affect the associations “between PHQ-9 severity and construct validity”.253   
A study of 2,294 primary care attenders in England had similar findings.251 Patients were 
assessed using one of three instruments: either the PHQ, HADs or BDI. Of 1658 patients 
tested with the PHQ, 83.5%  were categorised as having “moderate to severe” (PHQ10 or 
more, HADS 11 or more) depression, compared with only 325 (55.6%) of the 584 patients 
assessed with HADS. The authors suggest that this is the threshold at which “active 
intervention” is usually considered, but scores above of 10-14 on the PHQ are considered to 
be “moderate” in severity and “watchful waiting” for at least a month is the recommended 
action.263  
Despite these differences, doctors treated similar proportions of patients with 
antidepressants, suggesting that they did not rely heavily on the scale cut offs to make their 
decisions. This is in keeping with clinical guidance, which recommends that clinicians 
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consider other factors such as the degree of disability, previous history of depression, and 
patient preference when assessing the need for treatment.38   
3.6.2.4 Choice of depression scoring instrument for Doing Well 
The PHQ-9 was chosen for use in Doing Well for the following mix of practical and technical 
reasons.  
 It was developed for use in primary care and has been validated in a Scottish primary 
care population  
 It can be completed by either patient or clinician (typically the former in practice) 
 It is quick to complete (three minutes or less) 
 It has been validated for use in follow-up of clinical progress over time and able to 
be used for this purpose in practice 
 It is free 
 It was widely available to patients and staff online, and permission was given for it to 
be copied for clinical use after negotiation with the Copyright holder (Pfizer)  
 GPs gave positive feedback about the measure during the initial pilot phase 
 
3.6.2.5 Clinical improvement and remission  
Rates of remission may be more clinically relevant than rates of improvement, since early 
and complete remission is associated with better function, a better prognosis at follow-up 
and more stable longer-term outcomes.264,265 For this reason, remission has been proposed 
as a primary end-point for clinical trials.264  
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Primary care studies tend to have higher remission rates than trials with secondary care 
patients.266 A meta-analysis of remission rates for major depression in primary care settings 
found 13 relevant trials. The trials used a range of depression assessments, and defined 
“remission” in relation to scores on those tools (no trial used the PHQ). Overall remission 
rates (regardless of type of intervention but excluding placebo or usual care arms) ranged 
between 50% and 67%. Remission rates were lowest (50%) for four trials of “programmed 
care”, (which included collaborative care using other health professionals and educational 
programmes intended to improve quality of prescribing). Active treatment with 
psychotherapy or pharmacotherapy in isolation had remission rates of 54% for each 
intervention. The best outcomes were seen in three trials of psychotherapy plus 
antidepressant treatment, with a 67% remission rate, although this category included one 
arm with only 35 patients.267 
In the STAR*D study of 3671 American outpatients with major depressive disorder, 56.1% of 
patients had achieved remission after two steps of treatment, with a “theoretical” 
cumulative remission rate of 67% after four steps in treatment assuming no drop-outs from 
treatment.265 However this relatively high “theoretical” rate has been questioned by other 
authors.268 A meta-analysis of outcomes in secondary care for trials of pharmacotherapy or 
psychotherapy (cognitive-behaviour therapy, interpersonal therapy, problem-solving and 
social work counselling) found remission rates of 46% for each form of treatment.266  
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3.6.3 Issues that Doing Well sought to address 
Previous sections have reviewed how depression is understood by patients and the public, 
and outlined how services organise their response. The evidence relating to pharmacological 
and psychological therapies for depression was also outlined. Before going on to consider 
how systems can make improvements to depression care, this section provides a brief 
overview of some of the problems that are acknowledged to challenge the NHS in its 
provision of depression care in Britain. Some of these issues have been introduced in the 
previous sections. The following were issues that we sought to address, at least in part, 
when designing the Doing Well service. 
1. Clinicians and the public may conceptualise depression in different ways. Some 
people have difficulty in recognising their distress as a mental health issue, in 
acknowledging that this may benefit from professional help, and may not have ready 
access to accurate information about treatment choices. Patients have a “natural” 
reticence to discuss personal issues with professionals, and the particular stigma 
relating to mental illness reinforces this.  
2. GPs vary in their propensity to identify depression cases, and there is widespread  
variation in prescribing rates of antidepressants. GP consultation length may militate 
against not just the detection of mental health problems, but also their 
management. GPs may not have the time, skill or system support to (for example) 
educate and “activate” patients into behavioural changes, or to use simple 
psychological therapies like guided self-help.  
3. Concepts of depression developed and researched in specialist settings may 
translate poorly to the kind of problems seen in primary care. Some have argued 
that GPs emphasise “psychosocial context, stress, personality and coping” in their 
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management of mental health problems, compared with a more “categorical” and 
biomedical approach by psychiatrists,269 though such a distinction would be disputed 
by psychiatrists. 
4.  There is limited access to specialist care for common mental health problems in 
Britain.7 This is particularly true of access to psychological therapies; reports suggest 
that delays in accessing psychological therapies average six to nine months in 
England, and that waiting lists of up to two years are not uncommon.178 Longer 
waiting times adversely affect engagement in therapy270 and are associated with 
poorer patient outcomes.271 
5. Care for people with chronic depression may lack the kind of structured, 
coordinated care and monitoring of outcomes that has been shown to benefit 
people with other chronic conditions. However, practice may be changing in the UK 
through the introduction of QOF targets. For example, ninety-five percent of 
available QOF points for depression were achieved by practices in Scotland in the 
year 2007-8.272 
 
Bower and Gilbody endorse Shepherd’s view, first expressed in the 1960s,273 that  
“the cardinal requirement for improvement of the mental health services in this 
country is not a large expansion and proliferation of psychiatric agencies, but rather a 
strengthening of the family doctor in his therapeutic role”  
and suggest that  measures to involve secondary care may be more effective than those 
focussing on “education” or “liaison” with general practice.274  
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Doing Well sought to implement a form of service integration that was intermediate 
between primary and secondary care, retaining some aspects of each while functioning in a 
way that neither would conventionally recognise. The following section reviews the 
literature in relation to novel forms of service organisation.  
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3.7 Quality Improvement in depression care 
Health care organisations have a responsibility to provide the best possible quality of care 
for their patients, but many people do not receive optimal treatment in practice. In an 
influential report, the American Institute of Medicine concluded that “between the health 
care we have and the care we could have lies not just a gap but a chasm”.275  
The following description of routine deficits in depression care in the USA could equally 
apply to the situation in Britain:  
“The gap between what we do in practice and what we know is very large. We insist 
that remission is our goal, yet we do not routinely carefully measure symptoms in 
practice to determine if remission occurs. Yet we know that “better but not 
remitted” consistently leads to a worse prognosis than full remission. We often 
underdose or poorly titrate medication. Finally, we often combine treatments in 
practice, yet very few trials have assessed either safety or efficacy of these 
efforts.”136 
Quality improvement in healthcare is now recognised not only as a political and 
management imperative, but as an academic discipline in its own right. This section reviews 
some of the evidence relating to “generic” quality improvement in health care, before 
considering how these might be applied to care for people with depression. The evidence 
relating to quality improvement efforts in depression is then reviewed.  
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3.7.1 Components of health service redesign 
Clinicians could be forgiven a degree of scepticism about the shifting fashions in models of 
health service management, not least since the methodologies themselves have often not 
been subject to rigorous evaluation: 276   
 “The last two decades have seen the rise and fall of a number of concepts, ideas or 
methods in healthcare quality improvement (QI). We have progressed from medical 
audit to clinical audit and to clinical governance; from total quality management to 
continuous QI and to business process re-engineering; from statistical process 
control to six sigma and to lean thinking. At times, keeping abreast of the latest ‘new 
thing’ in healthcare QI can seem to require almost constant attention to the 
journals, conferences, books and training events in this field.” 277 
This thesis is primarily concerned with the influence of the Doing Well intervention on 
patients, rather than to assess how or why it might have affected health “delivery systems” 
in primary or secondary care. Yet quality improvement methodologies share common 
features, and successful interventions in one aspect of health care may be relevant to 
others. This section seeks to identify some common components of health service redesign, 
and to relate them to the approach taken by Doing Well.  
The literature reviewed so far in this chapter was the evidence that informed the design and 
implementation of the Doing Well intervention. However it is widely acknowledged that 
“having the right information” is often insufficient to bring about change in clinical settings. 
Although health care systems sometimes respond spontaneously to new clinical evidence, 
change more typically takes place in an environment where interventions are complex, 
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clinical evidence is not clear-cut, responsibilities are ill-defined, and interventions are carried 
out by a range of disciplines over prolonged periods of time.278  
3.7.1.1 Engaging stakeholders 
Engaging clinicians in change requires some understanding of group behaviour. For example, 
doctors have been characterised as a close-knit group of  
“Intelligent individuals with egos of all shapes and sizes and once in senior positions 
they are not likely to readily respond to the requirements of others. They play from 
a power base of ‘expert knowledge’ supported by a network of colleagues and 
collegiate bodies. Their individual priorities may not be in harmony with  
organisational goals and predictably they will resent imposed change.”279 
Effective engagement with GPs seems to require recognition of the skills and 
professionalism shared by primary care teams, and a practical recognition that participation 
in planning meetings represents costs to GPs in clinical time and money.279 
Passive dissemination is an ineffective method of changing practice, but 240 change can be 
supported by the following activities:280  
 the use of social-influence methods, such as local expert leaders 
 feedback on performance is provided 
 clinician workload is shifted to ancillary staff 
 multiple practice-change strategies are used 
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3.7.1.2 Understanding the problem 
Complex problems are by definition difficult to describe. A range of quality improvement 
tools have been described that allow for a relatively structured approach to understanding 
complex problems. These tools include cause/effect diagrams, process mapping or 
flowcharting, statistical process control, value streaming and comparative data analysis.277 
Many of these were promoted by the Centre for Change and Innovation in a review of 
evidence-based practice for service improvement for depression.281  
3.7.1.3 Maintaining and generalising gains 
Greenhalgh et al.248 conducted a large systematic review of diffusion, dissemination and 
sustainability of innovations in health service delivery and organisation. Succinctly titled 
“How to Spread Good Ideas”, the review identified a number of characteristics that 
supported the adoption and spread of innovation. There was strong, direct evidence to 
support the following:  
 Relative advantage: Clinicians will choose to modify what they do if they are 
presented with alternatives that are appropriate, fulfilling, and easier to accomplish 
than “standard” care. If stakeholders see no relative advantage, they tend not to 
consider the innovation further 
  Compatibility: Innovations that are compatible with the values  and perceived 
needs of a service will be more easily adopted and implemented 
 Trialability: Innovations that can be experimented with by intended users on a 
limited basis will be more easily adopted and implemented.  
 Observability: If the benefits of an innovation are visible to intended adopters, it will 
be more easily adopted and implemented. 
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3.7.2 Models of service redesign in depression 
Depression is a major public health problem, and tackling it effectively requires interventions 
beyond the treatment of individuals:282 “research demonstrates that treating depression is 
complicated and requires fundamental system redesign.”158 Rather than describe every 
variant of service model, this section sets out some key themes that underly much of the 
literature on quality improvement in depression care.  
3.7.2.1 “Complexity” in clinical systems 
Complexity is defined as “a scientific theory which asserts that some systems display 
behavioural phenomena that are completely inexplicable by any conventional analysis of the 
systems’ constituent parts. Reducing a complex system to its component parts may 
represent an ‘irretrievable loss of what makes it a system’”.283 
The traditional response to complexity in clinical systems has been to reduce uncertainty 
with the use of linear, mechanistic metaphors. We commonly speak of care that is 
“delivered” to patients on “journeys” along “care pathways” organised by “service 
frameworks”. But the fluid, interactive meshes of decisions and behaviours in healthcare 
organisations is not well-served by such reductionist approaches. An alternative is to think of 
them as “complex adaptive systems”.284  
This model accepts that clinical knowledge is often partial, that staff and patient behaviour 
may be irrational and unpredictable, and that the complex web of relationships that 
characterise health systems are constantly responding to their own feedback.  
Rather than think about “resistance to change” in relation to staff or patient behaviour, we 
should think about what governs current practice, and try to identify “attractors”285 that 
might encourage the kind of change we want. Qualitative studies of doctor-patient 
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interaction in relation to depression do not reveal lazy or ill-informed practice. Instead, they 
show doctors’ well-intentioned (though not always successful) attempts to respond to their 
perceptions of patient needs and preferences. 
Encouraging the rational use of antidepressants in this context may not be helped by more 
“education” about guidelines, but instead by a respect for the needs that are present in 
these consultations. 
3.7.2.2 Complex interventions 
A substantial literature has emerged that describes alternative models of depression care, 
mainly based on studies from the USA.286,287  Successful programmes typically require the 
implementation of complex interventions that bring about change in several areas 
simultaneously.288,289 The most effective interventions seem to be those that rely on 
multifaceted, integrated programmes.288,290 
In a systematic review of service delivery models for depression in primary care, Griffiths 
and Christensen291 identified the following interventions as being effective in improving 
depression outcomes relative to control conditions: 
1. “Care management: assistance within the practice in managing patient care (eg, the 
use of care managers such as a nurse to monitor and manage patients) 
2. Enhanced/extended care: the use of specialist practitioners or the direct provision of 
enhanced therapy within the practice (eg, cognitive behaviour therapy provided by a 
health professional) 
3. Guided self-help in general practice: the use of computer-based programs or other 
self-help materials supervised by a practitioner (eg, a nurse) 
Literature Review 119 
 
    p
4. Systematic tracking by a non-doctor: monitoring of patient progress and/or 
provision of enhanced care (eg, by a nurse or psychologist) 
5. Revision of professional roles: for example, a nurse assumes the role of case 
manager. Role shifting often involves greater involvement of non-health 
professionals in care delivery 
6. Incorporation of patient preferences into care” 
The following interventions were not effective: seeking to improve general practitioner 
training and feedback, involving the services of health professionals such as pharmacists, 
and linking services to mental health teams without proper infrastructure for follow-up. 
3.7.2.3 Chronic care 
 “Chronic care” is defined as “any condition that requires ongoing adjustments by the 
affected person and interactions with the health care system”. Problems identified with 
chronic care include: rushed practitioners not following established practice guidelines, lack 
of coordination between different care workers, a lack of active follow-up, and insufficient 
training for patients to help them manage their illness well.292   
Such a description applies to many people with depression, perhaps especially when their 
illness drains their motivation and hope: such a group is unlikely to respond well to 
conventional patterns of care in which follow-up is intermittent or at fixed intervals.73    
Wagner293,294 described a model for the management of chronic disease and gave examples 
of the changes to usual practice needed. The model envisages practice teams in productive 
interaction with informed, activated patients. Patient and clinician work collaboratively to 
identify the relevant problems, and jointly develop targets and treatment plans. Achieving 
this requires particular attention to improved “service delivery” systems, better clinical 
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information systems, and improved decision and self-management support for clinicians and 
patients respectively.295  
3.7.2.4 Stepped care 
Katon argued151 that conventional health systems were ill-suited to the needs of people with 
chronic disorders like depression. In order to understand why and how to manage their 
chronic illnesses, patients needed additional support.296 Optimal care would be “an 
interactive and iterative process between patients, their families and clinicians.”  
Building on the “chronic disease model” familiar to general practitioners from the 
management of hypertension, asthma, diabetes and other diseases, Katon and others 
working in the Group Health Cooperative in the United States developed what they call a 
“stepped collaborative care” model for the management of depression.297-299  
“Stepped care” describes an approach that minimises the intensity of the initial intervention 
for mild disorders.  Systematic monitoring of outcomes permits “stepping up” to more 
intensive forms of treatment where clinical response is inadequate.79 Stepped care models 
have been shown to be effective in the USA,297,298 and were recommended for use in the 
management of depression in the UK by the National Institute for Clinical Excellence 
(NICE).26  
Katon’s approach included four main components. Firstly, practice reorganisation created a 
register of people with depression and instigated proactive, flexible consultations, seeing 
people frequently during an acute phase and less frequently during remissions. Secondly, a 
range of materials were used to support patient education, and clinical practice guidelines 
were developed to aid diagnosis and the management of acute episodes, maintenance, and 
relapse. Thirdly, computer systems were established that recorded treatment and notified 
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staff when patient progress was not as expected. Finally, extensive use was made of 
assertive follow-up, particularly using telephone contact.73 
Others have endorsed the use of algorithm-driven care and “disease management 
programmes” to improve outcomes.300,301 Stepped care approaches have been estimated to 
have the potential to reduce the burden of depression by 10-30% by improving clinical 
outcomes.302  
The MAPLE (Multiple Access Point and Levels of Entry) model was an adaptation of stepped 
care proposed for the delivery of cognitive behavioural therapy in the UK health system.303 
Believing that “services characterised by 9-5 working, hourly appointments and face to face 
therapy disenfranchise the majority of people who would benefit from CBT”, Lovell & 
Richards303 proposed  three broad levels of entry to services: wide delivery of CBT, for 
example through self-help approaches, simple focused interventions and complex specialist 
interventions.  
3.7.2.1 Collaborative care  
Definitions of “collaborative care” vary, but this approach could broadly be described as a 
multifaceted organisational intervention designed to improve quality of care.  Collaborative 
care models are based on the principles of chronic disease management,293 and involve the 
integration of a number of elements into one “complex intervention”.  
The implementation of collaborative care varies between centres, not least in the range of 
treatment intensities they involve. Some, but not all, models incorporate interventions such 
as screening for depression, scheduled telephone contact to encourage antidepressant 
compliance, structured psychological interventions with intensive follow-up, or enhanced 
use of information technology.287,304  
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Bower et al80 helpfully categorise collaborative care interventions into three groups:  
(1) the introduction of case managers in primary care to support treatment; 288,305   
(2) efforts to improve liaison between primary and secondary care with case workers 
receiving supervision from secondary care;298 and  
(3) the introduction of methods to monitor and share information about the progress of 
individual patients  
In a 2006 review, Gunn306 emphasised the need for collaborative care to include a structured 
management plan (incorporating screening schedules and evidence-based treatment 
guidelines), scheduled patient follow-up to monitor treatment and progress, and 
mechanisms to improve inter-professional communication (such as team meetings, case 
conferences and shared clinical records). 
A meta-analysis by Gilbody287 identified 34 randomized studies of collaborative care in the 
provision of services for people with depression in primary care. The studies included a total 
of 12,355 patients with depression in primary care. Collaborative care showed significantly 
improved depression outcomes at 6 months, and there was evidence of longer-term benefit 
for up to 5 years. Effect size was directly related to medication compliance and to the 
professional background and method of supervision of case managers. The addition of brief 
psychotherapy did not substantially improve outcome, nor did increased numbers of 
sessions. Other meta-analyses have also supported the clinical effectiveness of collaborative 
care for depression286,301,306, though not necessarily their cost-effectiveness.306,307  
Unfortunately, the applicability of these studies to primary care in the UK is limited. For 
example, twenty-seven out of 34 studies included in the Gilbody287 meta-analysis were 
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located in the USA (where their effectiveness proved to be greater than in trials conducted 
elsewhere). In 18 trials, patients were specifically prepared to take antidepressant drugs and 
in 21 studies psychological therapies were not available as a treatment option. Since the 
service-level aspects of collaborative care will differ between health care systems, the 
effective transfer of service improvements into routine practice will relate to their 
adaptation to local needs and circumstances.308 
The outcomes of recent UK-based randomised controlled trials of collaborative care for 
depression are outlined in the discussion.309-311 Other trials of collaborative care for 
depression are underway in the UK,312 the Netherlands313 and Spain,314 so our understanding 
of the optimal configuration and effectiveness of this model of care is likely to improve in 
future. Issues in generating, spreading and sustaining change 
Once a new intervention has been implemented, it needs careful management to ensure 
that the changes can be maintained and spread. A review of the academic thinking behind 
the promotion of the “spread” of innovation in health care is beyond the scope of this thesis. 
But in simple terms, effective “spread” requires leadership (to set the agenda, make the case 
and accept responsibility for achieving the spread of ideas), good communication with 
potential and existing stakeholders, and an understanding of the relationships between the 
people who will be implementing the changes. Feedback about processes and outcomes is 
needed to monitor and adjust the response to spread as it progresses.315  
Heifetz and Linsky argue that ‘the sustainability of the change depends on having the people 
with the problem internalising the change itself’.316 This view is endorsed by May, who 
emphasises that “normalisation” focuses 
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“…on the conditions of use and the behaviour of everyday users rather than the 
special champions and early adopters so important to diffusion theories. It reflects 
the importance of stability, order, and practicability in professional and 
organizational behaviour in healthcare. 317  
A complex intervention that is completely “workable” becomes embedded into the routine 
of everyday healthcare activity, without disruption to the social relations and behaviour 
around it. May et al call this kind of successful assimilation “ecological success”,318 and argue 
that it is achieving this state of integrated “normalisation” that represents successful 
change, rather than achieving clinical or cost-effectiveness.  
According to this model, decision-makers in health care must consider two aspects when 
introducing a complex intervention: the workability, clinical and cost effectiveness of the 
change, and its capacity for successful integration into existing or new configurations of 
health services and professional practice.317 
 
3.8 Summary 
Depression is a common condition, though one which is difficult to categorise or describe. 
The causes and treatments for low mood are often poorly understood by the general public, 
and it can be difficult for GPs and patients to align their needs in the dynamic of the 
consultation 
. 
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 Service responses to depression have traditionally been organised on fixed, tiered models of 
care that are closely aligned to professional and service structures. “Stepped care” models 
are still being refined, but depend on smooth transitions between types of care and quality 
feedback about response to treatment.  
The efficacy of antidepressants, especially in mild depression, is complicated by a powerful 
“placebo” effect, and the tendency of depression in community settings to remit 
spontaneously over time. There may be some potential for services to harness “non-
treatment specific” factors, and minimal or “containing” interventions may be sufficient for 
many patients whose symptoms may remit without treatment. 
There is good evidence for the effectiveness of psychological therapies, though matching the 
duration, intensity and modality to the needs of individual patients may be difficult – and 
their resource-intensive nature makes it difficult to provide easy access.  
Influencing practitioners to change their clinical behaviour can be difficult, but systems 
which achieve this successfully are likely to do so by paying attention not only to 
information, “flow” through systems but also to the motivations and incentives that act to 
influence behaviour in systems.  
The following sections describe the implementation and outcomes of these factors as they 
apply to the Doing Well intervention in Renfrewshire. 
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4. Methods 
 
4.1 Setting  
The Doing Well programme was implemented in 14 general practices in Renfrewshire, 
Scotland. This is a mixed urban-rural area with pockets of significant deprivation, located 
about 10 miles south-west of Glasgow.  
The map in Figure 4-1 shows the geographical area covered by the Renfrewshire Community 
Health Partnership. The Doing Well intervention took place in practices covering the western 
part of this area.  
 
Figure 4-1: map of Renfrewshire Community Health Partnership area 
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The Renfrewshire Community Health Partnership covers a total of 30 GP practices with a 
total practice population of 177,548 people (at October 2006). The CHP area also includes 30 
dental practices, 44 pharmacies and 20 opticians. 
The age profile of the Renfrewshire population is not significantly different from that of the 
Scottish population. Table 4-1 summarises some health and economic parameters for 
Renfrewshire Community Health Partnership.319 People from ethnic minorities accounted for 
1.2% of the total population of Renfrewshire in 2001, compared with the Scottish average of 
2.0%. Life expectancy during 2001-5 was 72.5 years for men and 78.3 years for women, 
which is within two percent of the Scottish average.  
The Scottish Index of Multiple Deprivation (SIMD) is the official tool used by the Scottish 
Government to identify concentrations of multiple deprivation in small areas (called “data 
zones”) across Scotland. This provides a relative ranking of 6,505 such data zones in Scotland 
from the most deprived (ranked one) to the least deprived (ranked 6,505). 
The Index is derived from 38 indicators across 7 domains (income, employment, health, 
education, skills and training, housing, geographic access and crime). Each domain is 
allocated a weighting based on the relative importance of the domain in measuring multiple 
deprivation, and the robustness and availability of the data. The Index is then comprised of a 
weighted sum of the seven domain scores. For example, the domain weightings used in the 
2009 SIMD (expressed as a % of the overall weight) are: current income (28%), employment 
(28%), health (14%), education (14%), geographic access (9%), crime (5%) and housing 
(2%).320 
Renfrewshire is slightly more materially deprived than the Scottish average: 17% of the 
population of Renfrewshire live within the 15% most deprived postcodes in Scotland in 
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2006. Fourteen percent of the population are “employment deprived” (the proportion of the 
working age population who are unemployed or are not involved in the labour market due 
to ill health or disability), which is 8% higher than the Scottish average. Eleven percent of the 
population claim incapacity benefits and 21% of the population have a long-term limiting 
illness (10% and 3% above Scottish averages respectively).  
Eleven percent of people in Renfrewshire classify their own health as “not good”, compared 
to the Scottish average of 10.2%. Suicide rates during the period 2001-5 were 15.4 deaths 
per 100,000 population, which is similar to the Scottish average. Nine percent of people are 
prescribed drugs for anxiety and depression, compared with the Scottish average of about 
eight percent.  
Indicator  Number Measure  Relation to 
Scottish 
average 
Time 
period 
Male life expectancy 72.5 years -2% 2001-5 
Female life expectancy 78.3 years -1% 2001-5 
Minority ethnic groups 2,139 1.2% -38% 2001 
Suicide rate (standardised for age 
and sex) 
134 15.4/ 
100,000  
-2% 2001-5 
Self-assessed health “not good”  18,853 10.9% +7% 2001 
Incapacity Benefit & SDA Claimants 11,305 10.5% +10% 2007 
Long-term limiting illness 36,272 21% +3% 2001 
Prescribed drugs for anxiety or 
depression 
15,987 8.8% +9% 2006 
Income deprived 25,356 14.9% +7% 2006 
Employment deprived 14,748 13.9% +8% 2006 
Social grade E 31,310 22.8% +2% 2001 
Households without access to 
car/van 
28,030 37.2% +9% 2001 
Adults without qualifications 42,968 33.6% +1% 2001 
 
Table 4-1: Community health and wellbeing profile for Renfrewshire Community Health 
Partnership (total population 169.600 in 2007) 
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Twenty-three percent of the population are in social grade E (on benefits, unemployed or in 
the lowest grade work). Thirty-seven percent of the population do not have access to a car 
(nine percent higher than Scotland as a whole).  
There are 30 GP practices in Renfrewshire Community Mental Health Partnership. Although 
now managed as one group, a previous management arrangement allocated these practices 
to one of three Local Health Care Cooperatives (LHCCs): Paisley LHCC, West Renfrewshire 
LHCC and Renfrew LHCC. Investment in the Paisley LHCC had improved the provision of 
community mental health services, but when the Doing Well intervention was being planned 
in 2003, community services were very limited in West Renfrewshire and Renfrew. It was 
therefore decided to implement the Doing Well pilot in West Renfrewshire, which 
comprised 14 practices.  
There were significant differences in the profile of deprivation in West Renfrewshire and 
Paisley (the other part of the Renfrewshire Community Health Partnership).  Figure 4-2 
shows that almost half of the population of Paisley lives in the most deprived quintile of the 
Scottish Index of Multiple Deprivation, whereas the population in West Renfrewshire is 
more evenly spread between quintiles of deprivation.  
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Figure 4-2: percentage of population living in quintiles of deprivation for West 
Renfrewshire and Paisley 
 
4.2 Recruitment of participating practices 
The fourteen local practices in the previous West Renfrewshire LHCC were invited to attend 
an information evening held in June 2004. At least one representative from each eligible 
practice attended that meeting. Practices who might be interested in joining the Doing Well 
programme were asked to register their interest, and told that they would be contacted at a 
future date. The fourteen practices were told that their participation in the programme 
required them to meet three criteria: 
1. to make all referrals using the electronic referral system described in section 4.4.1 
2. to include a depression assessment using the Personal Health Questionnaire (PHQ, 
section 4.8.1) with every referral 
Quintile 1 
- Most 
Deprived
Quintile 2 Quintile 3 Quintile 4
Quintile 5 
- Least 
Deprived
West Renfrewshire 23% 23% 20% 17% 18%
Paisley 48% 13% 13% 13% 13%
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3. to provide a consulting room where Doing Well staff could see patients referred 
from that practice.  
All fourteen practices were able to meet these requirements, and all fourteen registered 
their interest. One practice was chosen to pilot the intervention between July and October 
2004, and then other practices were gradually invited to join the programme thereafter. The 
dates that practices were recruited to the programme are outlined in Table 4-2. 
Practice List size Date joined Doing Well 
1 10,058 Jul-04 
2 4,841 Nov-04 
3 6,553 Feb-05 
4 6,751 May-05 
5 2,661 Jun-05 
6 4,351 Jun-05 
7 4,992 Jul-05 
8 8,270 Aug-05 
9 6,034 Aug-05 
10 2,069 Oct-05 
11 5,908 Oct-05 
12 3,230 Oct-05 
13 6,051 Dec-05 
14 4,244 Feb-06 
total 76,013  
 
Table 4-2: date of practice recruitment to doing well 
 
By February 2006, the Doing Well recruitment target of 14 practices in West Renfrewshire 
was reached (a total of 76,013 registered patients).  
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4.3 Referral criteria 
Doing Well accepted GP referrals of new presentations of low mood, depression, mixed 
anxiety and depression or adjustment disorder from participating practices for people aged 
between 18 and 64 inclusive. There was no “threshold” of severity for referral to secondary 
care, meaning that Doing Well would see any patient who met referral criteria, no matter 
how mild or severe their mood problems were.  
"New” presentations were defined as people who had not sought professional help with 
affective symptoms in the previous six months, even if they had experienced mood 
problems before that time. A presentation was still considered “new” if the patient had 
begun GP treatment for depression within the preceding two months. This meant that GPs 
had some latitude to begin treatment for depression without having to refer to Doing Well 
immediately. Although Doing Well aimed to see new patients promptly, people requiring 
emergency assessment and treatment were referred to secondary care psychiatric services. 
Patients were not accepted onto the clinical Doing Well programme if they had the following 
problems: 
 A primary alcohol problem  
 A primary drug problem 
 A primary anxiety problem (significant comorbid anxiety was not an exclusion 
criterion)  
 Depression presenting as part of bipolar affective disorder 
 People with a terminal illness 
 People with medical or psychiatric emergencies 
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 Current psychosis 
 Significant cognitive impairment 
 
Although accepted for clinical care, people who were pregnant at the time of referral or who 
could not read English sufficiently well to use the self-help materials were not included in 
the evaluation of the service. This was because their treatment may have needed to deviate 
significantly from the research protocol in order to meet their needs.  
Suicidality was not an exclusion criterion, but high current risk of suicide was an indication 
for prompt referral to secondary care mental health services by the Doing Well team. 
People mistakenly referred to Doing Well who met exclusion criteria for the clinical service  
were either directly passed on to more appropriate services by Doing Well staff, or a 
discussion was held with the referrer to expedite a more appropriate referral.  
 
4.4 The Doing Well intervention 
4.4.1 Referral process 
The Scottish Care Information Gateway (“SCI Gateway”) is a national system that integrates 
primary and secondary care systems using secure Internet technology. All patients were 
referred by their general practitioners, using this system to link primary care electronic 
records with those in secondary care. Doing Well worked with software programmers at the 
Scottish Care Information Gateway to integrate the Personal Health Questionnaire into the 
online referral form. Clinicians were then asked to complete the online PHQ with the 
134 Methods 
 
patient; provision was made on the form for any brief additional information the GP might 
choose to add. Once the form was complete, the software would extract relevant 
information from the primary care system, and transfer it electronically to the Continuum 
system used in secondary care by Doing Well.  
 
Figure 4-3 shows a screenshot of the software as it appeared on the GP’s referral screen.  
 
 
 
 
 
 
 
 
Methods 135 
 
    p
 
Figure 4-3: screenshot from GP SCI screen showing referral form; "callout" box shows 
detail of PHQ online questions 
 
Occasionally exceptions were made when the electronic system could not be used; in these 
instances, paper referrals were accepted to minimise disruption and ensure patient needs 
were not compromised. The information was then manually transferred into the electronic 
system. 
Clinical and support staff in general practice received training in the use of the electronic 
referral system and assessment tools. 
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GP referrals were required to include the following information: 
1. Name 
2. Age 
3. Date of birth 
4. Community Health Index Number (CHI: the standard patient identifier used     
throughout the NHS in Scotland) 
5. Postal address with postcode 
6. Contact telephone number 
7. Email if available 
8. PHQ with individual scores for each question 
9. Current medication 
10. Brief past medical and psychiatric history (extracted from GPASS problem list) 
11. Brief text about presenting problem where GP feels this is appropriate 
Inclusion of the PHQ was mandatory. All referrals therefore included an assessment of 
depression severity using the Personal Health Questionnaire (PHQ) at the time of referral.  
GPs were asked to give all referred patients a copy of the Doing Well information leaflet. 
After a referral was received by Doing Well, patients were contacted directly by post. They 
were sent an information pack, which contained the following material:  
 An introductory letter detailing appointment date, time, venue and name of clinician  
 An information leaflet about the service 
 An information leaflet about depression (from the Royal College of Psychiatrists) 
 Information on the evaluation of the service 
 Consent form (to allow this to be read before the first appointment) 
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 A copy of the assessment scales used by Doing Well: the PHQ (Personal Health 
Questionnaire), EQ5D  and Work and Social Adjustment Scale (WSAS) 
The letters, information leaflets, consent form and assessment scales described above are 
available in the Appendix beginning at section 10.2. Patients were not required to complete 
the assessment scales prior to appointment, but they were included in the pack so that they 
could become familiar with them prior to attending their first appointment.  
Patients referred to the service were asked to confirm in writing or by phone that they 
wished to attend, and only those who responded were offered an initial appointment. 
Assessments were intended to be completed within two weeks of referral, though 
sometimes patient preferences and availability or staff absence caused the first assessment 
to be delayed.  
The PHQ noted at referral was the main determinant of care. People with a PHQ of less than 
15 (indicating “mild” or “moderate” depression) were allocated to initial assessment by the 
self-help support worker, and those with a higher score were initially allocated to a primary 
care liaison worker. However each referral was reviewed individually, and patient 
preference or clinical judgement could “overrule” this allocation where appropriate. 
Clinical information was gathered at each visit, and recorded in Continuum, the standard 
electronic record-keeping system used by South Clyde Mental Health services.  
 
4.4.2 Consent 
All patients included in this study gave written consent for their anonymised data to be used 
as part of this evaluation. Consent to involvement in the evaluation was recorded on every 
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patient’s electronic case record. Non-consent to participation in the evaluation did not 
influence clinical care in any way. Ethical approval for the study was granted by the Greater 
Glasgow and Clyde Local Research Ethics Committee (Ref AC04/073).  
All service users had the rights of privacy under the Data Protection Act (1998). Any 
unauthorised disclosures were potentially in breach of Section 55 of the Act. Individual staff 
members were also bound by the requirements of their professional body, with guidelines 
on matters of confidentiality clearly stated in the codes of practice. Each individual member 
of the Doing Well team was held accountable for his or her own practice in relation to 
confidentiality. In addition, all NHS Staff are governed by the NHS Scotland Code of Practice 
for patient confidentiality. 
 
4.4.3 Staff roles 
The function of the self-help support worker was to help people who have adjustment 
problems or mild to moderate depression to deploy appropriate coping skills and use guided 
self-help techniques to manage their low mood. Contact included telephone support and 
email-based contact where appropriate. The care protocol for self-help support workers is 
set out in appendix 10.7.  
Self-help support workers recruited to the programme had little previous clinical experience 
and were therefore not employed to generate treatment plans or to act as a therapist. 
Instead they used an operationalised protocol that set out a series of tasks that they were 
intended to work on to support the patient. In practice, the psychology assistants recruited 
to these posts were accomplished and ambitious psychology graduates who were keen to 
gain clinical experience.  
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The function of the primary care liaison worker was to provide support and help to people 
with moderate to severe depression. In addition to the tasks carried out by the self-help 
support worker, the primary care liaison worker was responsible for the following 
interventions:  
 Self-help support with the same materials, but with recognition of the increased 
level of distress and complexity that may be present in this patient group. 
 Development of appropriate care plans in conjunction with the patient 
 Provision of brief Cognitive Behavioural Therapy, Interpersonal Therapy or brief 
psychodynamic psychotherapy for practitioners with these skills. These forms of 
psychotherapy were chosen because they have an established evidence base, could 
be conducted during relatively brief interventions and were areas in which staff 
either already had accredited training or could be supported to acquire these skills 
 Make recommendations to GPs about antidepressant prescribing, after case 
discussion with the Doing Well psychiatrist where appropriate 
 Provision of information to patients about antidepressants 
 Close monitoring of any prescribed antidepressants, including assessment of 
concordance and review of any potential side effects 
The care protocol for primary care liaison workers is set out in appendix 10.8 on page 303.  
Governance of clinical safety and quality was achieved by measuring patient clinical 
outcomes, monitoring “process-related” aspects of treatment (like caseload, number of 
contacts, medicines use) and ensuring that a proportion of all cases were discussed openly 
at group supervision.  
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Experienced staff members were encouraged to modify their approach in response to 
individual patient need. These clinicians were encouraged to be open about any gaps in their 
skills or knowledge and to address any perceived deficits using the time available to them for 
continuing professional development.  
The primary care liaison worker posts proved to be popular when they were advertised, and 
it was possible to recruit high-quality candidates to the role. Staff appointed typically had 
more than ten years of clinical experience, which included a strong interest in psychological 
approaches to treatment (even if they did not have formal qualifications in this area). Doing 
Well was recognised locally to be an innovative project and was therefore likely to attract 
staff who were enthusiastic and progressive.  
 
4.4.4 Clinical interventions 
Patients were seen in their local health centre, where first assessments were scheduled to 
be of about 50 minutes duration. Patients referred with a Personal Health Questionnaire 
(PHQ) score less than 15 were allocated to a less intensive treatment programme based on 
guided self-help, whereas those with a score of 15 or more were allocated to a treatment 
programme that could access a range of pharmacological and psychological treatments in 
addition to guided self-help. These cut-off points are based on the original evaluation of the 
PHQ253 and subsequent guidance on its use,321 as discussed in section 3.7.2.3.  
All assessments included an evaluation of presenting symptoms, current social and work 
functioning, and previous personal, family and medical history. Clinicians enquired about 
other symptoms of mental health problems and of the patient’s expectations of treatment. 
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The GP referral automatically included a list of current medication, and this was checked for 
accuracy with the patient.  
All patients were introduced to self-help materials based on the “Overcoming Depression” 
text.194  The choice of materials and broader issues relating to the guided self-help approach 
were discussed in the literature review in section 3.5, page 90. “Guided self-help” of this 
kind was conducted in accordance with local training in “Practical Psychological Skills” 
mentioned above. Lifestyle advice with respect to exercise and alcohol use was given to all 
patients.  
The Personal Health Questionnaire was used to track progress over time, and non-
responders were “stepped up” to more intensive forms of treatment if needed. An 
“adequate” response was considered by Doing Well to be a reduction in PHQ score of five or 
more,321 or a reduction in total score of 50% or more,322 but in practice clinicians used this 
figure as a guide while exercising their own clinical judgement about an appropriate 
interpretation of response. 
Since patient recovery may not always correlate with a reduction in symptoms, a PHQ score 
might sometimes misrepresent a patient’s progress or mental state. For example, a patient 
might describe an increase in PHQ score while they tackled distressing issues in therapy, or 
continue to have poor sleep and appetite despite a significant improvement in social or work 
functioning.  
The “steps” in care are represented diagrammatically in Figure 4-4.
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Figure 4-4: schematic representation of “steps” in care related to response to 
treatment 
patient seen by GP:
if low mood, adjustment disorder, or depression
and onset <2 months ago and well for 6 months prior,
then PHQ and brief history
PHQ <15
seen by self-help support worker 
for 1h assessment:
lifestyle advice, guided self-help
review: 
check PHQ
continue guided self-help 
if improving: continue 3-6 sessions 
guided self-help
when recovered: discharge
if no improvement or PHQ>15, 
consider "step up" after team 
discussion
PHQ ≥15
seen by primary care liaison worker 
for 1h assessment: 
lifestyle advice, guided self-help and 
guidance on antidepressant use
review: 
check PHQ, 
consider/review need for 
antidepressant, 
deliver brief CBT or IPT
if improving: continue 3-6 sessions 
brief psychological therapy
if recovered: discharge
if no improvement or PHQ>15, 
consider "step up" or transfer of 
care after team discussion
"step up" involves review by 
Consultant Psychiatrist or 
Psychotherapist
add antidepressant if not already 
taken
referral transmitted 
electronically
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An assessment of suicidal ideation was included at each review point.  All patients would 
continue with the planned self-help intervention, as long as they showed an adequate 
clinical response. 
 
4.4.5 Prescribing 
Antidepressant treatment was recommended for patients scoring 15 or more on the PHQ, or 
who had a PHQ greater than 10 and had not shown improvement in mood with previous 
treatment during this episode of care. This treatment protocol was based initially on the 
recommendations of the MacArthur Initiative on Depression in Primary Care in the USA.263 
Antidepressant treatment recommendations were made in keeping with a 3-drug local 
formulary (fluoxetine, citalopram or lofepramine). Work to promote the use of the local 
antidepressant formulary was undertaken in collaboration with the Prescribing Advisors for 
NHS Greater Glasgow and Clyde. The development of the formulary in early 2004 used the 
evidence available at the time, which suggested that all antidepressants were of equivalent 
efficacy. A view was taken that it was sometimes helpful to try a drug of a different class 
where the initial agent had been ineffective. On this basis, the cheapest available Selective 
Serotonin Reuptake Inhibitors (SSRIs) were chosen (fluoxetine and citalopram) and the 
tricyclic lofepramine added since it was a different drug class, and considered relatively safe 
if taken in overdose.  Particular attention was paid to patient information and education 
with regard to medicines. Education and support for primary care staff in relation to 
prescribing is described in more detail in section 4.7.2. 
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4.5 Discharge and follow-up 
Once a period of treatment was considered to be complete by the team, patients were 
formally discharged. In order to discharge a patient, the relevant clinician would:  
 Record discharge status in patient’s electronic record 
 Use the electronic record to produce a written discharge letter detailing length and 
type of treatment and send this to the patient’s GP with a note of any other services 
used or referred to 
 Inform patients that they were free to self-refer to the Doing Well team for up to six 
months after discharge and encouraged to use the PHQ again themselves if they had 
concern about deteriorating mood.  
 Give the patient a “discharge pack” of measures and ask that they complete the 
Work and Social Adjustment Scale, the EQ-5D and Client Satisfaction Questionnaire. 
Recognising that it might be difficult for patients to give unbiased answers to the 
latter questionnaire when the clinician was present in the room, patients were 
invited to complete the measures in the waiting room or at home, and provided with 
a stamped addressed envelope (if required) to return the questionnaires.  
 Four months after discharge, the team administrator sent participants the following 
measures as a “follow up” assessment: the PHQ, Work and Social Adjustment Scale, 
the EQ-5D and Client Satisfaction Questionnaire. A stamped, addressed envelope 
was provided to return the measures to the team. At least one reminder letter or 
phone call was sent to each non-responding patient. 
This approach to discharge was used because a programme based on brief interventions for 
large numbers of people needs to maintain a “flow” of patients through the system. Doing 
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Well did not necessarily need to maintain contact with all patients until they had recovered, 
although this did happen for many people. Instead, the goal of the service was to provide 
people with the tools and confidence to begin to get better, and to be able to manage their 
ongoing recovery themselves. Patients were therefore discharged as soon as it was felt that 
they could recover on their own, even if they were not fully well. Patients who needed 
longer-term or other treatments were transferred to appropriate services as soon as their 
needs became clear.  
Maintaining the safety and clinical appropriateness of these rapid patient “flows” required 
the service to be readily accessible to people who ran into unexpected difficulties after 
discharge. It was considered important that they could arrange further treatment with their 
key worker through phone or email contact, without having to negotiate access through 
their GP or other parts of the service.  
For those who did not attend (DNA) or disengaged from treatment (left treatment before 
agreed sessions had been completed), the relevant clinician would try to contact the patient 
to ask about the reasons for their disengagement. 
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4.6 Staff training and skill mix 
The Doing Well team consisted of the following staff (Figure 4-5): 
staff WTE notes 
Self-help support worker 1.0 One full time psychology assistant with 
additional clinical training 
Primary care liaison worker 4.5 3.5 WTE Psychiatric nurses and 1.0 WTE 
occupational therapist 
Consultant psychiatrist 
 
0.2  
Team manager 0.5 Remaining 0.5 WTE of this post included  in 
clinical sessions as primary care liaison 
worker above 
Team administrator 
 
1.0  
 
Figure 4-5: staff employed by Doing Well 
 
The self-help support workers were psychology graduates who received local training in 
“Practical Psychological Skills”. This is a skill-based course lasting 30 hours which trains 
practitioners to use the self-help book “Overcoming Depression: A Five Areas Model”,194 as 
described in section 3.5.1.1 of the literature review. Their work was clinically supervised 
both by senior Doing Well clinicians, and by the local psychology department. Total 
individual clinical supervision amounted to two hours per week.  
Primary care liaison workers were experienced psychiatric nurses or occupational therapists 
with expertise in mental health. They were trained in the use of guided self-help techniques, 
but had additional training in Cognitive Behavioural Therapy and/or Interpersonal Therapy 
and the pharmacological treatment of depression. A consultant psychiatrist (the author) was 
part of the team, acting to review more complex clinical cases, and to supervise other 
clinicians. This amounted to 8 hours of clinical input per week.  
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Each non-medical "Doing Well" clinician worked to a timetabled 10-session weekly 
“template” that comprised of:  
 1-2 sessions administration 
 1 session of group supervision 
 5-6 sessions of direct patient contact 
 2 sessions professional development 
“Professional development” sessions were allocated to a range of tasks, depending on a 
shared assessment of staff members’ training needs and preferences. 
Weekly clinical supervision was conducted in group format, involving all Doing Well 
clinicians.  These meetings were held to review clinical cases and individual staff workload. 
Doing Well information systems allowed for the ready identification of patients who were 
not responding to treatment and needed a change in their care. The workload for individual 
clinicians (number of cases, duration of treatment, number of contacts per patient) could 
also be monitored and amended as necessary.   
 Doing Well staff worked in collaboration with the primary care team who retained overall 
responsibility for prescribing and for the physical health care of people referred to the Doing 
Well programme. 
All staff members were required to meet their professional responsibilities in relation to 
their duty of care to patients as set out in professional codes of conduct and registration 
requirements. Staff also had a professional obligation to recognise and observe the limits of 
their training and competence, and to be sure that anyone else to whom Doing Well staff 
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may refer was also appropriately qualified and competent. These aspects of clinical 
governance were emphasised during induction and ongoing team development. 
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4.7   Education and support 
A range of “educational” activities was undertaken by Doing Well to support the 
implementation and development of the programme. These educational activities are 
described below.  
4.7.1 Doing Well staff 
 “Professional development” sessions were allocated to a range of tasks, depending on a 
shared assessment of staff members’ training needs and preferences. Examples of 
professional development undertaken by different staff members included  
 Completing a 2-year diploma course in cognitive-behavioural therapy 
 Going on a 1-year secondment to a department of psychotherapy 
 Completing a course in Interpersonal Therapy 
 Attending a conference in primary care mental health 
 Writing or analysing research papers  
 Developing group work teaching materials 
 Going on a 2-day course on “mentalisation” approaches to psychotherapy 
 Training in website development 
In addition, self-help support workers (who were recruited as graduates in psychology) were 
allocated to spend 2 sessions per week in the local psychology department, where they took 
on a small caseload and received one hour direct supervision from clinical psychologists each 
week. Quarterly meetings for all Doing Well staff were held away from base in order to 
review performance data and review or formulate protocols and standards for the clinical 
service.  
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4.7.2 Primary care staff 
Prior to formally joining the Doing Well programme, the software required to make 
electronic referrals was installed in practices (where this was required) and training was 
offered to practice staff in the referral system.  
Between July 2004 and October 2006, three evening meetings were held to which all GPs in 
Renfrewshire were invited (roughly double the number of GPs already participating in the 
Doing Well programme). These evening meetings combined “didactic” teaching in relation to 
depression management and antidepressant use from local/regional clinical and academic 
speakers with information about the progress of the Doing Well programme and an 
opportunity to share feedback from primary care.  
The formulary was rewritten to give advice on non-drug approaches to depression 
treatment, to emphasise the use of the PHQ to assess depression severity and to give advice 
on using the minimum effective dose of any antidepressant. These messages were 
reinforced by practice visits throughout Renfrewshire by Prescribing Advisors from the 
Health Boards and by ongoing contact with Doing Well staff amongst participating practices.  
The formulary message was supported by the “marketing” by Doing Well of a fictional drug 
called “FluCitamine” to local GPs and secondary care (Figure Figure 4-6). “FluCitamine” was 
actually a mnemonic device to remind prescribers of three formulary choices, and was 
presented to them in a light-hearted way. “FluCitamine” summarised “NICE guidance on a 
pen”. Seven words conveyed a serious message: PHQ assessment should be used to support 
prescribing of one of three formulary drugs for more severe depression only.  These 
activities were made available to all Renfrewshire practices, not only those participating in 
Doing Well.  
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Figure 4-6: "marketing" logo to promote reminder about formulary 
antidepressant use 
 
The Doing Well logo and website address was used on all communications and also 
distributed on promotional mugs to local GPs and other stakeholders (as shown in Figure 4-
7). 
 
 
 
 
 
 
 
Figure 4-7: Doing Well logo and contact details 
www.doingwell.org.uk
info@doingwell.org.uk
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4.7.3 Patients and the public 
A range of printed materials were prepared to support the Doing Well programme. These 
included an information leaflet about Doing Well and depression, and local copies of the 
PHQ that included information about local resources on the reverse side of the measure.  
A website at www.doingwell.org.uk was written which included an online version of self-
assessment using the PHQ, downloadable copies of the PHQ, information about depression 
and “user stories” from people who had benefited from the programme. The website was 
launched by Douglas Alexander, a Member of Parliament for the local area. 
Doing Well received media coverage from the Scottish national newspaper “The Herald”, the 
Scottish national newspaper “The Sunday Post”, the TV news programme “Reporting 
Scotland”, and other publications. Doing Well was also featured on local radio stations “Q-
FM” and the community radio station “Foxbar Radio”.  
Two 8-session courses in self-help using a Cognitive Behavioural Therapy approach were 
delivered by Doing Well staff at a local Further Education College in 2006. Both courses were 
over-subscribed. A range of books, including self-help books, relating to depression were 
purchased for local libraries and a shared publicity event to promote their use was held with 
the Libraries Service of Renfrewshire Council. 
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4.8  Outcome measures 
4.8.1 Clinical outcomes in participating patients 
Four outcome measures were intended to be used to manage clinical care within Doing Well 
and to assess the outcomes of the programme. The measures were as follows. 
1. The Personal Health Questionnaire256  (“PHQ”, completed at referral and each 
subsequent contact) 
2. The Work and Social Adjustment Scale323 (completed at assessment, discharge and 
4-month follow up) 
3. The EQ-5D,324 completed at assessment, discharge and 4-month follow up. 
4. The Client Satisfaction Questionnaire325 (completed at the end of treatment and at 
4-months follow-up) 
Each of these measures is reproduced in the format they were presented to patients in 
Appendix 10.5. 
The PHQ is a self-administered nine-item scale capable of producing a depression rating 
consistent with the Diagnostic and Statistical Manual of Mental Disorder 4th edition (DSM 
IV). The reasons for choosing this clinical outcome measure, and other details regarding its 
validity and reliability were set out in section 3.6.2.4. 
The Work and Social Adjustment Scale323 is a self-complete instrument that asks about 
functioning in five domains: at work, at home, in “social” and “private” leisure activities and 
in close relationships. Originally a 4-item scale (work, home, social, and private leisure) used 
to rate disability in phobia research, Mundt et al323 adapted it to measure the outcome of 
most patients in treatment and later added its fifth item concerning interpersonal relations. 
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The measure was chosen for this study in order to measure functional impairment relating 
to depression. The scale is simple, sensitive and reliable and has been validated for use in a 
primary care population.323  
The EQ-5D is a standardised instrument for use as a measure of health-related quality of life. 
Developed by researchers from seven countries in the “Euroqol” group (including the UK), 
the EQ-5D includes five 5-level dimensions: morbidity, self-care, usual activities, pain and 
anxiety/depression. It is applicable to a wide range of health conditions and treatments, and 
provides a simple index value for health status. The measure is designed for self-completion 
by respondents and can be used in postal surveys, in clinics and face-to-face interviews. It is 
cognitively simple, and takes a few minutes to complete. Population norms have been 
published for a range of countries, including the UK.326 
The Client Satisfaction Questionnaire (CSQ)325 is an 8-item self-completed measure that is 
able to provide a brief, standardised assessment procedure applicable to a range of service 
settings. It is designed to be a direct measure of an patient’s personal experiences with a 
service, rather than with health care services in general.327 The measure has been shown to 
have high internal consistency, and to relate to change in client-reported symptoms.328  
Although patients completed each of these measures, this research used only the PHQ to 
assess clinical outcomes in practice. The Work and Social Adjustment Scale, EQ-5D and Client 
Satisfaction Questionnaire were completed as part of the standard assessment by Doing 
Well staff, and completion rates at intake for the former two measures were high. However 
the rates of completion for the measures at discharge and particularly at follow-up were 
very low. Despite written and telephone reminders requesting patients to complete and 
return the measures at discharge and four-month follow-up, only a minority did so, and only 
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about 20% of patients completed the follow-up assessment at four months. These measures 
have not therefore been subjected to further analysis.  
Following Frank,329 response was defined as a clinically significant reduction in symptoms 
following the onset of treatment, and remission as the virtual absence of depressive 
symptoms. In operational terms, “remission” was considered to be a final PHQ score of five 
or less.253,263,264 “Response” was defined as either a drop of five or more in PHQ score or a 
reduction of at least 50% in PHQ score during the course of treatment.321,322  
Clinical outcomes were analysed by age at referral, gender, and deprivation quintile derived 
from the Scottish Index of Multiple Deprivation (SIMD).   
 
4.8.2 Measures of prescribing change 
The primary outcome measure for this study was change in the Defined Daily Dose (DDD) of 
antidepressants prescribed for the catchment population covered by the Doing Well service, 
compared with local and national controls. A Defined Daily Dose is a theoretical unit of 
measurement defined by the World Health Organisation as the “assumed average 
maintenance dose per day for a drug used for its main indication in adults.” This measure 
and its strengths and weaknesses are described in section 3.3.6.  
The Gross Ingredient Cost (GIC) is a standard measure of drug cost, and represents gross 
ingredient cost to the NHS for an individual drug, before any discount is applied. Alternative 
measures of drug costs include “Net Ingredient Cost” (the cost of drugs and appliances after 
deduction of any discount, plus special payments made to dispensing doctors) and Gross 
Cost (Net Ingredient Cost, plus any additional payments, dispensing fees and allowances 
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centrally paid). Gross Ingredient Cost was chosen for the pragmatic reason that it is routinely 
available.330 Formulary compliance is also reported for the Doing Well practices, being the 
proportion of all antidepressant defined daily doses accounted for by the formulary drugs 
fluoxetine, citalopram and lofepramine.  
Prescribing information in Scotland is collated and published by the Information and 
Statistics Division of the Scottish Government, and that data is the source of the prescribing 
information reported in this study. This information is gathered nationally based on 
pharmacy returns, and reported at practice level. Data is reported quarterly, and is 
independent of Doing Well or any local stakeholder. 
Routinely-collected prescribing information in Scotland only counts the amount of drug 
dispensed, but not the dose to be taken or the duration of treatment. The implications of 
this for the assessment of prescribing change are discussed in section 3.3.6 of the Literature 
Review.  
Scottish data does not allow for a linkage to be made between drug use and the condition 
for which it was prescribed. For example, it is not possible to know what proportion of 
amitryptiline use relates to depression and what proportion is prescribed for other 
indications such as enuresis or neuropathic pain. 
The information about antidepressants that is collected by the Information Services Division 
is based not on prescriptions written, but on drugs dispensed.  There is significant, regular 
variation in the defined daily doses dispensed each month, as discussed in section 3.3.6.2 of 
the literature review.  
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For these reasons, analysis of prescribing in this study uses WHO definitions of DDDs, reports 
prescribing rates by month (adjusted for days in the month), and makes comparisons against 
equivalent periods year-to-year. The study analyses DDDs per 1,000 population using 
monthly practice populations for local areas and annual population estimates for 
comparison with the rest of Scotland. These are the most detailed data available in both 
instances. Although the evaluation of clinical outcomes represents the first 27 months of the 
implementation of Doing Well to October 2006, prescribing data is presented to February 
2008, since there may be a time lag between the implementation of a new service and a 
response in terms of prescribing practice.  
 
4.8.3 Comparisons of antidepressant prescribing 
Neighbouring practices (referred to as “non-Doing Well” practices) were part of the 
Renfrewshire Community Health Partnership. They had access to the same secondary care 
mental health services, and also were able to attend educational meetings held by Doing 
Well during which the key messages – only prescribe for more severe depression, and use 
formulary choices whenever possible – were promoted. Non-Doing Well practices also 
received some Doing Well-authored promotional and educational material, just as the Doing 
Well practices did. The main difference between the Doing Well and non-Doing Well groups 
was therefore in terms of their access to the Doing Well clinical service for people with 
depression. Unable to use this resource, non-Doing Well practices would instead have used 
the local community mental health team and psychology resource.  
These 16 practices served a population of 101,000 people. All practices in NHS Argyll and 
Clyde had access to Prescribing Advisors at the time of the study. These were pharmacists 
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employed by NHS Greater Glasgow and Clyde to review prescribing in the Health Board area 
and offer feedback and guidance on best practice.  These pharmacists operated 
independently of Doing Well.  
The characteristics of the differing groups are set out in Table 4-3.  
 Access to full 
Doing Well clinical 
intervention 
Doing Well 
promotional/ 
educational 
material 
Prescribing 
advisors 
Doing Well  
(Renfrewshire, 76,000 pop) 
   
Doing Well neighbours 
(Renfrewshire, 101,000 pop) 
   
Inverclyde 
(~90,000 pop) 
   
Scotland 
 
  +/- 
 
Table 4-3: characteristics of areas used to compare changes in antidepressant 
prescribing 
 
Three outcomes were measured: 
 change in defined daily doses of antidepressants per 1,000 population  
 change in gross ingredient cost  
 change in proportion of prescriptions consistent with a three-drug local 
antidepressant formulary (Renfrewshire/Inverclyde only) 
 
For each of these three parameters, data was averaged for January to June 2004 (the six 
months before the Doing Well programme was implemented) and for September 2006 to 
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February 2008 (the most recent data then available). Defined Daily Doses per 1,000 
population for each participating and control practice was used to calculate the actual DDDs 
prescribed for each practice each month. Dispensed Gross Ingredient Cost (GIC) per practice 
per month was recorded. Since these data sources record all dispensed prescriptions in 
Scotland, there was no missing data.  
 
4.8.4 Service throughput 
Referral rates from each GP practice, waiting times and duration and number of total 
contacts were recorded for every patient. The system also collated information about age, 
gender and postcode. Deprivation was measured by linking each postcode with the 
deprivation decile or quintile for that data zone according to Information Services Division 
data.    
 
4.8.5 Statistical Analysis  
Baseline demographic statistics are shown descriptively.  
The primary outcome measure was an assessment of change in Defined Daily Doses of 
antidepressants prescribed by the Doing Well practices compared with other practices in 
Renfrewshire and Inverclyde, and in Scotland as a whole.  
Secondary analyses were conducted to describe the characteristics of the patients using the 
service, and to assess the clinical outcomes for patients in terms of change in PHQ scores.  
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Variables were compared between groups with 2-sample t-tests or ANOVA. Within-group 
differences were compared using paired statistical methods.  
Relationships between numerical variables were measured using correlations. χ2 was used to 
test associations between categorical variables. Multiple regression analysis was used to test 
the effects of several variables on the main outcomes of interest.  
All analyses were carried out with Minitab statistical software (version 15.1), using 
significance levels of five percent. 
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5. Results 
 
5.1 Service use 
All patients referred to "Doing Well" during the three-month pilot period (July 04-Oct 04) 
and all patients referred during the first 24 months of the full programme implementation 
(Oct 04- Oct 06) are included in the following analysis, with the exception of two patients 
who declined consent for anonymised information about their care to be used for research 
purposes.  
5.1.1 Referral patterns 
The number of referrals to the service gradually increased each month as more practices 
joined the programme. The monthly referral rate for all practices is represented in Figure 5-
1.  It shows, as anticipated, that there was a gradual increase in monthly referrals to the 
programme which stabilised after February 2006, by which time all practices had been 
recruited.  
The capacity of "Doing Well" to cope with new referrals had been estimated to be about 100 
new referrals per month. The average referral rate from March 2006 after full recruitment of 
practices was 99.5 referrals per month.  
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Figure 5-1: number of referrals by month 
 
However, after the “pilot” period ended in October 2004, monthly referrals remained 
broadly stable, averaging 1.20 referrals/month/1,000 population (Figure 5-2).  
 
 
Figure 5-2: Referral rate per month per 1,000 catchment population 
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As Figure 5-3 shows, there was substantial variation in referral rates between practices, with 
a range between 0.77 referrals per month per thousand population and 2.24 referrals per 
month per thousand population. 
 
 
Figure 5-3: Referral rate per month per 1,000 practice population by practice 
 
In other words, even after adjustment for list size and date of joining, some practices still 
referred three times more than others. Regression analysis did not show any association 
between the referral rate and the mean deprivation decile (regression coefficient -0.11; 
p=0.215) or mean PHQ at referral (regression coefficient 0.09; p=0.167). The observed 
variation in referrals must therefore relate to other factors, including individual practitioner 
behaviour. 
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5.1.2 Waiting times 
The mean waiting time between referral and first appointment was 17 days, and the median 
wait 15 days as shown in Figure 5-4. One thousand and eleven out of 1165 patients (87 %) 
were seen within 4 weeks of referral. Longer waiting times often resulted from patient 
requests, or reflected reduced staffing because of absence or annual leave. 
 
Figure 5-4: Duration of patient waiting times by week 
 
5.1.3 Flow of patients through the service 
Patients were grouped into the following “outcome categories” for further analysis (Table 5-
1).  
  
1w 2w 3w 4w >4w
% 19% 32% 23% 13% 13%
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Category 
 
Definition  
Inappropriate referral Did not meet inclusion criteria for participation 
Did not attend  
People offered an appointment but who then: 
declined referral to service, or 
did not attend any appointment offered, or 
did not “opt-in” to revised appointment system introduced in August 
2006 
Transfer of care 
Required input from other services and discharged to their care 
 
Disengaged  
Dropped out of treatment after at least one contact and did not 
respond to further invite to re-engage 
Treatment complete 
All care and assessments carried out in keeping with protocol 
 
 
Table 5-1: definition of outcome categories 
 
A total of 1,584 patients were referred during the study period. Eighty-one patients referred 
(5%) did not meet inclusion criteria and are not included in further analysis. This group 
included 28 people aged over 65 years. Two further patients were excluded from analysis at 
their request. The experience of the programme was that the proportion of inappropriate 
referrals was highest within the first few weeks of practice recruitment, and diminished 
thereafter in response to feedback from "Doing Well" clinicians. 
Of 1,501 patients eligible for inclusion in the study, 294 (20%) did not attend any 
appointment offered. Thirty-eight people (3% of those eligible) declined the offer of an 
appointment.  Therefore 332 (22%) people were appropriately referred but dropped out of 
the programme before assessment.  
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Of this 1,501 people eligible to join the study, 1169 (78%) attended at least one 
appointment.  Six hundred and fifty-four people (44% of eligible patients) completed 
treatment in accordance with the protocol.  
Three hundred and twenty people (21%) “disengaged” from treatment after being seen at 
least once. This group includes one patient who died and ten who moved away, as well as 
those who chose not to maintain contact with the service. The one death known to the 
service was the result of suicide. An internal review was conducted of this suicide and did 
not find any deficiencies in care provided by the Doing Well team. The “disengaged” group 
includes people who did not respond to treatment as well as people who had been showing 
signs of clinical improvement.  
One hundred and ninety-five of the 1501 eligible patients (13%) were transferred to other 
services for ongoing care.  
In total therefore, 849 patients (57%) either completed treatment or had their care 
transferred to more appropriate services. 652 patients (43%) either did not attend for 
treatment or dropped out of care before the planned treatment had been completed.  
The flow chart in Figure 5-5 outlines the numbers of patients falling into the “outcome 
categories” described above.    
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All patients referred 
1584 
654 
 (44%) Treatment 
complete 
1169 (78%) attended at 
least once  
195 
 
 (13%) Transfer of 
care 
320 
 
 (21%) Disengaged 
Figure 5-5: Flow chart of subjects referred to programme July 04- October 06 
Not seen:  81 (5%)  
did not meet inclusion criteria 
 Met inclusion criteria 
1501 (100%) 
Not seen:  332 (22%)  
 
38 (3%) declined service 
294 (19%) did not attend any appointment 
 
Not included: 2 (<1%) 
Excluded from analysis at patient request 
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5.1.4 Demographic characteristics of people referred 
The demographic characteristics of all patients who met inclusion criteria are summarised in 
Table 5-2. Comparisons between groups for these parameters are made in the following 
subsections.  
Outcome category 
Mean age  
(standard 
deviation) 
percentage 
female 
Mean 
deprivation 
decile 1-10 
(standard 
deviation) 
Mean PHQ 
score at 
referral 
(standard 
deviation) 
All  
(n=1,501) 
37.46  
(12.19) 67% 
5.21 
(3.01) 
17.05 
(5.20) 
Did Not Attend 
(n=332) 
33.05 
(11.78) 66%  
4.55 
(2.82) 
17.12  
(5.50) 
Disengaged 
(n=320) 
35.25 
(11.48)  68%  
4.86 
(2.96) 
17.33  
(5.01) 
Transfer of care 
(n=195) 
38.83  
(11.87) 65% 
4.94 
(2.98) 
17.54  
(5.55) 
Treatment complete 
(n=654) 
40.38  
(11.98) 68% 
5.79  
(3.02) 
16.73  
(5.01) 
 
Table 5-2: demographic characteristics of patients referred, shown for all referrals and 
for outcome categories.  
 
5.1.4.1 Age & Gender 
Sixty-eight percent of people referred to the programme were female, as shown in Table 
5-2. The gender ratio in the outcome categories varied slightly, but was not statistically 
significant (χ2 test).  
The mean age of patients referred to the service was 37.5 years. Between-group differences 
were examined using one-way ANOVA, which showed that the “disengaged” and “did not 
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attend” groups were significantly younger than the “treatment complete groups” (p<0.001 
for both); there was no significant difference in age between the “treatment complete” and 
“transfer” groups (p=0.442). Mean ages for the different outcome categories are shown in 
Figure 5-6.  
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5-6: age at referral for different outcome categories showing 95% confidence intervals. 
Note y axis does not start at zero. 
 
The chart in Figure 5-7 shows the proportion of Doing Well referrals in different age 
categories, compared with the proportion of the Renfrewshire population in those 
categories.331 Note that census data for the Renfrewshire area is only available for the 15-24 
age category,331 although Doing Well only received referrals for people aged 18 or more. 
Nonetheless, the data shows that Doing Well received a greater proportion of referrals for 
people aged less than 45 years than would be expected in the general population. Seventy 
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percent of eligible Doing Well referrals were for people aged under 45 years, although this 
group represent only 62% of the general population.  
 
Figure 5-7: histogram of referrals by age group to Doing Well (DW) compared with 
equivalent age categories in the Renfrewshire population. Note that the “15/18-24” age 
group shows the proportion of people in Renfrewshire aged15-24, but Doing Well 
referrals were aged 18-24.  
 
5.1.4.2 Deprivation 
Referrals were received from patients living in postcodes in all deprivation quintiles.  
Analysis of variance was used to test for differences between the outcome categories in 
relation to deprivation scores, and the “treatment complete” group were found to be 
significantly less deprived than any other category (p<0.001 for disengaged and DNA groups, 
p=0.004 for “transfer of care” group). Mean deprivation deciles for each of the outcome 
categories are shown in Figure 5-8. 
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Figure 5-8: mean deprivation decile for patients in each outcome category 
 
These figures are compared with population data for Renfrewshire as a whole in Figure 5-9, 
which shows the proportion of the Renfrewshire population living in each deprivation 
quintile, and the proportion of Doing Well referrals received from that quintile.  
There were slightly more referrals to Doing Well from the two most deprived quintiles  (47%) 
than would have been expected from the proportion  of the population living in those areas 
(41%). Conversely, there were slightly fewer referrals from the most affluent quintiles (35%), 
although 38% of the population live in those areas.  
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Figure 5-9: Renfrewshire population and referrals by deprivation quintile 
 
5.1.4.3 Ethnicity 
Information about ethnicity was not routinely collected as part of this study.  
5.1.4.4 Depression severity at referral 
Overall, 453 (30%) of the 1501 referrals had mild to moderate depression (PHQ<15 at 
referral), and 1050 (70%) of patients had moderately severe to severe clinical depression 
(PHQ=>15 at referral), as shown in Figure 5-10.  
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Figure 5-10: number of referrals by PHQ category at referral 
 
The mean PHQ score at referral for women was 17.3 and was 16.6 for men, a statistically 
significant finding (p=0.041, 95% confidence interval for difference 0.025- 1.280). There was 
no significant difference in depression severity at referral (as measured by average PHQ) 
between people in the different outcome categories (Figure 5-11).  
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Figure 5-11: mean PHQ score at referral for outcome categories. Note y axis does not 
start at zero. 
 
5.1.5 Number of contacts and duration of treatment 
The mean number of clinical contacts for subjects in different outcome categories who 
attended at least one appointment is shown in Figure 5-12. Patients completing treatment 
had an average of 5.0 contacts, and those disengaging from treatment had 4.1. The fewest 
contacts (3.8) were seen in the “transfer” group who continued treatment in other settings. 
Both the “disengaged” and “transfer of care” group were significantly different from the 
“treatment complete” group (p<0.001 for both), but the “disengaged” and “transfer of care” 
groups were not significantly different from each other (p=0.203).  
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Figure 5-12: mean number of clinical contacts by discharge category 
  
“Treatment time” was recorded as the time spent in personal contact with a patient, which 
was principally accounted for by face-to-face meetings, but also included some telephone 
and email contact. Administrative time (writing letters or completing paperwork) was not 
included in “treatment time”. There were significant differences in total treatment time 
between groups.  
Figure 5-13 shows the mean duration of treatment time by outcome category. Mean contact 
time was 151 minutes for patients completing treatment (median 135 minutes), 95 minutes 
for the “disengaged” group (median 80 minutes) and 125 minutes for the “transfer” group 
(median 100 minutes).  
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Figure 5-13: mean duration of treatment time by outcome category 
 
When the three groups were compared using one-way ANOVA, the differences between the 
treatment “complete”, “transfer” and “disengaged” groups were all statistically significant 
(p<0.001).  
Figure 5-14 shows that the “treatment complete” group spent an average of 102.5 days in 
treatment. The corresponding time in treatment was 79.5 days for the “disengaged” group 
and 67.1 days for the “transfer” group. Analysis using one-way ANOVA showed that there 
was no significant difference between the “disengaged” and “transfer of care” groups 
(p=0.238), but that the “treatment complete” group was different from both the 
“disengaged” and “transfer of care” groups (p<0.001 for both).  
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Figure 5-14: mean duration of treatment in days from first to last appointment  
 
5.1.6 Characteristics of “Did Not Attend” group 
The following figures compare the characteristics of the “Did Not Attend” group with people 
who attended at least once (“treatment complete”, “transfer” and “disengaged” groups).  
The 332 people in the “Did Not Attend” group were significantly more likely to be younger 
than the 1169 patients who attended for treatment (mean difference -5.6 years, p<0.001) 
and more likely to come from a more deprived area (mean deprivation quintile -0.04, 
p<0.001).  
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There was a slightly higher proportion of men (34.2%) in the “Did Not Attend” group 
compared to those who were seen (33.3%), but this was not statistically significant (χ2 test, 
p>0.1). However, there was a significant difference in the mean wait to be seen, with those 
who did attend for treatment having a slightly shorter waiting time (Table 5-3; p<0.001).  
 Wait time to first 
appointment 
Mean 95% CI 
DNA 19.1 17.8- 20.5 
Seen 17.0 16.3-17.6 
 
Table 5-3: wait time to first appointment for “Did Not Attend” group 
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5.2 Clinical outcomes 
5.2.1 Change in PHQ by outcome category 
The primary clinical outcome measure was depression severity as measured by the Personal 
Health Questionnaire (PHQ). The change in PHQ score was derived by subtracting the last 
available score recorded by the "Doing Well" team from the score recorded by the GP at 
referral.  
A decision was made not to include the “did not attend” (DNA) group in analysis of 
outcomes because the only PHQ score available for this group was that recorded by their GP 
at referral. This group did not receive any further treatment or have any other PHQ scores 
recorded.  
A conservative analysis might consider the DNA group part of the “intention to treat” cohort, 
and carry forward this referral PHQ to represent the “final” observation as if treatment had 
been completed. However including the DNA group in this analysis would bias the outcomes, 
particularly as the drop-out mechanism was non-random (since younger patients, males and 
people living in deprived areas were more likely to drop out than others).332   
For the treatment complete groups the last available score was the PHQ recorded on 
discharge. For the disengaged and transfer groups, the PHQ was the “last observation 
carried forward” from the final contact. Since a low initial PHQ score has less scope for 
absolute change than higher scores, percentage change in PHQ score was also used to 
describe clinical change.  
The analysis of change in PHQ will be done two ways. The following measures will be 
reported for the whole cohort:  
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 the mean change in PHQ from referral to last available score 
 the percentage change in PHQ from referral to last available score 
 the proportion of patients showing a reduction of 50% or more in their PHQ (“clinically 
significant” change)  
Patients referred to Doing Well with a PHQ score of ten or more (indicating depression of at 
least “moderate” severity253) were included in a subgroup analysis of the following 
measures: 
 the proportion of patients showing a drop of PHQ of 5 points or more (“clinically 
significant” change) 
 the proportion of patients showing a reduction in PHQ to 5 points or less (“recovery”) 
 The proportion of patients showing a reduction in PHQ to 10 points or less (“remission”) 
Analysis was conducted in this way because it would not be clinically or arithmetically 
appropriate to attempt to calculate PHQ change of five or more points in patients who may 
have scored below that level on referral. Similarly, anyone referred with a PHQ below ten 
would be considered to be “in remission” before treatment had begun.   
 
5.2.1.1 Mean change in PHQ 
The mean change in PHQ for each outcome category is shown in Table 5-4. Analysis of the 
change in mean PHQ before and after treatment using paired samples t-tests is significant 
for the total cohort (p<0.001), and individually for the transfer group (p<0.01), disengaged 
and treatment complete groups (p<0.001).  
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Mean 
Difference 
t df significance 
95% Confidence 
Interval  
All  5.08 27.65 1497 < 0.001 4.72- 5.44 
Treatment 
Complete 
10.60 44.80 653 < 0.001 10.14-11.07 
Disengaged 1.37 4.76 314 < 0.001 0.80- 1.94 
Transfer of 
Care 
1.26 2.73 189 .007 0.35- 2.18 
 
Table 5-4: change in PHQ from referral to last available score by outcome category 
 
Although statistically significant, the small changes in PHQ noted in the disengaged and 
transfer groups (drops of 1.37 and 1.26 PHQ points respectively) do not represent a clinically 
meaningful change. The mean drop of 10.6 PHQ points in the treatment complete group is 
both statistically significant and clinically meaningful.  
5.2.1.2 Percentage change in PHQ 
 
Figure 5-15 shows the percentage change in PHQ from assessment (change in PHQ 
score/PHQ at referral) over the course of treatment. PHQ changed by only 3% in the 
disengaged and transfer of care groups, but there was a 61.8% reduction in PHQ score for 
the treatment complete cohort.  
Oneway ANOVA showed significant differences between the outcome categories in relation 
to percentage change in PHQ. The treatment complete group was significantly different 
from both the transfer of care and disengaged groups (p<0.001), but the transfer and 
disengaged groups were not significantly different from one another (p=0.99).  
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Figure 5-15: mean percentage change in PHQ from assessment to last observation for 
disengaged (n=320), transfer (n=195) and treatment complete (n=654) groups 
 
5.2.1.3 Proportion of patients showing improvement of 50% or more 
Figure 5-16 shows the proportion of patients in each discharge category showing an 
improvement in PHQ of 50% or more. The difference in outcomes for the “treatment 
complete” cohort was statistically significant when compared with people in the 
“disengaged” and “transfer” categories (n=1157, χ2=504, p<0.001). 
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Figure 5-16: percentage of patients with a PHQ fall or 50% or greater by discharge 
category 
 
5.2.1.4 Proportion of patients improving by five or more PHQ points 
A drop of 5 points or more was considered a clinically significant change in depression 
status.263 The following analysis was conducted on the 1,082 patients who were referred 
with a PHQ of ten of more.  
Figure 5-17 shows that 90% of the treatment complete group (n=602), 30% of the 
disengaged group (n=300) and 26% of the transfer group (n=180) achieved a “clinically 
significant” change in their depression status by the end of their engagement with Doing 
Well by this definition.  Comparing patients in the “treatment complete” group with 
“disengaged” and “transfer of care” groups showed a statistically significant difference in the 
frequency of patients showing clinically significant change (χ2= 371.644, DF = 2, p<0.001). 
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Figure 5-17: percentage of patients with a PHQ fall greater or equal to 5 by discharge 
category (initial PHQ ≥10; n=1082) 
 
 
5.2.1.5 Recovery or partial remission  
A final PHQ score of less than five was considered to be “remission”,253 and a PHQ score of 
less than ten was considered to represent partial recovery. Since such terminology is only 
appropriate for clinical cases, the following analysis was conducted for the 1,082 people 
referred to Doing Well with a PHQ score of 10 or over in the “treatment complete” (n=602), 
“transfer of care” (n=180) and “disengaged” (n=300) groups.  Figure 5-18 shows that the 
proportion of patients referred with a PHQ score of ten or more who left treatment with a 
PHQ of less than five was 42% in the treatment complete group, and 1% and 3% in the 
disengaged and transfer of care groups respectively. Seventy-nine percent of people in the 
treatment complete group had a PHQ score between of less than ten at the end of 
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treatment, compared with 7% in the “disengaged” and 10% in the “transfer of care” groups. 
These changes are statistically significant (χ2= 248.471, DF = 2, p< 0.001) 
 
Figure 5-18: proportion of patients with a final PHQ of less than 5 ("remission") or less 
than 10 ("partial recovery") categories (initial PHQ ≥10; n=1082) 
 
5.2.2 Factors associated with PHQ change 
5.2.2.1 Gender 
There was a significant effect of gender on PHQ outcomes, with women (who had a slightly 
higher PHQ score at referral) showing an average PHQ improvement of 1.36 points greater 
than men in all the groups (p=0.006, 95% confidence intervals  0.40- 2.33).   
Disengaged Transfer of care Treatment complete
% final PHQ<5 1% 3% 42%
% final PHQ<10 7% 10% 79%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
pe
rc
en
ta
ge
 w
it
h 
fin
al
 P
H
Q
le
ss
 th
an
 5
or
 le
ss
 th
an
 1
0 
186 Results 
 
5.2.2.2 Age  
A normal linear regression model was used to examine the association between the age of 
subjects and change in PHQ by the end of engagement with treatment.  
There was no statistically significant association between age and PHQ change at endpoint 
for any group (disengaged p=0.16; transfer of care p=0.51; treatment complete p=0.70). 
These results are shown in Figure 5-19 for the treatment complete group only. 
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5-19: interval plot showing means (circles) and 95% confidence intervals (bars) for the 
mean for the relationship between age and PHQ change (treatment complete group only 
shown here).  
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5.2.2.3 PHQ at referral 
There was a clear positive association between the severity of the PHQ score at referral and 
the absolute reduction in PHQ at discharge for all groups (disengaged R2=0.21, p<0.001; 
transfer of care R2=0.18, p<0.001; treatment complete group R2=0.38, p<0.001).  
However this is in part an arithmetic effect, since low initial PHQ scores have less scope for 
absolute change than higher scores. Expressing change during treatment as the “percentage 
change” (i.e. change in PHQ score during treatment divided by PHQ at referral) eliminates 
most of this effect. However there is still a significant association between higher PHQ 
scores at referral and percentage reduction in PHQ score (treatment complete group 
R2=3.2%, p<0.001). Figure 5-20 shows mean percentage reduction in PHQ for different 
categories of PHQ scores at referral.   
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Figure 5-20: interval plot showing means (circles) and 95% confidence intervals (bars) 
for PHQ at referral against percentage change in PHQ (treatment complete group only 
n= 654). 
 
5.2.2.4 Deprivation 
A normal linear regression model was used to examine the association between the 
deprivation and reduction in PHQ after treatment. The model suggested that patients living 
in the most deprived areas were more likely to show the least clinical improvement 
(p=0.020). Although statistically significant, the effect was small (regression coefficient of 
2.32, R2= 0.5%), and not evident when the outcome categories were examined individually 
(“disengaged” R2=0.1%, p=0.52; ”transfer of care”R2=1.0%, p=0.17; “treatment complete” 
R2=0.2, p=0.22). The relationship between percentage reduction in PHQ and deprivation 
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scores are represented in Figure 5-21 for the “disengaged”, “transfer” and “treatment 
complete” groups, and in Figure 5-22 for the “treatment complete” group alone .  
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Figure 5-21: interval plot showing means (circles) and 95% confidence intervals (bars) 
for influence of deprivation on PHQ change for “disengaged”, “transfer” and 
“treatment complete” groups. 1 is the most and 5 the least deprived quintile. 
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Figure 5-22: interval plot showing means (circles) and 95% confidence intervals (bars) 
for influence of deprivation on PHQ change in the treatment complete group only; 1 is 
the most and 5 the least deprived quintile. 
 
5.2.2.5 GP practice  
There was no significant association between GP practice and clinical outcome as expressed 
by “percentage PHQ change”. Figure 5-23 shows an interval plot of PHQ change for patients 
in each participating GP practice.  
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Figure 5-23: interval plot showing means (circles) and 95% confidence intervals (bars) 
for percentage change in PHQ by GP practice for the “treatment complete” group, 
n=654.  
 
5.2.2.6 Number of visits 
A similar pattern is observed when the mean PHQ change is plotted for each patient contact. 
Subjects who subsequently disengaged from treatment showed little early change in their 
PHQ scores, unlike those in the treatment complete group (Figure 5-24).  
By contrast, there is a clear reduction in PHQ score at each visit after the first for the 
treatment complete group. Most people were discharged from Doing Well with a fall in PHQ 
to around ten or below. Most people achieved this fall in PHQ within four or five treatment 
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contacts. A minority of patients required a much longer period of contact to achieve the 
same PHQ reduction.  
 
Figure 5-24: Graph showing mean PHQ scores and number of subjects at each contact 
point (1= referral PHQ) for disengaged and treatment complete groups. Data not shown 
for contacts beyond 7 as n<20 in disengaged group.  
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5.2.3 Antidepressant use 
5.2.3.1 Antidepressant use and PHQ score 
There was a clear correlation between the severity of the PHQ score at referral and the 
likelihood of receiving an antidepressant prescription (Figure 5-25). PHQ scores at referral 
were significantly higher in patients taking antidepressants at some point during treatment 
(p<0.001, 95% CI for difference -4.1, -3.0; Figure 5-26). 
 
5-25: percentage of patients receiving an antidepressant prescription by PHQ score 
(total subjects 1169; PHQ 0-4 n=10; PHQ 5-9 n=76; PHQ 10-14 n= 259; PHQ 15-19 
n=408; PHQ 20-27 n=385) 
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5-26: graph showing relationship between PHQ score at referral and patients taking (Y, 
n=358) or not taking (N, n=283) an antidepressant during treatment for treatment 
complete group. 13 missing data points. NB y axis does not cross at zero.  
 
5.2.3.2 Antidepressant use and deprivation 
There was no significant correlation between the mean deprivation decile for patients 
referred in each practice and the proportion of patients from that practice who received an 
antidepressant (Pearson’s r= -0.07, R2=43%, p=0.82). 
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5.2.3.3 Antidepressant use and clinical outcomes 
641 of 654 subjects in the treatment complete group had their antidepressant use recorded 
at the beginning of treatment. Self-reported antidepressant initiation or concordance was 
recorded at each subsequent Doing Well visit.  
People who took an antidepressant in the treatment complete group showed a mean fall in 
their PHQ score by end of treatment of 11.71 points, whereas those who did not take an 
antidepressant showed a fall of 9.20 points (paired t-test p<0.001, 95% CI for difference:  -
3.423, -1.588). 
However, once again, analysis of the mean fall in PHQ is confounded by the fact that higher 
PHQ scores have more scope to reduce than lower scores, and patients with higher PHQ 
scores were more likely to be prescribed an antidepressant. Repeating this analysis but using 
percentage PHQ change rather than absolute PHQ change did not show any significant 
difference between patients who did or did not take an antidepressant (p=0.415, 95% CI for 
difference -6.91, 2.86; Figure 5-27).  
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Figure 5-27: mean and 95% confidence intervals for percentage PHQ change over 
baseline for treatment complete group. No= no antidepressant prescribed (n=283); 
Yes= antidepressant prescribed (n=358); 13 missing data points 
 
An analysis of antidepressant effect was not carried out for the disengaged and treatment 
complete groups, since they may not have taken antidepressants for a sufficient period to 
gauge an effect of treatment.  
The mean percentage PHQ change is shown for people who did and did not take 
antidepressants in Figure 5-28 for different categories of PHQ score at referral. As discussed 
above, the severity of depression at referral (plotted on the x axis) was associated with the 
amount of change in PHQ over the duration of treatment. However antidepressant use was 
not associated with a statistically significant effect for subjects with equivalent depression 
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severity at referral. However data was only available to show whether the patient was taking 
an antidepressant at some point during contact with Doing Well, and there is no information 
to record dose or concordance. This data is therefore not robust enough to be analysed 
further. 
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Figure 5-28: Percentage PHQ change from referral to discharge, shown by PHQ at 
referral and antidepressant use (“N”= no antidepressant prescribed, n=253; 
“Y”=antidepressant prescribed, n=358; 13 missing data points). Bars show 95% 
confidence intervals.  
 
198 Results 
 
5.2.4 Transfer of care 
One hundred and ninety-five people (13%) were transferred to other services for ongoing 
care (represented in Figure 5-29). Of this group, 21 (11%) were referred to psychiatry, 23 
(12%) were referred to psychology and 16 (8%) referred to psychotherapy. Psychiatry, 
psychology and psychotherapy therefore took over the care of 1.4%, 1.5% and 1.1% 
respectively of the 1501 eligible referrals respectively. 
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Figure 5-29: services used for the 195 patients (13% of eligible subjects) transferred 
requiring non-""Doing Well" care 
 
The Community Mental Health Team received 15 transfers from Doing Well, which 
represents 1.0% of all eligible patients referred to Doing Well. Thirty-one patients (16% of all 
transfers) were referred back to their GP because they required further management for 
problems other than depression. Twenty-nine patients (14.9% of transfers of care) were 
referred on for counselling outside the NHS, and 36 patients (19% of transfers of care) were 
referred on for other treatment outside the NHS. A common source of referrals was to a 
local employment support service; other resources included a local authority funded family 
support centre, support groups run by the local voluntary sector and benefit and housing 
advice centres.  
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5.3 Prescribing change 
Prescribing information in this section includes data from the study period used to describe 
clinical outcomes (July 04 to Oct 06) but has been extended to June 2008, so as to include 
more information about population prescribing available at the time of analysis. This allows 
for a fuller evaluation of prescribing trends than the more limited clinical dataset affords, 
and takes account of any latency in effect from the introduction of a new service to any 
possible change in prescribing.  
5.3.1 Defined Daily Doses 
Figure 5-30 shows the change in defined daily doses (DDDs) of antidepressants prescribed in 
four areas: the practices participating in this evaluation (“DW”), the practices in the rest of 
Renfrewshire who did not have access to the clinical service (“non-DW”), Inverclyde (which 
does not include Renfrewshire) and Scotland as a whole.  
Note that the Scottish data includes the Doing Well practices, since it was not possible 
accurately to remove these practices from the national dataset. Since the Doing Well 
practice population (76,013) represents only 1.49% of the General Register Office mid-year 
2006 estimate for the Scottish population (5,116,900), any effects will be minimal, and will 
tend to underestimate the effect of any change as a result of Doing Well.  
It can be seen that the Doing Well practices prescribed slightly more than the Scottish 
average in the year prior to the Doing Well programme beginning. As the programme 
recruited the fourteen practices by August 2005, the defined daily doses prescribed began to 
fall below the Scottish average, and continue to diverge through to the end of this period in 
June 2008.  
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Figure 5-30: mean defined daily doses (DDD) prescribed per 1,000 population for the 
each quarter between July 2003 and June 2008 for Doing Well (DW) practices, 
neighbouring practices in Renfrewshire (non-DW), Inverclyde and Scotland. Note y axis 
does not cross at z 
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By contrast, prescribing in the non-Doing Well Renfrewshire practices and in Inverclyde 
continued to increase, broadly in keeping with the Scottish national average. Prescribing in 
both these areas was significantly higher than the national average or that in the Doing Well 
practices before the programme began.  
The mean DDD/1000 for each of the twelve months before the Doing Well intervention (July 
03 – June 04) were compared with the twelve months to June 08 using paired samples t-
tests. Significant changes in Defined Daily Doses of antidepressants prescribed before and 
after the Doing Well intervention were observed in all the areas of interest. However, the 
mean change was much less in the Doing Well practices compared with “control” areas.  
area 
Mean 
change in 
DDD/1000 
Standard 
Deviation 
95% 
Confidence 
Intervals 
t p 
Doing Well  107.8 108.1 39.1- 176.5 3.5 0.005 
Non-Doing Well 313.2 119.2 237.5- 389.0 9.1 < 0.001 
Inverclyde 448.6 84.1 395.2- 502.0 18.5 < 0.001 
Scotland 309.4 101.8 244.7- 374.2 10.5 < 0.001 
 
Table 5-5: mean change in monthly DDDs/1000 population before (July 2003 to June 
2004) and after (July 2007 to June 2008) the Doing Well Intervention. 
 
The same information is also presented graphically in Figure 5-31. 
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Figure 5-31: increase in DDD/1000 population between 2003/4 and 2007/8 for four 
areas of interest. DW= “Doing Well”, IC= Inverclyde, non-DW= “non-Doing Well” 
 
Comparison of between-group increases in prescribing over the same period using one-way 
ANOVA showed significant differences (F=13.71, p<0.001). The increase observed in Doing 
Well practices was significantly less than that seen in non-Doing Well, Inverclyde and 
Scotland-wide areas (p<0.001 for all; 95% confidence intervals shown in Figure 5-32). There 
were no significant difference in change in prescribing over this period between the non-
Doing Well and Scottish practices (p=0.996). However, Inverclyde showed a significantly 
higher increase in prescribing than any other control area (p< 0.02 for all).  
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Differences in 
mean DDD/1000 
p 
95% Confidence 
Intervals 
DW  
compared to 
Non-DW -205.4 < 0.001 -322.8-  -88.0 
Inverclyde -340.8 < 0.001 -458.2-  -223.4 
Scotland -201.6 < 0.001 -319.0-  -84.2 
Non-DW  
compared to 
DW 205.4 < 0.001 88.0 -  322.8 
Inverclyde -135.3 0.016 -252.8-  -17.9 
Scotland 3.8 1.000 -113.6- 121.2 
Inverclyde  
compared to 
DW 340.8 < 0.001 223.4- 458.2 
Non-DW 135.3 0.016 17.9- 252.8 
Scotland 139.1 0.012 21.7- 256.5 
Scotland  
compared to 
DW 201.6 < 0.001 84.2- 319.0 
Non-DW -3.8 1.000 -121.2- 113.6 
Inverclyde -139.1 0.012 -256.5-  -21.7 
 
Figure 5-32: Between-group comparison for change in Defined Daily Doses in Doing Well 
and control areas 2003-4 to 2007-8  
 
Figure 5-33 shows the increase in average DDDs for practices in the Doing Well programme 
and neighbouring geographical areas between the 12-month period before Doing Well 
started to recruit practices (July 2003- June 2004) and the 12 months to June 2008. There 
was a 5.3% rise in antidepressant use in the Doing Well area, compared with a 15.8% 
increase in Scotland, and significant rises in neighbouring areas.  
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Figure 5-33: percentage change in Defined Daily Doses (DDDs) from July 03-Jun 04 to 
July 06-Jun 08 by area 
 
Figure 5-34 represents the prescribing rate of DDDs per capita relative to the Scottish 
national average for each of the five years from July 2003 to June 2008. Prior to the advent 
of Doing Well, those practices prescribed above the Scottish average, although markedly 
below other practices in neighbouring areas. However while those other practices 
maintained their relative position, prescribing in Doing Well practices fell below the national 
average from the year 2005-6 onwards.  
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Figure 5-34: Defined Daily Doses per capita relative to Scottish average, July 2003- 
June 2008 
 
5.3.2 Gross Ingredient Cost  
Figure 5-35 shows the fall in Gross Ingredient Cost (GIC) by quarter, standardised to costs in 
the quarter July-September 2003. The fall in costs was very similar for both Doing Well (to 
55% of baseline) and non-Doing Well practices (to 56% of baseline). These reductions were  
significantly more than the reductions in cost seen in Inverclyde (62% of baseline) or in 
Scotland as a whole (65% of baseline). 
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Jul 04-
Jun 05
Jul 05-
Jun 06
Jul 06-
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Jul 07-
Jun 08
DW 1.04 1.01 0.99 0.96 0.94
non-DW 1.17 1.17 1.16 1.17 1.15
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Scotland 1.00 1.00 1.00 1.00 1.00
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5-35: relative fall in Gross Ingredient Cost, standardised to costs in the quarter July-
Sept 03 by area. Note y axis does not start at zero. 
 
Figure 5-36 summarises this reduction in the average Gross Ingredient Cost (GIC) of 
antidepressants prescribed between the twelve months to June 2004 and the twelve months 
to June 2007. The fall in GIC was significantly greater for the Renfrewshire practices (both 
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Doing Well and non-Doing Well), compared with the falls seen in Inverclyde and Scotland as 
a whole.  
 
Figure 5-36: Percentage reduction in total Gross Ingredient Cost (GIC) from July 03-
June 04 to July 07-June 08 by area 
 
Table 5-6 shows the within-group reductions in mean gross ingredient cost (GIC) over this 
period, with paired samples t-tests used to examine differences between mean gross 
ingredient cost during the 12 months to July 2004 and the 12 months to July 2008. The 
within-group differences are all highly significant (p<0.001 for each).  
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area 
Mean 
reduction in 
GIC 
dispensed 
Standard 
Deviation 
95% Confidence 
Intervals 
t p 
Doing Well  -34593.9 4801.5 -31543- -37644 25.0 < 0.001 
Non-Doing Well -54042.9 8322.0 -48755- -59330 22.5 < 0.001 
Inverclyde -40742.9 5984.9 -36940- -44545 23.6 < 0.001 
Scotland -1690128.2 345054.1 -1470891- -1909365 17.0 < 0.001 
 
Table 5-6: Within-group comparison for change in total Gross Ingredient Cost (GIC) in 
Doing Well and control areas between July 2003-June 2004 to July 2007-June 2008  
 
Table 5-7 shows a between-group comparison for the four geographical areas. There is no 
statistically significant difference between the fall in Gross Ingredient Cost observed in both 
the Doing Well and non-Doing Well areas (p=1.000), but this was significantly greater than 
the fall seen in Inverclyde (p=0.004) and Scotland as a whole (p<0.001). Inverclyde and 
Scotland showed statistically similar reductions in Gross Ingredient Cost (p=0.446).  
  
Mean % change 
in GIC 
p 
95% Confidence 
Intervals 
DW  
compared to 
Non-DW 0.18% 1.000 -5.39- 5.76 
Inverclyde 
7.59% 0.004 2.01- 13.17 
 
Scotland 10.73% < 0.001 5.15- 16.30 
Non-DW  
compared to 
DW -0.18% 1.000 -5.76- 5.39 
Inverclyde 7.41% .005 1.83- 12.99 
Scotland 10.54% < 0.001 4.96- 16.12 
Inverclyde  
compared to 
DW -7.59%0 0.004 -13.17-  -2.01 
Non-DW -7.41% 0.005 -12.99-  -1.83 
Scotland 3.13% 0.446 -2.44-  8.71 
Scotland  
compared to 
DW -10.73% < 0.001 -16.30-  -5.15 
Non-DW -10.54%  < 0.001 -16.12-  -4.96 
Inverclyde -3.13% 0.446 -8.71- 2.44 
 
Table 5-7: Between-group comparison for change in Gross Ingredient Cost (GIC) in Doing 
Well and control areas 2003-4 to 2007-8 
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5.3.3 Formulary compliance 
Antidepressants approved in the formulary (fluoxetine, citalopram and lofepramine) were 
amongst the cheapest available at that time. Since there was not a significant difference 
between Doing Well and neighbouring Renfrewshire practices in terms of formulary 
prescribing, data for these practices is shown together in the following graphs.Data for 
Scotland is shown for comparison purposes, but it should be noted that antidepressant 
formularies vary between Health Boards. All Scottish Health Boards recommend fluoxetine 
as a first line drug; citalopram is frequently also a first-line option, and is always included as 
a second-line choice. Lofepramine is mentioned specifically in a minority of Board 
formularies. 
Figure 5-37 shows that the proportion of formulary drugs prescribed as a percentage of all 
prescribed antidepressants increased more rapidly in Renfrewshire (from 43% to 57%) than 
in Inverclyde (39% to 49%) or in Scotland as a whole (41% to 49%). The change in prescribing 
within each area between the 12 months to June 2004 and the 12 months to June 2008 was 
statistically significant (paired t-tests, p<0.001). This will account for some of the reduction 
in costs noted above. Between-group comparisons using one-way ANOVA showed that the 
differences between Renfrewshire, Inverclyde and Scotland were all highly significant 
(p<0.001).  
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Figure 5-37: fluoxetine, citalopram and lofepramine prescribed as a percentage of total 
antidepressant prescriptions per 12 month period, July 04 to July 08  
 
Figure 5-38 shows that the use of lofepramine been declining in Scotland and Inverclyde. 
However this drug showed relatively modest decreases in Renfrewshire. Paired t-testing of 
within-area change between the year to July 2004 and the year to July 2008 showed a 
statistically significant reduction in lofepramine use in all areas (p<0.001). Differences 
between Renfrewshire and Inverclyde (which share the same formulary) were highly 
significant (p<0.001).  
This suggests that prescribing practice in Renfrewshire did diverge from that in Inverclyde 
and Scotland over this period. Since Inverclyde and Renfrewshire shared the same 
formulary, the difference observed may have been related to the work done by Doing Well 
in Renfrewshire to promote the use of these drugs.  
2003-4 2004-5 2005-6 2006-7 2007-8
Renfrewshire 43% 46% 51% 54% 57%
Inverclyde 39% 42% 45% 47% 49%
Scotland 41% 42% 44% 47% 49%
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Figure 5-38: lofepramine prescribed as a percentage of total antidepressant 
prescriptions per 12 month period, July 04 to July 08 
  
2003-4 2004-5 2005-6 2006-7 2007-8
Renfrewshire 3.0% 2.7% 2.8% 3.1% 2.6%
Inverclyde 2.8% 2.4% 2.2% 1.9% 1.5%
Scotland 2.5% 2.3% 2.3% 2.1% 1.8%
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6. Discussion 
 
6.1 Chapter outline 
This thesis describes the implementation of “Doing Well”, a programme designed to deliver 
depression care for a population of 76,000 people in 14 general practices in Renfrewshire, 
Scotland. This was an area that had previously had little input from community mental 
health services, so the relative lack of provision provided an opportunity to design, 
implement and evaluate an entirely new service.  
Three main steps were required to implement the Doing Well programme as part of the 
Centre for Change and Innovation’s drive for quality improvement: 
1. To understand what best practice in depression care might be, and to resolve gaps 
or uncertainties in clinical evidence 
2. To design and then implement a system of care that could reliably deliver effective 
treatment in a safe way 
3. To design a system that was able to find a sustainable niche within the network of 
existing service provision, and was suitable for generalisation to other areas and 
different settings 
Each of these steps presented their own challenges, and each was resolved in different 
ways; sections 6.2 and 6.3 discuss the limitations and strengths of the study respectively.  
A large research literature has established the effectiveness of pharmacological and 
psychological treatments for some people with depression in some settings, and this is 
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reflected in NICE guidance about appropriate interventions. But there are still substantial 
gaps in our knowledge. How, for example, should we seek to predict whether psychological 
or pharmacological treatment would be most appropriate for a patient presenting with a 
new case of low mood? What are the optimal frequency, intensity and duration of 
psychological treatments? Which of the 25 NICE treatment recommendations are 
indispensable, and which “packages” of different interventions would represent optimal 
care? 
This study was a limited evaluation of a complex intervention. The research challenges 
presented by this type of intervention are discussed in section 6.4. The clinical outcomes and 
prescribing change associated with the implementation of the Doing Well programme are 
then discussed in sections 6.6 and 6.7 respectively.  
There is an acknowledged gap between our knowledge of the best available treatments, and 
the care that is actually delivered in practice. This gap can only be bridged by careful 
attention to healthcare systems design.113 Section 6.8 reflects on the difficulties of managing 
uncertainty in practice, and section 6.9 examines how health services can design and 
implement systems to support effective decision-making and quality care.  
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6.2 Limitations of this study 
6.2.1 Study design 
The national Doing Well by People with Depression programme was intended to be a 
complex health and social care intervention that required local systems to change the way 
they delivered care. The national evaluation was designed as a “formative comparative case 
study” using a range of methods, including “workshops, significant event analysis and the 
use of routine audit and outcome data to review and improve practice”.333 The programme 
did not ask participating areas to formulate or answer research questions, and there was no 
government support or funding for randomised controlled trials.  
This study was therefore developed with an observational design, without a control group 
for the clinical intervention. As will be discussed in section 6.4, this approach may have some 
advantages over randomised controlled trials for the investigation of “complex 
interventions”, at least in the initial phases. Nonetheless, it was not possible to compare 
directly the outcomes for patients receiving care from Doing Well with those receiving 
"treatment as usual".  
Lack of a control group may be especially problematic in studies of depression, since mild to 
moderate episodes tend to remit spontaneously, with a median time to recovery of 12 
weeks or less.334 Whether psychological or pharmacological interventions are being 
evaluated, it is likely that 50% of subjects will recover within 8 weeks.335 Furthermore, the 
placebo effect in antidepressant trials is unusually large- accounting for about 60% of the 
improvement shown by active drug groups in clinical trials.125 This study has shown 
substantial improvement in the 654 patients out of 1,501 referred who met the eligibility 
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criteria. It is possible that similar improvement would have been found with treatment as 
usual. 
Operational policies supported by clinical governance procedures in Doing Well acted to 
monitor and maintain appropriate standards in relation to waiting times, consultation 
length, number of contacts and the service response to patients who did not improve during 
the course of treatment. Weekly clinical meetings provided an opportunity for 
multidisciplinary review of complex or problematic cases, and each clinician had weekly 
individual supervision of their caseload. As described in the Methods section, each clinical 
encounter began with an introduction to the “Overcoming Depression” self-help workbook, 
and a standard template for the clinical history was completed. However the use of 
subsequent self-help modules (for the Self Help Support Workers) or psychological therapy 
approaches (for the Primary Care Liaison Workers) was not specified. Although clinicians 
were expected to work within an approved framework (of guided self-help, cognitive 
behavioural therapy or interpersonal therapy), the “fidelity” of adherence to these 
approaches was not monitored.  
 This lack of information about “fidelity” makes it harder to identify the “active ingredient” 
associated with the intervention, and limits the generalisability of this study. These are 
significant limitations. They reflect not only the pragmatic exigencies of an observational 
study carried out in routine care, but also genuine uncertainty about what type of 
intervention is most appropriate in this setting. As described in section 3.4.1 (What types of 
therapy are effective for depression?), there are no “specific” treatments for depression, and 
most clinical effectiveness relates to a limited number of “common factors”. 
Section 6.4 (The evaluation of complex interventions) discusses how this study might be 
considered part of the “modelling” or “exploratory” phases of the evaluation of a complex 
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intervention that precede a randomised, controlled study, and reviews the issue of how “out 
of control” a randomised controlled trial can be.336 
The changes made by Doing Well influenced not only the content and context of individual 
patient consultations, but also to changes in the wider system of care. These changes will 
have evoked a response from the catchment population and health system, which in turn 
influence the nature of the original intervention. It was not possible to evaluate all the 
factors that may have influenced the effectiveness of the programme.  
For example, one consequence of Doing Well was that the waiting time for brief 
psychological therapy for people with depression reduced from six to twelve months to 
about two weeks. Referrals were also accepted for patients with any level of depression 
severity. These changes represent a marked increase in the accessibility of psychological 
therapies, and could be anticipated to make GPs more likely to make a referral. Unless this 
“increased demand” for a service was matched by appropriate capacity, waiting times for 
the Doing Well  service would be expected to increase again. At some point a dynamic 
equilibrium will be reached between demand and supply for a service (meaning the 
accessibility and capacity it can provide).  This study did not examine possible changes in 
service use or service adaptation elsewhere in the health system. 
Population and prescriber behaviour in relation to depression will respond to social, political 
and economic factors as well as more direct health service issues. It is possible to identify a 
number of factors that were beyond the control of the Doing Well programme. For example, 
significant investment was made in local community mental health services during the 
period of this evaluation (which continue at the time of writing in 2010).  Most of the new 
investment was made in West Renfrewshire, where Doing Well happened to be located.  In 
keeping with UK policy, the NHS in Scotland also received significant additional investment 
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during the study period, and clinical services in NHS Argyll and Clyde were subjected to a 
series of high-level managerial interventions that ultimately led to the merging of South 
Clyde mental health services with those in NHS Greater Glasgow from April 2006. Scottish 
Government initiatives like the “see me” campaign against the stigma of mental illness 
(launched in 2003), and the national “Breathing Space” phone helpline for people with low 
mood (launched in 2004) may have raised the profile of depression and encouraged people 
to seek help.  
Although none of these changes had a direct effect on the provision of primary care mental 
health services or psychological therapies, it is likely that general improvements in 
secondary care mental health services would have had some influence on the outcome for 
patients with depression. This study was not designed to examine ways in which such 
nationally-led initiatives might have influenced care for people with depression at a local 
level.  
An expert panel of opinion has proposed that response should only be taken to have 
occurred when symptom reduction has persisted for three weeks or more.264 Clinical 
protocols used in this study did not specify that outcomes should have stabilised in this way. 
However clinical staff did use their judgement to assess whether the “trajectory” of PHQ 
scores was likely to indicate a stable improvement after patient contact had ceased. 
Concordance with antidepressant medicines has been noted to improve outcomes in a 
number of studies,337 but this study was not designed to assess concordance.  It is therefore 
not known to what extent elements of the Doing Well treatment approach which were 
intended to provide “compliance support” could have influenced clinical outcomes.  
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Data was not collected on ethnicity, disability or sexual orientation. There was no health 
economic evaluation. The views of patients and GPs about the service were not assessed 
directly. 
 
6.2.2 Limitations of the prescribing measures 
High-quality data was obtained from national sources about practice-level prescribing. This 
allowed for analysis of the type of antidepressant, the defined daily doses and the gross 
ingredient cost of medicines prescribed. But since data could not be linked to individual 
patients at the time of this study, it was not possible to distinguish between antidepressants 
used to treat depression from the use of these drugs for other indications. There was 
significant variation in defined daily doses from month to month through the calendar year.  
Some of this variation is accounted for by non-random factors (like the dates of public 
holidays), but there is also significant “noise” in the system caused by random or unknown 
factors. This means that change in prescribing practice can only be assessed reliably over 
periods longer than one month. 
 
6.2.3 Limitations of the clinical outcome measures 
The use of the PHQ to track patient response to treatment was a critical component in the 
Doing Well model of care evaluated here. But the use of the PHQ to guide care in this way 
has four potential limitations. Firstly, the PHQ score itself may be too simplistic a measure 
for a condition as complex and varied as depression. Secondly, technical issues relating to 
the sensitivity, specificity, reliability and validity of the measure may limit its clinical utility. 
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Thirdly, investigators need to consider whether definitions of response and remission which 
are based on the PHQ are appropriate or meaningful when evaluating clinical practice.  
Finally, the use of the PHQ both as a “process” measure (to guide the delivery of appropriate 
care) and an an “outcome” measure (to assess the effectiveness of treatment overall) is a 
potential source of bias. The PHQ was usually completed by the patient, often away from 
their Doing Well consultation. However at other times they would complete the PHQ during 
an appointment, with or without the support of their Doing Well worker. Although the PHQ 
was intended to assess symptom frequency in the preceding two weeks, recall bias may limit 
the accuracy of the scores recorded. The PHQ score might be influenced by a patient’s wish 
to convey difficult sentiments to the clinician (eg “I might look better, but I don’t feel ready 
to be discharged yet”), or be subject to (intentional or subconscious)  transference reactions 
emerging from the patient-clinician relationship. To some extent these forms of bias and 
communication will be interpreted and responded to as part of the normal therapeutic 
process. However the PHQ as a final “outcome” measure may not be free of such influences, 
and yet will come to stand for the efficacy of treatment overall.  
Two approaches might have minimised the influence of this potential bias. Firstly, the final 
“outcome” score for each patient could have been completed and recorded “anonymously” 
(ie away from the clinician and not communicated to them). Secondly, the use of other 
measures to complement the PHQ would have presented a fuller picture of “outcomes” as 
distinct from the process variables.  Low response rates prevented their use in this study, 
but systematic reviews have established that a number of factors (e.g. shorter 
questionnaires, telephone follow-up, use of stamped addressed envelopes and first class 
and registered mail, University rather than health service letterheads) can improve low 
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response rates to questionnaires.338,339 Future studies would need to take account of these 
findings when seeking to improve response rates. 
The use of scoring systems as clinical indicators is well established within chronic disease 
management protocols: for example, the use of peak flow measurements in asthma care, or 
blood sugar levels in the management of diabetes. Part of the rationale for developing and 
using equivalent tools in depression is that such a chronic disease management approach is 
presumed to be of potential benefit in depression care.  
But the scores generated by the use of depression assessment tools differ significantly from 
the measures used in physical health conditions.  The pathophysiology of diabetes or 
hypertension is causally and directly linked to blood sugar and blood pressure, but there are 
no such biomarkers currently available for depression. The PHQ therefore measures a 
constellation of subjective experiences that are associated with a condition that we have 
called “depression”- but which has no identifiable “endophenotype”,340 and for which there 
are very limited objective measures of severity.  
Depression scoring tools like the PHQ are therefore necessarily based on clinician 
assessment or user self-report about a limited, pre-selected range of possible symptoms. 
Even though scales may have good inter-rater and test-retest reliability, sensitivity and 
specificity, they are based on human qualitative assessment, which is inherently variable. 
Evidence published since the advent of the Doing Well programme suggests that the PHQ 
may overestimate the severity of depression compared with other measures; this issue is 
discussed in more detail in section 6.8.1.3. 
Depression assessment tools are inherently limited, since symptom counts of the kind 
recorded by the PHQ make no reference to the previous personal experience or current 
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living situation of the patient, even though both are highly relevant to an understanding of 
their current depressive symptoms. While a symptom count may be useful in determining 
the likelihood of response to antidepressant medicines, it has limited utility in assessing the 
likely response to psychological treatments. For this reason, all Doing Well assessments were 
based on a 40-60 minute initial assessment. 
As described in section 4.4.4, these interviews enquired about a range of areas not covered 
by the PHQ, such as previous personal, family and medical history, medicines taken, anxiety 
symptoms, subjective well-being, satisfaction with treatment, understanding of treatment, 
and social and work functioning. An important rationale for the Doing Well clinical 
intervention was that patients would be offered enough time to discuss these issues with an 
appropriately skilled clinician.  However, there was no measure of the extent to which these 
topics were covered during assessment and follow-up visits.  Nor was there any assessment 
of the appropriateness of therapeutic interventions made during appointments. 
This study sought to assess outcomes using measures other than the PHQ (The Work and 
Social Adjustment Scale (WSAS), EQ-5D and Client Satisfaction Questionnaire). But poor 
completion rates prevented their use in further analysis. This limited the study’s ability to 
assess more holistic aspects of care, including functional ability, quality of life and 
satisfaction with treatment. The main reason for the low rates of return was that it proved 
difficult to acquire rating scale scores for measures not completed during the consultation. 
This was especially true of the Client Satisfaction Questionnaire (which was completed away 
from the clinician to minimise bias) and the four-month follow-up evaluation, simply 
because the passage of time meant that participants had other priorities. Other influences 
on score use and return rates are discussed in section 6.3.  
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6.2.4 People not referred for care 
This study did not provide any information about the outcomes for those who did not attend 
appointments, or who dropped out of treatment. This aspect of care was not the principal 
focus of this evaluation. Information about subsequent progress for this group of patients 
will be recorded in general practice notes, but this study was not resourced to investigate 
further, and ethical approval had not been sought to allow retrospective case note review 
for those who did not attend or dropped out of treatment. Asking prospective study 
participants to consent to such a review of primary care records may have adversely 
affected recruitment. 
Anecdotal evidence suggests that some people unknown to Doing Well did present to other 
local programmes, for example the "Choose Life" initiative to reduce the prevalence of 
suicide, or a "Condition Management" programme run outside the Health Service which was 
intended to support people with mental and physical health problems to return to work. No 
assessment was able to be made about the proportion of people who accessed alternative 
forms of help, nor why they made use of interventions other than Doing Well. Data was not 
available to assess change in the use of secondary care services. 
Of those people who experienced depressive symptoms but were not referred to the 
service, a proportion would continue to be managed by their general practitioner.  One 
aspiration of the Doing Well programme was that the care received by patients who were 
not referred to Doing Well would nonetheless be consistent with the Doing Well approach  
(for example, providing access to self-help materials and encouraging adherence to 
formulary guidance on antidepressants). In this way, improved depression care could 
become the responsibility not just of the Doing Well team, but of clinicians in primary care 
too. However no assessment of this aspiration was able to be made as part of this study.  
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6.3 Strengths of this study 
This is an observational study examining a “real life” intervention, including large numbers of 
patients referred from primary care.  
Only five percent of potential subjects were excluded from the study because they did not 
meet inclusion criteria. This low exclusion rate compares favourably with other similar 
studies in the UK, as will be discussed in section 6.5.2. Similarly, retention within the study 
compares favourably with other UK trials, as discussed in the same section. 
This study sought to appraise not just the clinical outcomes for individuals, but also to 
identify any prescribing change that took place in the catchment population served by the 
Doing Well practices. Using national prescribing data, it was possible to make “before and 
after” comparisons, and to use geographical controls to compare changes in the catchment 
and neighbouring areas. 
The electronic referral system was implemented successfully, and the "paperless" clinical 
information system used by Doing Well meant that virtually all the clinical data acquired 
during treatment was retained by the system and subsequently able to be used for analysis.  
This was particularly true of PHQ measurements and information about service use (such as 
number of contacts, and duration of treatment).   
The principal outcome measure of this study was changes in rates of prescribing. This 
information is collated nationally, is accurate and complete, and is independent of the local 
service.  
The successful completion of PHQ scores for almost every patient in this study stands in 
marked contrast with the poor returns from the other assessment measures.  The Work and 
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Social Adjustment Scale, EQ-5D and Client Satisfaction Questionnaire were all “post-
treatment” measures that were not used to inform clinical decision-making, but instead to 
record the consequences of earlier decisions. In this respect the PHQ can perhaps best be 
described as a "decision aid", whereas the other measures in this study were effectively 
"audit tools". PHQ completion rates were probably high because staff found it to be a useful 
way of tracking progress with the patient, and in guiding the choice of intervention that they 
might require. However some other factors contributed to its near-universal use: the PHQ 
was an essential component of the referral and electronic note-keeping system, it was quick 
to complete, readily understood by most patients and easily available in paper and 
electronic formats without charge. 
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6.4 The evaluation of complex interventions 
“Complex interventions” can be broadly defined as “a deliberately initiated attempt to 
introduce new, or modify existing, patterns of collective action in health care”.317 Within the 
narrower context of clinical trials, the Medical Research Council defines “complex 
interventions” as trials “that include several interacting components”.341   
NICE identified 25 interventions that support effective depression care,26 almost all of which 
were implemented by "Doing Well " (Figure 6-1). There is therefore some justification for 
assuming that the implementation of this pragmatic approach is likely to have had a real 
effect. But since the components of an intervention may act independently or 
interdependently, it can be difficult to analyse the relationships between them,318  and a 
conventional evaluation may struggle to identify individual or combinations of “active 
ingredients” 342 within such a multifaceted intervention.  
Although the Doing Well programme was clearly a “complex intervention”, this study is a 
description of the intervention, rather than a full evaluation, for the reasons set out in 
section 6.2.1.  
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Figure 6-1: NICE guidance on management of depression (National Institute for Clinical 
Excellence 2004)  
11 Key Priorities: 
1. Screening in primary care and general hospital settings1 
2. Watchful waiting 
3. Antidepressants in mild depression 
4. Guided self-help 
5. Short-term psychological treatment 
6. Prescription of an SSRI 
7. Advice on adverse effects of antidepressants  
8. Management of initial presentation of severe depression 
9. Maintenance treatment with antidepressants2 
10. Combined treatment for treatment-resistant depression 
11. CBT for recurrent depression 
 
Other Guidance:  
 Patient preference, information and consent 
 Integration of primary and secondary care 
 Clear treatment protocols 
 Use of telephone support 
 Comprehensive assessment 
 Alternative treatment options (eg voluntary sector, non-clinical services) 
 Suicide risk assessment 
 Advice about sleep and exercise 
 Psychological interventions (inc CBT & IPT) 
 Attention to quality of psychological interventions 
 Counselling on beginning pharmacological treatment 
 Avoidance of drug treatment for mild depression 
 Use of serotonin reuptake inhibitors and generic antidepressants 
 Liaison with secondary care about treatment resistance 
Notes  
1. "Doing Well” did not carry out population-based screening for depression, but would systematically assess 
individuals on the basis of their individual presentations. 
2. Although the intervention is designed to be brief, "Doing Well” does advise on continuing treatment. 
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Generally speaking, approaches to evaluation seek to answer three broad questions:  
1. What are the characteristics of an effective package of interventions?  
2. How can the causality of any observed change be assessed and attributed?  
3. How should standard trial methodologies be adapted to the issues posed by 
complex interventions?  
Reducing the complexity or variability between groups in a randomised controlled study 
designs may enhance the accuracy of comparison, but can limit the “real world” applicability 
of such research.  “Context level adaptation” may be required to adjust the intervention to 
local needs or preferences.336 For example, the methods section explains that Doing Well 
treatment protocols did not standardise the type or content of psychotherapeutic 
interventions provided by the service. Instead, staff were trained and supported to deliver a 
brief depression-focussed therapy from an accepted modality in a way that met patient 
needs. The function – appropriate brief therapy – is therefore defined, even though the 
composition of the consultation is not.  
Some have advocated that more attention needs to be paid not just to the outcomes of 
interventions, but also to the processes by which they become “normalised” and embedded 
into practice, so that they become workable and integrated “in settings that are themselves 
dynamic and complex.”318  
Pawson and Tilley343  suggest that the efficacy of changed systems emerges as a 
consequence of the action of stakeholders. The “causal potential” of an initiative therefore 
“takes the form of providing reasons and resources to enable program participants to 
change”. This perspective on complexity emphasises the importance of the context in which 
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change takes place, and the “internal” conditions which may encourage or discourage 
participants to make and sustain change.  
Campbell et al suggest that the development of complex interventions can be considered in 
phases analogous to those used in the trials of new medicines (Table 6-1),344 and this 
provides a useful framework to consider the stage of evaluation described here.  
 Implementing Doing Well required an initial “preclinical” phase to design the intervention 
on the basis of the relevant evidence. The evaluation reported here probably represents a 
mix of the “modelling” and “exploratory trial” phases outlined in section 6.4. Future 
evaluation of Doing Well might require a Phase 2 or Phase 3 study. Evaluation may itself 
enable the embedding or “normalisation” of a new intervention.345 
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Preclinical Theory Explore relevant theory to ensure best choice of 
intervention and hypothesis and to predict major 
confounders and strategic design issues 
Phase 1 Modelling Identify the components of the intervention and 
the underlying mechanisms by which they will 
influence outcomes to provide evidence that you 
can predict how they relate to and interact with 
each other 
Phase 2 Exploratory trial Describe the constant and variable components of 
a replicable intervention and a feasible protocol 
for comparing the intervention with an 
appropriate alternative 
Phase 3 Definitive randomised 
controlled trial 
Compare a fully-defined intervention with an 
appropriate alternative using a protocol that is 
theoretically defensible, reproducible and 
adequately controlled in a study with appropriate 
statistical power 
Phase 4 Long-term 
implementation 
Determine whether others can reliably replicated 
your intervention and results in uncontrolled 
settings over the long term. 
 
Table 6-1: Sequential phases of developing randomised controlled trials of complex 
interventions: from Campbell344 
  
Recognising that there is a balance to be struck between the complexity of “in vivo” real 
world settings and the accuracy of “in vitro” randomised controlled clinical trials, the UK 
Medical Research Council recommended that investigators evaluating complex interventions 
should:341 
 Carefully evaluate processes to identify instances where implementation problems  
(rather than the intervention itself) may have impeded effectiveness 
 Use larger sample sizes to take account of the extra variability caused by contextual 
adaptation  
 Use a range of measures rather than identifying a single primary outcome.  
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6.5 Service use 
6.5.1 Referral rate of people with depression 
The incidence of depression in the Doing Well area is not known, so the proportion of new 
cases of depression referred to Doing Well cannot be calculated. However, routinely collated 
national information (based on Practice Team Information practices) suggests that 4.4% of 
registered patients aged 15-64  in Scotland consulted a GP, Practice Nurse, District Nurse, or 
Health Visitor at least once for depression during the year 2005-6.346 Not all of these cases 
will have consulted with a “new” depressive episode. Between February and October 2006 
(the period of full recruitment to this study), an average of 2.4% of registered patients aged 
15-59 in the study practices were referred to Doing Well. It is therefore plausible that just 
over half of patients experiencing low mood in the community in this area were referred to 
Doing Well during this time.  
This estimate is consistent with epidemiological studies examining the incidence of 
depression outside the UK (although such studies are scarce, their methodologies diverse 
and the generalisability of their findings to UK settings may be limited). A systematic review 
of studies examining the prevalence and incidence of mood disorder published in English 
between 1980 and 2000347 found a pooled annual incidence rate of 2.9 cases per 100 
population (confidence intervals 1.3 to 4.8). Two subsequent epidemiological studies 
reported incidence rates of 0.99 per 100 in Canada,348 and 0.28 per 100 (for men) and 0.41 
per 100 (for women) in Sweden.349 The observed incidence of referrals to Doing Well of 2.4 
per 100 therefore falls within the higher range of these international studies.  
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6.5.2 Access and service use 
6.5.2.1 Access to Doing Well  
Doing Well was designed to be a “low intensity, high capacity" intervention that would 
provide depression care for a whole population. It was also designed to be convenient for 
patients to use: waiting times were kept as short as possible, all consultations were in the 
local GP practice, and the primary care setting and ethos minimised the stigma that can be 
associated with psychiatric treatments. Psychological and pharmacological approaches were 
combined in each consultation, since inconvenience in accessing separate medical and 
psychological services may act as an obstacle to appropriate care.136   
The "Doing Well" service was used by about twice as many women as men, in keeping with 
similar trials and population surveys of depression prevalence.350 It is not known why twice 
as many women consult with depressive problems than men.  It may be that depression is a 
condition that occurs more frequently than women, that women are more likely to seek help 
with emotional problems than men, or that depression in men presents differently from 
women in a way that conventional diagnostic and health care systems do not adequately 
recognise.351 Whatever the case, it seems as if the Doing Well response to gender-based 
differences in depression is no different from conventional care.   
There was a significant effect of gender on PHQ outcomes, with women in the Doing Well 
group showing an average PHQ improvement of 1.36 points greater than men (p=0.006).  
Age groups over 35 years had significantly better outcomes in this study than people in 16-
25 year age group (p<0.001).  
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6.5.2.1 Deprivation 
There is a correlation between income inequality and rates of mental illness,352,353 and an 
international study suggests that the prevalence of depression in lower income groups is 
between 1.5 and two times as frequent as in higher income groups.1 There are a number of 
possible reasons for this.  
Firstly, low socio-economic status may be a direct cause of depression, or be closely 
associated with other factors known to increase the prevalence of depression. Such factors 
include chronic physical health conditions,354 social exclusion,355 substance misuse, 
unemployment, poor built environment356 and lack of access to green space357 or 
recreational facilities.358  
Secondly, if the experience of depression makes it harder to find or keep a job, “social drift” 
may account for a greater proportion of people with depression living in areas with cheaper 
housing. Although anxiety, impulse control disorders and severe mental illness are all 
strongly correlated with inequality, mood disorders may be less so, especially for men.359 
Finally, people living in deprived areas may have different patterns of illness recognition and 
help-seeking behaviour which may influence their ability to respond to the kinds of care that 
might be offered.   
Consultation rates for depression amongst Practice Team Information (PTI) practices in 
Scotland in 2007-8 were 25 per 1000 males and 50 per 1000 females in the most deprived 
quintile, compared to 13 per 1000 and 29 per 1000 respectively in the least deprived 
quintiles.360 In other words, consultation rates were roughly double in the most compared to 
the least deprived quintiles. 
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Some Doing Well practice referral rates were three times higher than others, and we would 
have anticipated a positive correlation between greater deprivation and higher referral 
rates. However no such association was found. This would be compatible with a situation in 
which GPs were referring a lower proportion of patients with depression from more 
deprived areas.  
This may be because GPs were less likely to recognise depressive symptoms in people 
presenting from more deprived areas, that there were greater rates of primary substance 
misuse disorders or other problems in this group that made patients ineligible for referral, or 
because GPs did not believe that the Doing Well intervention would benefit these patients.  
It is not known why GPs should refer at such different rates, though such variation is not 
confined to mental health care. Work from our group suggest that half the variation in 
antidepressant prescribing rates in Scottish general practices are explained by nine factors, 
most prominent being deprivation and long-term limiting illness, but also including the age, 
gender and training of the GP, the location of the practice and the training status of the 
practice.21 Given that antidepressant prescribing behaviour will be strongly influenced by 
rates of detection and diagnosis of depression, it seems likely that the referral rate to Doing 
Well may be influenced by similar factors. However it was not possible to examine such 
potential associations in this study.   
Once referred to the programme, there was a slight association between deprivation and 
outcomes when all groups receiving some treatment were analysed together. There was no 
significant effect for the “treatment complete”, “transfer” and “disengaged” groups when 
examined independently. It therefore seems likely that any disparity in outcomes between 
more and less deprived groups is primarily related to factors operating prior to and including 
the decision to refer.  
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6.5.2.2 Impact on workload in primary and secondary care 
Recruitment to the Doing Well programme continued at a relatively stable rate of 1.3 cases 
per 1,000 population per month throughout the study period. There were no financial or 
other incentives for general practitioners to recruit or refer to Doing Well, other than the 
expectation that their patients would receive an appropriate clinical service.  In this respect, 
continuing referral rates acted as a proxy indicator of the usefulness of the service to general 
practitioners, and thereby suggested that the programme was helpful in a “real world” 
setting. The programme continued to be resourced by NHS Greater Glasgow and Clyde after 
funding from the Centre for Change and Innovation ended. At the time of writing in February 
2010, Doing Well covered 25 out of 30 practices in Renfrewshire, and is planned to provide a 
service to all 30 practices by summer 2010. 
The impact of "Doing Well" on GP workload was not directly examined in this study, but we 
note that the programme was initially welcomed by all local GPs, and sustained by 
participating practices for more than two years.  
Some psychiatrists are adamantly opposed to any extension of their involvement to include 
people with mild symptoms or psychosocial distress rather than identifiable psychiatric 
disorders. Their opposition is based on a number of concerns, but prominent amongst them 
is the fear that services open to mild problems in living will be overwhelmed by demand, and 
so exclude people with more clearly medical disorders (like bipolar disorder and 
schizophrenia) from accessing a finite mental health resource.361  
The Doing Well experience suggests that minimal psychiatrist involvement is required to 
maintain an adequate depression service. The investment by secondary care in other 
resources in Doing Well may act to protect secondary care services by dealing with mild 
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problems in a different way. However this study was not designed to assess that possibility 
directly.  
6.5.2.3 Duration of treatment 
Doing Well saw patients for an average of 14.6 weeks in total. During that period of time, 
the mean number of contacts was 5.0 and total treatment contact time was a mean of 151 
minutes (median 135 minutes) for the treatment complete group. An average of two and a 
half hours of clinician contact would be considered to be a “brief intervention”, even though 
the total duration of contact was nearly four months. It was not possible in this study to 
distinguish the therapeutic effect of direct “contact time” from that of longer duration of 
treatment overall (since depression tends to remit over time). 
In the Doing Well cohort, almost all the benefit was also seen within three contacts, a similar 
finding to another UK study which found the greatest symptom reduction arose in those 
patients who ended treatment after three sessions.309  
6.5.2.4 Retention within the programme of care 
In this study, 78% of eligible patients attended for a least one appointment. Twenty-one 
percent of eligible patients subsequently disengaged from treatment, meaning that 44% of 
people completed treatment per protocol with a further 13% referred for treatment 
elsewhere (the "transfer of care" group).  
Younger patients and those from areas of increased socio-economic deprivation were less 
likely to complete treatment in this study. The outcomes for patients who “disengaged” 
were significantly worse than for those who continued in treatment; this may also be true of 
those who failed to attend any appointments. Given the difficulties that people with 
depression may have in accessing treatment because of their condition, this finding requires 
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further investigation. The lack of response to treatment in the disengaged group was evident 
early in treatment.  
Retention within the programme can also be compared with other work. There was a 
significant attrition rate between referral and first appointment: 22% of eligible subjects 
either declined to take part or did not attend any appointment. However, this rate of non-
attendance is consistent with a 20% non-attendance rate in psychiatric outpatient 
settings,362 and significantly lower than the 39% non-attendance rate observed in one 
primary care mental health team.309 Attrition rates in the first six weeks can be up to 50% in 
naturalistic settings363 and up to 36% in clinical trials of antidepressant treatments.364 
These figures can be compared with similar programmes established in Doncaster and 
Newham as part of the Improving Access to Psychological Therapies (IAPT) programme in 
the NHS in England,311,365 and an earlier trial of a primary care mental health team in Leeds, 
England.309 The findings from these studies are summarised in Table 6-2. 
The Doncaster site was set up to accept GP referrals for patients with depression and a PHQ 
of 10 or more, and/or of anxiety and a GAD-7 score257 of at least 10.365  Eighty-three percent 
of subjects who met these criteria had a diagnosis of depression. Patients who had 
experienced “repeated treatment failures” were excluded from the pilot. Of 3,994 patients 
referred, 57 (1.4%) were considered unsuitable and were not offered an initial appointment. 
Of the 2,290 patients whose experience could be evaluated, 457 (20%) did not attend or 
refused a service and 569 (25%) dropped out of treatment. 1178 (51%) patients completed 
treatment per protocol.311  
A second Improving Access to Psychological Therapies site in Newham, London was set up as 
a Cognitive Behavioural Therapy service for a range of disorders.365 The service accepted 
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self-referrals and referrals from employers, community groups and Job Centre Plus as well as 
GPs. Staff were all CBT therapists, working between bands 5 and 8 of the NHS pay scale. Only 
46% of referrals received were for depression, and this range of non-clinical referrers may 
explain the high rate of “ineligible” referrals (35%).  A majority of subjects (78%) had 
experienced their symptoms for six months or more. Overall, 154 (36.1%) patients 
completed treatment, with 15.7% of patients being transferred to other services and 27.9% 
dropping out of treatment.  
Gilbert et al309 describe a service designed to offer assessment and brief psychological 
therapy for common mental health problems, principally anxiety and depression. Staffed by 
“primary care mental health workers” (with a background in social work, counselling, 
community psychiatric nursing and occupational therapy), the service operated in Leeds in 
the North of England. 75% of patients had problems with depression. Of 5,539 patients able 
to be analysed, 214 (3.9%) were considered to be inappropriate for treatment. Overall, 982 
(18.4%) of patients completed treatment, with a further 968 (18.2%) being referred for 
treatment elsewhere. 
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Site  
(n=total 
referrals) 
Eligibility (% all 
referrals 
ineligible) 
Did Not 
Attend 
disenga
ged 
Transfer 
of care 
Completed 
treatment 
per protocol 
Completed 
treatment or 
transfer of 
care 
Doing Well 
n=1585 
Depression of 
any severity, 
including 
depression with 
anxiety (5.1%) 
22.5% 20.9% 13.0% 43.6% 56.6% 
Doncaster311 
n=3994 
“Moderate to 
severe 
depression or 
anxiety unless 
repeated 
treatment 
failure” 
(1.4%) 
20.0% 24.8% n/a 51.4% 51.4% 
Newham365 
n=1043 
“common 
mental health 
conditions” 
(35.1%) 
20.4% 27.9% 15.7% 36.1% 51.8% 
Leeds309 
n=5539 
“common 
mental health 
problems” 
(3.9%) 
41.5% 18.2% 21.9% 18.4% 40.3% 
 
Table 6-2: comparison of treatment completion rates in UK primary care mental health 
services. “Ineligible” patients expressed as a percentage of total referrals; other 
parameters expressed as a percentage of referrals meeting inclusion criteria. 
 
With the exception of the Newham site, which accepted referrals from a much wider range 
of sources, and acknowledged difficulties in managing this, each of the programmes had 
similar rates of “ineligibility”. Although Newham excluded far more people than Doing Well 
or Doncaster, the proportion of people “completing treatment” (if this is taken to include 
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transfers to other services as well as treatment within the receiving programme) were 
generally similar at just over 50%.  
This study was unable to establish whether retention in treatment was associated with 
better outcomes, but it seems plausible that this would be the case- especially if “retention” 
included being referred on for more specialist services where an initial intervention failed to 
be effective. If so, measures to improve retention should be associated with better overall 
outcomes, and could be presumed to be particularly applicable to younger subjects, men 
rather than women and people coming from areas of socio-economic deprivation. 
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6.6 Clinical outcomes: comparison with similar programmes 
The mean change in PHQ after treatment in this study was 10.6, a fall of 62% in the 
depression score. In this study, 42% of patients entering treatment with a PHQ score of ten 
or more in the “treatment complete” group had a final PHQ score which could be considered 
to indicate “remission” (a PHQ of 5 or less) at the point of discharge. Seventy-nine percent of 
this group showed a “partial remission” with a final PHQ score of less than ten. Such changes 
represent important clinical improvement, and are similar to those arising from other 
studies of depression in primary care.  
This section compares the "Doing Well" intervention described here with two similar 
observational studies and two randomised controlled trials that were published after the 
Doing Well programme started. The observational studies were:  
1. the “Doncaster”  Improving Access to Psychological Therapies (IAPT) pilot, which was 
funded by the Improving Access to Psychological Therapies programme in the NHS in 
England365  
2. the “Leeds” trial of a primary care mental health service for 54 GP practices in Leeds, 
England 309   
The Newham Improving Access to Psychological Therapies (IAPT) programme is not 
discussed here because it did not deal principally with depression and used a different 
model of therapeutic intervention. The two randomised controlled trials were: 
3.  The “Northern England” exploratory study of enhanced care for depression in 
practices in the North of England.310  
4. The Threshold for Antidepressant Response study121 
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The two observational studies were introduced in Section 6.5.2.4.  The Northern England 
study was a Phase II patient-level randomized controlled trial in primary care, nested within 
a cluster randomised trial. Subjects were allocated either to a “collaborative care” arm (with 
case manager-coordinated medication support, brief psychological treatment and enhanced 
specialist and GP communication) or to usual care. Practices were randomised to provide 
either the intervention or treatment as usual, and patients in the intervention practices were 
further randomised to receive either enhanced care or treatment as usual. This “nested” 
design allowed for practice-level and patient-level effects to be discerned. The study was 
intended to estimate the effect size of the intervention in order to support the study design 
for a future “Phase III” trial. Recruitment to this randomised controlled trial was low: 114 
patients from a total practice population of 213,360 people.  
The Threshold for Antidepressant Response study121 examined the treatment of mild 
depression in primary care. Two hundred and twenty patients with a “new” case of mild 
depression were treated with supportive care from their GP or supportive care plus an SSRI 
antidepressant. New cases were defined as not having received antidepressant treatment 
for the previous twelve months, and mild depression was defined as a Hamilton Depression 
Rating Scale score of 12-19 (roughly equivalent to a Personal Health Questionnaire score of 
12-18366). Symptoms were required to have been present for at least eight weeks. Follow-up 
was at 12 and 24 weeks, and used the Hamilton Depression Rating Scale and Beck 
Depression Inventory to assess change in depression status. 
This study sought to investigate “real world” practice in primary care. However only one in 
ten of patients with a new episode of depression were referred into the study, and only 37% 
of those referred did participate. One third of observer ratings had become “unblinded” by 
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26 weeks, and there was some “cross-contamination” of the two arms, with twenty percent 
of subjects in the “supportive treatment only” group receiving an antidepressant, and 
thirteen percent of subjects in the “supportive treatment and antidepressant group” who 
did not actually receive drug treatment. 
Table 6-3 summarises the data from Doing Well and the two observational studies. Although 
no direct comparisons can be made across all parameters, some trends do emerge. Both the 
Doing Well and the Doncaster programme focussed on depression treatment using a 
stepped care model that included guided self-help, and both initiatives showed clear 
similarities in referral rates, age, gender, severity of illness at referral, cost per year, 
proportion of patients completing treatment per protocol, mean number of contacts, and 
mean treatment duration.  
Although the “Leeds” trial recruited a lower proportion of subjects with depression, and had 
lower completion rates, the number of contacts is also comparable. 
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Feature Doing Well  Doncaster 
IAPT311,365 
Leeds309 
GP referral 100% 96% 97.5% 
Diagnosis of depression 100% 83% 75.4% 
Study participants 1501   
Total catchment population 76,000 290,000 n/a 
Referral rate /1000 total 
population 
15.6 14.2 n/a 
Staff WTE  per 1,000 pop 0.096 0.011 n/a 
Cost £/year 
(per head/year) 
£240,000 
£3.16 
£1,460,000 
£5.03 
n/a 
% complete treatment or 
transfer per protocol 
57% 51% 40.3% 
Duration<6m 100% 26%1 n/a 
PHQ score>14 at referral 70% 62% n/a 
Mean PHQ at referral 17.0 16.0 n/a 
% female 66% 66% 69% 
Mean age 37.5 39.0 36.2 
Median wait 15 days 21 days n/a 
Mean contacts 5.0 4.9 4.6 
Duration of treatment 2.5 hours 2.8 hours n/a 
 
Table 6-3: comparison of Doing Well service parameters with comparable UK 
observational studies. Note 1: mean duration 11 months 
 
Table 6-4 summarises the change in primary clinical outcome measure for these four UK 
studies, which show a range of improvement of between 49-63%.  The studies use the PHQ, 
CORE or HADS, so direct comparisons between the outcome measures cannot be made. 
Differences in recruitment, intervention and duration of treatment and follow-up also mean 
that the studies are not directly comparable. Doing Well, for example, did not have a lower 
cut-off for depression severity, whereas the Threshold for Antidepressant Response trial 
only included patients with an HDRS score of 12-19.  
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 Before 
treatment 
score 
After 
treatment 
score 
% reduction 
in score 
absolute 
fall 
Doing Well (PHQ) 
“treatment complete”, n= 654 
16.73 6.13 63% 10.6 
Doncaster (PHQ)311 
“completers”, n=869 
15.39 6.31 59% 9.08 
Leeds (CORE)309   
Intervention, n=553 
17.7 8.8 50% 8.9 
Northern England (PHQ)310 
Intervention, n=35 
17.51 8.80 50% 8.71 
THREAD (HDRS)121 
“SSRI plus supportive care”, n=112 
15.45 7.92 49% 7.53 
 
Table 6-4: change in primary clinical outcomes measures (PHQ or HDRS) for Doing Well 
and comparable recent UK studies 
 
The Doing Well and Doncaster studies both used the PHQ and had similar methodologies.  
Clinical outcomes in the two services were comparable, with a mean PHQ fall of 9.1 points in 
the Doncaster cohort (for patients with depression of less than three months duration) 
similar to the reduction after treatment in "Doing Well" of 10.6 points.  
Although no direct comparison can be made between the PHQ and the Clinical Outcomes in 
Routine Evaluation measure used in the Leeds study, the study used a “clinical score” with a 
cut off of 11.9 for men and 12.9 for women to distinguish clinical from non-clinical 
populations. The mean change in scores from 17.7 before to 8.8 after treatment suggests a 
transition to “non-clinical” status. The equivalent change for Doing Well and Doncaster 
cohorts was a shift from “moderately severe” depression to “mild” depression.  
The “Northern England” trial recruited patients with a similar depression severity at referral, 
and showed a slightly smaller reduction in PHQ score by the end of treatment. 
246 Discussion 
 
The Threshold for Antidepressant Response trial found that the antidepressant drug plus 
supportive treatment group did slightly better than the supportive treatment only group 
over 26 weeks. But the differences were relatively small, and reduced over the follow-up 
period: 2.3 HDRS points at 12 weeks and 1.7 HDRS points at 26 weeks. These differences are 
probably not clinically significant.121 As the authors acknowledge, the trial was not placebo-
controlled, so it is not possible to know whether the small benefit seen in HDRS scores was a 
specific pharmacologic effect of antidepressant treatment. No significant change was found 
in the self-completed Beck Depression Inventory scores.  
A major American trial was published after the closure of recruitment for the Doing Well 
study described here. Although not directly comparable to UK work, it is worth describing 
briefly.  
The STAR*D research programme was a series of randomised controlled trials funded by the 
US National Institute of Mental Health that aimed to investigate the optimal sequence and 
combination of depression treatments if initial drug treatment was not successful. Patients 
were included in the study if they had non-psychotic major depressive disorder, and were 
suitable for drug treatment as the first step in care. Patients who did not achieve remission 
or could not tolerate a treatment step progressed to the next step in the treatment protocol.  
This “broadly representative group” of 3,671 outpatients in primary and secondary care 
included those with complex, comorbid, and recurrent depression: two-thirds of patients 
had at least one concurrent general medical condition, two-thirds had at least one other 
psychiatric disorder, over half reported a mood disorder in at least one first-degree relative 
and over half met criteria for anxious features.136 
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An “equipoise stratified randomised design” allowed patients to either switch 
antidepressant agents or augment their antidepressant with another drug or cognitive 
therapy. Level two offered four switch and three augmentation options; the latter included 
cognitive therapy with or without antidepressant treatment. Levels three and four 
represented specialist medication options, and do not relate to this study. Remission was 
defined as a reduction to five or less in the Quick Inventory of Depressive Symptomatology–
Self-Report scale (QIDS-SR16). Remission was achieved by 36.8% at step one, and by 30.6% 
at step two. The remission rate at step 1 was higher for those who had not previously been 
treated for depression compared to those who had received treatment in the past (42.7% vs 
35.6%). Longer duration of illness did not of itself influence the likelihood of remission.367  
The response rate (50% or more symptom reduction from intake) was 49% at step 1, 29% at 
step 2, 17% at step 3 and 16% at step 4. Overall, about one-half of patients responded in the 
acute phase of treatment when drop-outs were taken into account.268 Longer-term data 
suggests that only about one-half of patients stayed well at one year.265 
Updated NICE guidance on depression published in 2010368 reviewed the evidence relating 
to collaborative care in depression. The guideline recommended that collaborative care 
should be an important part of the care for people with depression associated with 
comorbid physical health problems. However the guidance did not recommend the 
implementation of collaborative care for other groups as part of usual care in the UK. This 
decision reflected considerable variation in the patient group, type of treatment, intensity of 
intervention and staff skill mix in the studies considered relevant to the guideline review. 
Collaborative care was more effective than standard care, but the effect sizes were small. 
Concordance with antidepressant medicines was enhanced in collaborative care settings. No 
UK-based studies examining the cost effectiveness of collaborative care were identified, 
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though it was anticipated that costs would be greater, given the increased resource implicit 
in the provision of multidisciplinary input to patients. Modest clinical benefit and uncertainty 
about cost-effectiveness therefore prevented the Guideline Development Group from 
recommending this form of collaborative care model in the NHS. However the guideline 
does acknowledge that low-intensity interventions (such as behavioural activation and 
medication management)312 may shift the cost-benefit balance. Advocates of this form of 
service delivery anticipate that low intensity care models may constitute a radical “new 
paradigm” for future mental health systems.369  
6.7 Prescribing outcomes  
6.7.1 Influences on levels of prescribing 
The level of defined daily doses prescribed are influenced by a number of factors,17 which 
could be summarised as follows:  
1. The incidence and prevalence of the condition for which the drug is prescribed 
The prevalence of depression in Scotland is not increasing. Antidepressants are 
commonly prescribed for conditions other than depression, including anxiety, eating 
disorders, insomnia (tricylics and related drugs), obsessive-compulsive disorder, 
post-traumatic stress disorder, neuropathic pain (tricyclics and related drugs), pre-
menstrual syndrome (SSRIs) and enuresis (tricyclic drugs). The drug duloxetine has a 
dual indication for both depression and urinary incontinence. 
2. The consultation and detection rates for that condition 
Consultation rates for depression in primary care in Scotland may be falling. As 
discussed in the literature review in section 3.2.2, many cases of depression will not 
be picked up by the GP at a first visit. As discussed in section 1.1.2, the recorded 
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incidence of depression in Scotland seems to be changing. The reasons for this are 
not clear, but may relate to the implementation of the Quality Outcomes 
Framework, to changes in Reid codes for depression, or a reduction in psychosocial 
distress as suggested by the Scottish Health Survey. 
3. The decision to prescribe for that condition 
As discussed in section 3.3.4, not all episodes of low mood require antidepressant 
treatment, and the GP’s decision to “medicalise” such an episode by treating with 
drugs will depend on a range of factors, including the availability of other forms of 
treatment and the doctor’s perception of patient preference 
4. The dose of drug(s) prescribed 
As discussed in Methods section 4.8.2, Selective Serotonin Reuptake Inhibitor (SSRI) 
drugs are often prescribed at multiples of daily doses because the “standard” dose 
in the British National Formulary is equivalent to the DDD. The defined daily doses 
for tricyclic drugs and venlafaxine are lower than the standard dose, although these 
drugs are often prescribed far below a standard dose for an antidepressant effect.  
The dose-response curve for SSRIs is flat, and there is little evidence to support dose 
increases for other drugs.370 Nonetheless, routine practice commonly prescribes at 
higher doses, and dose escalation is a common strategy deployed when patients fail 
to respond to the standard dose.  
5. The duration of the course of treatment 
Compliance with antidepressant prescriptions reduces quickly over time, with about 
70% of drugs still being taken one month after the prescription, 30 to 50% of drugs 
still being taken three months after the prescription, and only 20% of patients still 
compliant with medicines six months after the prescription was first issued. 110,118,156  
Recent evidence suggests that most of the increase in Defined Daily Doses in recent 
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years can be attributed to longer treatment in a minority of patients, rather than an 
increase in the numbers of people taking these drugs.110 
 
6.7.2 Mechanism of Doing Well prescribing change 
Doing Well had an explicit remit to encourage “rational” prescribing, and this took two 
principal forms. Firstly, prescribers were asked to comply with formulary antidepressant 
drugs unless there were clear contra-indications to their use. Secondly, doctors were 
encouraged to limit prescribing for people with “mild” depression: not to use drug 
treatment first-line for patients with a PHQ of less than 15, and to “watchfully wait” before 
prescribing for patients with a PHQ of 16-20.  
Monitoring prescriptions made for Doing Well patients suggests that antidepressants were 
used in relation to the severity of depression, in keeping with NICE guidance. Similar results 
were reported following the introduction of the Hospital Anxiety and Depression scale into 
routine practice in primary care in Southampton.40 
Doing Well practices had a lower rate of rise of antidepressants compared with neighbouring 
areas and the Scottish national trend. Doing Well practices, however, did not differ from 
other practices in Renfrewshire (the “non-Doing Well” group) with regard to the reduction in 
cost of antidepressants. The significant additional cost reductions seen in Renfrewshire 
practices compared to those in Inverclyde and Scotland would largely be accounted for by an 
increase in formulary-compliant prescribing.  
This information suggests that GPs may respond to guidance and support to change what 
they prescribe, but that they are unlikely to change how much they prescribe unless they are 
able to access a service that provides an alternative to drug treatment.  
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Improved formulary compliance will reduce prescribing costs, since the formulary drugs 
were cheaper than almost all other non-formulary items. But guidance on when to prescribe 
could have resulted in an overall increase or decrease in antidepressant use. Firstly, general 
practitioners in Scotland may not have been using antidepressants inappropriately for 
people with mild depression,205 but may have been under-detecting and under-treating 
people with more severe depression. In that situation, “rational” prescribing practice would 
have resulted in an increase in the Defined Daily Doses of antidepressants used. Secondly, 
there is some evidence that quality improvement programmes for depression care increase 
compliance with medicines,113 and this may have led to an appropriate increase in the 
duration of drug treatment.  
These possible interacting influences on antidepressant prescribing are set out in Table 6-5. 
factor 
possible Doing 
Well effect 
rationale 
Likely 
influence on 
DDDs 
Detection of 
new cases of 
depression 
more detection  
Increased GP and public awareness of 
depression as a local health issue 
increase 
Referral of 
new cases for 
specialist 
support 
more referral 
Prompt access to depression service 
which patients and GPs seemed to 
find acceptable/helpful; less reliance 
on drugs alone to manage depression 
reduce 
Decision to 
prescribe 
more rational 
GPs encouraged not to prescribe for a 
PHQ score <15, but to consider 
antidepressants for higher scores 
reduce or 
increase 
Prescribing- 
dosing  
better adherence 
to formulary 
guidance on 
dosing 
Formulary recommended using 
standard doses of antidepressants, a 
message strongly endorsed by Doing 
Well. If mainly tricyclics, it would 
mainly increase; if SSRIs probably 
decrease 
reduce or 
increase 
Prescribing- 
duration 
better adherence 
to formulary 
guidance on 
duration 
Individual work with all patients to 
stress importance of continuing drug 
treatment 
increase  
 
Table 6-5: possible mechanisms of Doing Well influence on prescribing practice 
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The effect of the Doing Well programme on prescribing change was statistically significant 
but clinically modest. This may be because the most important factor in DDD usage is the 
consumption of antidepressants by patients with long-term illness. Recently published UK 
data found that 78% of all antidepressant prescriptions were for less than 30 days.110 If this 
proportion were correct, then any influence on prescribing for a new episode will be diluted 
by the large majority of patients who discontinue medicines within a few weeks anyway. In 
addition, a short-term intervention like Doing Well would have relatively little influence on 
the minority of patients who did take long-term antidepressants. Nonetheless, it may be 
that a reduced incidence of new scripts will slowly act over time to reduce the level of long-
term antidepressant use.  
Possible influences on GP behaviour were set out above, but as sections 3.3.4 and 3.7.1.1 of 
the Literature Review describe, prescribing decisions are complex, and influencing clinical 
behaviour is usually difficult. Although it was not possible in this study to investigate which 
aspects of Doing Well did or did not influence prescribers, the following characteristics of 
the programme are consistent with the principles of successful “change programmes” 
reviewed in section 3.7.1.1. Doing Well was established in collaboration with local GPs and 
sought to respond to their feedback and comments. It offered a simple and plausible way to 
manage depression care, which was consistent with published guidance (such as the NICE 
guidance) and local formulary recommendations. It may be that some of the “marketing” 
approaches taken to promote local formulary usage did influence the choice of 
antidepressant drug.  
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6.8   Service responses to clinical uncertainty 
The Doing Well intervention was conceived and delivered as part of the Scottish 
Government's strategy to improve care for people with depression. Doing Well was 
therefore not established to question or re-examine fundamental aspects of depression, but 
instead to develop a pragmatic programme of care.  
Nonetheless, some of the assumptions that underpin conventional depression care are open 
to question. These assumptions generally hold true, at least for many people for most of the 
time. But they are simplifications of the “real life” situation in which clinicians find 
themselves, and it might be appropriate here to make them explicit. The assumptions could 
be summarised as follows:  
 that depression is a recognisable clinical entity that is identifiable by trained 
clinicians   
 that the appropriate threshold, intensity and duration for delivering both 
antidepressant medicines and psychological therapies can be determined for 
individual patients 
 that assessment of symptoms and clinical outcomes will guide service delivery 
Rather than gloss over these simplifications, Doing Well aspired to acknowledge and “work 
through” such assumptions rather than avoiding them. These issues are discussed in the 
following sections. 
6.8.1.1 Managing clinical depression, sadness and distress 
As described in section 3.2.1 of the literature review, the authors of NICE guidance on 
depression came to a view that depression “is too broad and heterogeneous a category, and 
254 Discussion 
 
has limited validity as a basis for effective treatment plans”.26 Fundamental to this diagnostic 
uncertainty is the ability to distinguish between depressive illness and “normal” sadness:   
“the very success of the DSM and its descriptive criteria at a practical level has 
allowed the field of psychiatry to ignore some basic conceptual issues that had been 
lacking at the foundation of the DSM enterprise, especially the question of how to 
distinguish disorder from normal suffering"43 
Unless this distinction can be made, the concept of depression may come to “engulf all the 
problems that life poses”.43 Low mood or stress undoubtedly causes much population 
distress, but how much of this is attributable to a medical condition? How much remits 
without treatment? Which people are likely to benefit from treatment? The broad definition 
of depression used by Doing Well meant that GPs were not required to make judgements 
about who should or should not be “medicalised” and referred for specialist help.  
Rather than seek to separate patients into distinct categories of either illness or distress 
based on diagnostic criteria, Doing Well worked to a loose definition of affective problems, 
accepting for assessment and treatment anyone that GPs felt had “low mood, depression or 
adjustment disorder”. Although access to the service required a medical referral including a 
PHQ score, there was no “severity cut-off” that determined whether so-called mild, 
moderate or severe depression would be accepted by the team.  
This approach reduced the risk of people with so-called “mild” disorder being excluded from 
care. In doing so, it opened up the possibility of a mental health service accepting 
responsibility for people who would not be considered “ill” in a conventional clinical sense. 
This change introduced two potential problems. Firstly, Doing Well had to be confident that 
the team had the skills to be able to help people with emotional problems, even if these did 
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not conform to a clinical diagnosis. Secondly, the service as a whole needed to have the 
capacity to deal with the large numbers of people with “mild” mental health problems in the 
community.  
Since most mild low mood will remit spontaneously over relatively brief periods of time, the 
service design also needed to ensure that professional involvement did not impede or 
complicate a recovery that might have taken place without professional help. NICE guidance 
suggests that guided self-help is an effective response to mild depression.26 Provision of this 
service in Doing Well used non-clinical staff and encouraged engagement and responsibility 
on the part of patients. This low intensity approach was relatively “non-clinical”, and 
probably reduced the likelihood of unproductive contact with secondary care mental health 
services.  
6.8.1.2 Making decisions about the type and intensity of treatment  
Even if the of qualitative assessment of thoughts, feelings and behaviours could be 
accurately translated into a numbered score, depression care differs fundamentally from 
other types of chronic disease management.  "Stepped care" implies that the complexity and 
intensity of treatment increases in proportion to the severity of the condition, but this 
assumption is open to question for depression.   
People with severe "biological" depression may respond very well to drug treatment, 
requiring relatively little additional support or therapy.  "Mild" depression, on the other 
hand, is the traditional province of long-term psychotherapy.  Psychotherapies of this kind 
may require highly skilled practitioners to implement treatment over several months or 
years.  For some people, therefore, the intensity, complexity and duration of treatment may 
be greater with a low PHQ than with a high one. This inversion of the “stepped care” 
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assumptions for at least some people calls into question the validity of the model for 
depression in general.  
Unfortunately, there is little evidence available at present to answer some of the 
uncertainties encountered by services such as Doing Well. For example, although people 
exposed to brief psychological interventions seem to do better than waiting list controls (as 
discussed in section 3.4.2.3 of the Literature Review), we do not know whether this applies 
to all patients, nor how the long-term outcomes of people receiving brief therapy compared 
with those receiving longer treatments.  
This issue is relevant for service managers (because conventional psychotherapies are so 
resource-intensive), but also for our wider public health (since the prevalence of depression 
is so high). Which provides the greater benefit: prompt access to a “good enough” brief 
treatment for all who need it, or a long wait for a “gold standard” treatment for a minority 
of people with depression? We cannot answer this question without longer-term follow up 
studies with a full health economic assessment. However the Doing Well intervention (and 
the results from a similar service in Doncaster, as described earlier in this chapter) does 
suggest that it is feasible to integrate a “low intensity, high capacity” model of care for 
depression into conventional primary and secondary care services.  
More work requires to be done to optimise some operational characteristics of such “low 
intensity” models. For example, what mix of face-to-face, telephone or email contact is most 
appropriate? What type, level and mix of skills are needed to make a staff team most 
clinically effective? How can we better identify patients for whom “watchful waiting” – 
which represents a kind of therapeutic containment – would be more appropriate than a 
usual clinical intervention? To what extent are interventions “done to” patients, and to what 
extent do they enable people to manage their own recovery over time? 
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6.8.1.3 Assessing symptoms and outcomes in practice 
The PHQ became the central feature of care delivery within the Doing Well system.  
Although there was no "PHQ threshold" for a referral to the service, once that referral had 
been made, the PHQ was used to define or guide treatment at several points in care. This 
approach had its limitations, as described earlier in section 3.6.2.4.  
There are significant differences between the various depression scoring tools available, 
which differ in sensitivity, specificity and inter-rater reliability.  In a recent direct comparison 
of the PHQ and the Hospital Anxiety and Depression Scale (HADS) scores in a study set in 
Scottish Primary care, Cameron et al259 suggest that the PHQ may overestimate the 
prevalence of major depression, and this is consistent with two other comparison 
studies.371,372 There is no doubt that a PHQ score is not directly equivalent to a HADS score, 
and the “pragmatic” cut-off points described by Kroenke253 may be inaccurate, as the author 
himself acknowledged.  
All depression scoring systems share some limitations, but the PHQ is at least as accurate as 
the other systems in common use, and significantly better than physician judgement 
alone.372 These uncertainties can be managed in practice, since the PHQ is only one of 
several factors that were used to guide care. Patient preference, previous response to 
antidepressants, family history of depression or other mental illness, and the developmental 
history of the patient all had an important bearing on clinical decisions in relation to 
appropriate treatment. 
The PHQ also proved to be useful as clinical "shorthand" that could express symptom 
severity in a simple number, rather than having to describe each symptom in detail. 
Although it is difficult to evaluate this objectively, there was a clear sense from the team 
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that the PHQ did form part of a new "shared language" around depression that facilitated 
communication between the patient and primary and secondary care.  The use of the PHQ 
probably also gave staff some confidence that their own clinical opinion about a patient's 
progress was referenced in a relatively objective way, and could be used to independently 
corroborate their actions.  
6.8.1.4 Monitoring clinical activity 
An assessment that has been “operationalised” in order to be applicable to a range of 
people in a population will lose significant contextual and other information compared with 
an individual assessment. There is a tension between a “generalisable but reductionist” 
model, and the more complete traditional formulation which has to be developed anew for 
each individual.  
Similarly, rigid adherence to a “system” of treatment may adversely care: 
“Effective clinical decision making requires a holistic approach that accepts 
unpredictability and builds on subtle emergent forces within the overall system… 
complexity theory saves both clinician and  patient from a futile quest for certainty 
and upholds the use of intuition and personal experience when general scientific 
rules are to be applied to the individual in  context.”373 
But there are also risks in implementing a system that is inadequately controlled. Care 
programmes that do not manage idiosyncratic practice or place some limits on variation 
from protocols may provide inappropriate treatment. It has been estimated that 30%–40% 
of patients do not receive treatments of proven effectiveness, and 20%–25% of patients 
receive unnecessary or potentially harmful care.374  
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Implementing new systems requires some thought to be given to the detail in which the 
operational instructions for following the new approach should be described.  New systems 
of care may then choose to check the "fidelity" to the model by tracking various process 
outcomes. 
For example, assessments of cognitive behavioural therapy for depression would typically 
specify the number of treatments, the grade of therapist, the outcome measures and also 
have some mechanism by which the content of the consultation itself could be monitored. A 
view was taken before the implementation of Doing Well that this degree of specification 
would be difficult to implement in routine practice, and also might diminish the 
effectiveness of the intervention, if it limited the therapeutic options available to clinicians 
within the team. 
It was therefore decided that tracking a small number of outcome and process measures 
would adequately monitor the quality of care provided to patients.  Clinical progress was 
assessed by the PHQ, and a range of process measures were routinely reviewed (for 
example, waiting time to first assessment and the number and duration of clinical contacts). 
There was no more intrusive examination of the therapeutic modality or content of clinical 
sessions. 
Tracking clinical performance in this way devolved considerable responsibility and autonomy 
to individual practitioners.  This presents a significant opportunity, if it were to allow 
committed, well-trained staff to individualise care according to their assessment of patient 
needs. But it also presents some risks, in that less control over treatment might permit 
inappropriate or ineffective interventions.  
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6.8.2 Staff development and support 
Doing Well clinicians were expected to be able to practise effectively with a significant level 
of autonomy. The skills, commitment and personal factors that staff brought to their work at 
Doing Well will have had a significant influence on the outcomes of the programme. To 
make this work, Doing Well actively supported continuing development of professional skills, 
the airing of uncertainty or errors in a group setting, and a system of care that fostered both 
quality and safety in practice.  
The staff training budget for members of the community mental health services where 
Doing Well is sited was about £30 per annum per staff member. The direct expenditure by 
Doing Well on staff training during the period covered by this study was about ten times that 
sum.  
Examples of professional training were described in the methods section (4.9.1). Quarterly 
meetings for all "Doing Well” staff were held away from base in order to review 
performance data and review or formulate protocols and standards for the clinical service.  
As described in section 4.6, roughly one day each week was given over to professional 
development.  This policy was initially implemented because of concern to avoid over-
burdening staff with excessive direct “one to one” clinical contact with patients.  It was felt 
that clinicians were unlikely to remain effective if they had to spend more than five or six 
sessions (20 to 24 hours per week) directly treating patients.  Since group supervision and 
administration would not take up more than a further eight hours per week, there was a 
need to find some other form of productive activity for the remaining hours. 
Allocating time to professional development therefore emerged from a practical need to 
limit the risk of burn-out.  However, in retrospect this policy had a number of additional 
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benefits, some direct and others indirect.  The most obvious benefit was the direct 
improvement in staff skills that were achieved at relatively low cost. 
In terms of indirect benefits, the policy seemed to support low sickness absence rates, which 
may be a proxy indicator for workplace stress or burn-out.  Investing in skills and 
development also conveyed an important message to staff that their views, attitudes and 
skills were valued by the organisation. 
Another consequence of a relatively broad approach to continuing professional 
development was that staff would bring into their daily practice a range of approaches and 
techniques acquired during this learning.  As described above, the Doing Well ethos was to 
be relatively "permissive", in the sense of trusting clinicians’ professional judgement about 
what approaches were relevant and safe. 
262 Discussion 
 
6.9 Clinicians and service change 
Clinicians know how difficult it can be to bring about behavioural change in individuals, but 
the support needed to bring about effective clinical behavioural change in staff is less well 
recognised. Changing practice is almost always difficult, and “educational” interventions to 
enhance care by GPs, or to improve information available to patients have generally been 
ineffective. The challenge for Doing Well and other forms of system redesign is therefore not 
only to ensure clinicians can be effective during individual consultations, but also to 
rationalise and coordinate the “health system” in order to support that clinical interaction.  
Managers and clinical leaders need to develop new ideas about how work should be done, 
how relationships are managed, and how patients can be engaged to participate in their 
care. System-level change typically requires coordinated change in a number of areas 
simultaneously,375 and the organisational and technical processes of delivering such changes 
merit attention and evaluation in their own right.318 
Heifetz376 defines three types of change situations: “technical” change (Type I) represents 
situations where the problems are well defined, their solutions are known and those with 
adequate expertise and time can implement the solution. By contrast, in an “adaptive” 
situation (Type III), the actual nature of the problem is often less clear and the solution is 
either not clear or requires people to change their attitudes, beliefs or behaviours. Heifetz 
proposes an intermediate (Type II) situation, in which there are both technical and adaptive 
changes to be made. 
Table 6-6 sets out come examples of challenges facing the Doing Well programme according 
to this framework. As anticipated, “Type I” changes were generally easier to implement and 
monitor than “type III” changes. It was relatively straightforward, for example, to train staff 
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in the use of the PHQ and then to implement information systems that required it to be 
recorded for each clinical contact.  
Key issues Problem Definition  Solution and 
Implementation 
Change 
Type 
Uncertainty about 
the assessment of 
depression 
severity 
Staff inconsistent or 
inaccurate in their 
assessment of depression 
severity, even though this is 
critical to the function of the 
service 
Implement system 
whereby PHQ is used to 
rate depression severity 
and to guide treatment 
decisions 
Type I 
Technical 
Insufficient 
capacity to provide 
long-term 
psychological 
therapy for all 
patients 
Although longer-term 
psychological therapy is 
needed by some patients, 
many will respond to briefer 
and less intensive 
treatments (like CBT) 
Use PHQ to identify 
“mild” depression. 
Implement “stepped 
care” system that 
evaluates response to 
treatment and increases 
intensity of intervention 
for non-responders 
Type II 
Technical 
and 
Adaptive  
Lack of clarity 
around definition 
of depression 
Depression is too broad a 
term to be useful as a 
diagnostic concept – though 
not everyone agrees with 
this. 
Current definition 
incorporates both normal 
loss responses and 
maladaptive responses –
though not everyone agrees 
this is problematic. 
Not clear; may be 
supported by use of PHQ 
in association with a 
“holistic” assessment by 
suitably trained 
practitioners 
Type III 
Adaptive 
 
Table 6-6: challenges faced in the development of Doing Well according to the Heifetz 
model 
 
It was not possible to manage “adaptive” changes in this way. As mentioned in the previous 
section, clinical complexity requires staff to respond flexibly to each individual situation. This 
represents “distributed” clinical responsibility that is consistent with General Medical 
Council guidance on working within multi-disciplinary teams.377 Since it is not possible in 
practice (and probably not desirable in principle) to operationalise or directly monitor 
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everything that staff do, Doing Well had to find different ways of ensuring adequate quality, 
as discussed in previous sections.  
This success of the Doing Well intervention therefore depended in part upon a shared sense 
of cooperation and accountability which may represent a form of “distributed leadership”,378  
in which leadership tasks can be collectively performed across a range of individuals. This 
concept is backed by the research by Denis et al,379 who argues that major substantive 
change is rarely led by one person, requiring instead collective leadership. They refer to the 
concept of a “leadership constellation” where members play a distinct role and work 
together harmoniously. 
6.9.1.1 The effect of a new project 
The Doing Well programme was supported by national funding that sought to promote 
innovation. Staff recruited to the team knew that they were required to make improvements 
over the care that had been provided historically in that area, and over standard care in 
other parts of the country. This generated a tone and culture that was characterised by 
enthusiasm, optimism and commitment.   
Like similar projects in the early stages of their development, Doing Well became quite 
distinct from other teams providing “treatment as usual”. The interpretation of the 
outcomes of the study therefore require to be conducted with some caution, since well-
established programmes, programmes without "special" funding, or programmes that 
cannot pick and choose the staff that they recruit are likely to have more difficulty in 
achieving the same outcomes. 
Such team positive or “special” team dynamics have been recognised to be important.  A 
sense of being in the forefront of progressive change can often be powerful motivators for 
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staff and have a positive influence on clinical outcomes.  However, such advantages may 
dissipate quickly when leaders move on, funding ceases, or the projects themselves become 
mainstream and so less "special”. 
It is difficult for services to gain insight into their own behaviour in this regard, not least 
when the author of this evaluation is the same clinical leader whose behaviour might be 
subject to evaluation. An impartial observer might suggest that anyone naming a new 
service “Doing Well” is not well-placed to make an independent assessment. 
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7. Conclusions and recommendations 
 
This evaluation suggests that it is feasible for a relatively small staff team to deliver 
depression care with appropriate outcomes, yet also has the capacity to see large numbers 
of patients. The Doing Well approach was grounded in psychological therapies, and based in 
primary care.  The rate of increase of defined daily doses of antidepressants was lower than 
that in areas which did not implement a Doing Well model of care. Doing Well and 
neighbouring practices achieved greater cost reductions than comparison areas. These 
prescribing changes seem to be compatible with “rational” prescribing practice.  
The observational design and lack of economic analysis preclude a formal comparison with 
usual services. Nonetheless it is likely that the Doing Well approach provided modest, 
incremental improvements over usual care. The implementation of Doing Well required 
significant changes in four areas of service delivery.  
Firstly, Doing Well represented a substantial service reorganisation. This was a complex 
intervention, implementing a number of changes simultaneously. It was also an “integrating” 
intervention, making sense of a range of existing therapeutic options, including self-help, 
pharmacotherapy and psychotherapy. Secondary care expertise was deployed in primary 
care, and “service delivery systems” were developed to minimise waits and waste.  
Secondly, the redesigned system sought to make better use of information. The Personal 
Health Questionnaire was recorded electronically at every contact, and was routinely used 
to guide care, monitor outcomes and distribute work within the team. It became useful 
“shorthand” for talking about depression severity and was widely used in discussions 
between GPs, mental health workers and patients.  
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Thirdly, Doing Well provided a psychological approach to care (guided self-help) as the 
default intervention for all patients, supplemented by antidepressants or more intensive 
psychotherapies where required. The emphasis on prompt (though brief) psychological 
intervention inverts traditional practice, which tends to lead with drug treatment or to refer 
a small proportion of patients to specialists for relatively lengthy and sophisticated 
psychological treatment.  
Finally, Doing Well invested in staff training and wellbeing so as to support effective clinical  
engagement with patients. Staff encouraged patient choice and participation in the 
decisions about treatment. Feedback from staff suggested that they valued feeling 
autonomous, respected, confident and supported in their work. It seems likely that this 
sense of confidence and optimism shared between staff and patients was an important 
aspect of the therapeutic relationship, but investigation of this relationship was beyond the 
scope of this project. 
These four changes were all the consequence of deliberate service redesign, in keeping with 
the original objectives of the “Doing Well by People with Depression” programme proposal. 
However Doing Well was also designed to be able to reflect and respond to the information 
gathered by the programme and the feedback provided by patients. The clearest example of 
this reflexivity is perhaps the way in which Doing Well became formally subject to health 
policy changes (Integrated Care Pathways250 and the HEAT target380) that the Doing Well 
programme and staff had helped to inform. More detail about this involvement in policy is 
set out in section 9.2.  
Although not an explicit part of the initial programme design, it seems in retrospect that one 
of the most important functions of Doing Well was to be able to “contain” distress without 
necessarily having to “treat” it. The service responded relatively promptly to people who 
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requested help from their GPs, and came to place great emphasis on the supportive nature 
of the first long consultation. Many people achieved full remission within three such 
contacts, and many others were clearly on such a recovering trajectory that they were 
discharged from the programme before fully well. In this way, Doing Well allowed for (and 
perhaps encouraged) the “spontaneous” recovery that naturalistic studies suggest happen 
to many primary care patients without treatment.  
This evaluation was not designed to investigate which elements of the Doing Well approach 
most enabled this recovery. Any study would probably find it difficult to disentangle what 
might be considered the active components of insight-oriented therapy from a more generic 
sense of distress being “contained” in a helpful way. Randomised controlled trials would be 
expected to show a large placebo effect, but “placebo” is an unhelpfully vague term for the 
critical mix of non-specific service elements that seems to influence recovery so positively.  
Patients who had this experience would typically have met with a therapist within two or 
three weeks of referral, have reached a shared understanding of their problems within the 
first or second visit, and have received enough support or therapy to be able to leave the 
programme by a third or fourth visit. People who had not improved at that point would be 
seen by a psychiatrist or psychotherapist and either treated more intensively within the 
programme, or transferred on for specialist care elsewhere.  
At the point of discharge, a Doing Well patient might have had a better understanding of the 
causes of their problems, some thoughts about how to prevent or respond to another 
episode in future, and known that they had access (by telephone or email request) to their 
Doing Well clinician in future should they request it.  
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While this evaluation could not measure whether these changes represented improvements 
over standard care, they do seem like sensible indicators of a quality experience. Without 
access to the Doing Well service, some of these patients may have received antidepressant 
drugs they did not need, or waited up to twelve months to see a psychologist or other 
secondary care staff.  
The PHQ may be able to measure “severity” of symptoms, but it cannot distinguish 
depression from “normal distress”, nor predict whether drug- or talking-based treatments 
are more likely to be effective.  By complementing the PHQ with an hour-long, 
psychologically-aware initial assessment, Doing Well enhanced the potential to allocate 
patients to the right mix of care. A skilled, psychologically-oriented formulation can be 
developed with the patient at a first visit.  
Sometimes it is clear from that first appointment that longer-term support will be needed 
(for example, for people with problems relating to a history of childhood abuse). Often, 
however, it is not: as discussed in the literature review, the cross-sectional symptom profile 
of depression, adjustment disorder and acute distress are often identical. The most effective 
way to distinguish between them may be to observe the patient over a period of time. 
Similarly, the best way to establish whether a patient is likely to respond to brief therapy is 
simply to try it and monitor the response. In other words, symptom duration as well as 
severity is important in adjusting treatment to meet patients’ needs.  
The incorporation of “time” into stepped care models is therefore an under-recognised 
aspect of their benefit. “Containing” distress in a supportive way allows this “watchful 
waiting” to take place without disadvantaging the patient. 
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7.1 Recommendations  
A range of innovations in depression care have been implemented in Western countries in 
the last decade or so.  The main themes in recent research have been the implementation 
and assessment of "stepped" care models, and the design of "low intensity cognitive 
behavioural therapies”, mainly based in primary care.  
Randomised controlled trials of the Doing Well and other “low intensity, high capacity” 
models of care are needed to better understand the generalisability of this type of 
intervention in a British NHS context. Such trials would be powered to establish whether 
outcomes are different compared with standard care, but should also seek to identify the 
critical elements within a "complex intervention" of this type. It is not known which the most 
effective elements are, how the various interventions interact with one another, nor what 
the "cost-benefit" relationship for each intervention is.  
For example, some interventions have used relatively unqualified caseworkers to provide 
telephone support or face-to-face guided self-help; other studies have used much more 
experienced staff to supervise or deliver treatment.  Both approaches have been shown to 
be effective, even though their deployment of therapeutic skills is very different.  Formal 
comparison of these two approaches would be worthwhile. 
Future research in this area should consider extending investigation of depression to include 
depression and anxiety, since these conditions are so commonly comorbid 
It would be helpful to try to identify packages of care that best meet the needs of particular 
patient groups. For example, would some people benefit more from group, rather than 
individual therapy?  Can we use demographic and other information acquired early in the 
referral process to understand the likely response to treatment, and design care pathways 
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better to meet those needs?  We know that the prevalence of depression is twice as high in 
women compared to men, but we manage depression in both genders in more or less the 
same way.  Is this appropriate?  How can we improve outcomes for people living in more 
deprived areas, particularly to reduce the rates of drop-out from treatment? 
We need to know more about the long-term outcomes for people treated with brief 
interventions.  Was there any change in the duration of symptoms, or the risk of recurrence 
in future? This would require a long-term cohort study. 
Three particular aspects of future trials would be beneficial. Firstly, an economic analysis 
would help to understand not only the direct cost of treatment, but also the broader social 
costs of depression, and their response to treatment. Secondly, it would be helpful to know 
more about how GPs perceived their access to interventions such as Doing Well, and in 
particular to measure the impact of such services on the workload in primary care. Thirdly, 
the natural history of untreated depression is poorly understood, and outcomes of 
depression treatment in primary care have not been systematically assessed in routine 
practice.  The advent of depression outcome measures as part of the Quality Outcome 
Framework in primary care offers an opportunity to examine the response to treatment for 
large numbers of people.  
The public health impact of depression is so large that service models to improve depression 
care should consider interventions that integrate more closely with resources directly 
targeted at the general public. Measures to reduce the stigma of mental illness, to educate 
the public about the causes of mental health problems and their treatment, and 
interventions that provide “direct access” help (such as online self-help, or telephone-based 
therapies) should be considered.  
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8. Reflections 
 
“All who drink of this remedy recover in a short time, except those whom it does not help, 
who all die. Therefore, it is obvious that it fails only in incurable cases.” 
Galen, quoted in Leber381 
Depression is a common and protean problem that is experienced by most people as a 
relatively brief, if recurrent condition. For others, it is a chronic, “treatment resistant” 
condition. The challenge to clinicians and health systems is to be able to distinguish between 
a “chronic disease” and an illness that has not yet received the right treatment.  
While our understanding of the causes of depression and the most effective treatments may 
be improving, much remains unknown. Given this partial state of knowledge, we cannot 
prospectively define what the “right” treatment would be for any individual. Perhaps the 
best health services can do is to aspire to a system whereby “standard” pharmacological and 
psychological treatments are adjusted in response to patient feedback until depression 
remits, or care for that person can be shown to have been optimised.  
This approach requires access to the relevant information, investigations and treatments. 
But it also critically depends upon disparate networks of clinicians responding appropriately. 
Managing the human aspect of this change is perhaps the most difficult. However, clinicians 
are most likely to choose to modify what they do if they are presented with alternatives that 
are relevant, understandable, motivating or fulfilling in some way. This is particularly true 
where the alternatives are easier to accomplish than “standard” care.  
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The following list outlines some approaches to improving the system response to depression 
(gleaned from complex systems theory,283 lean approaches to management382 and personal 
reflections about the Doing Well programme). Systems that aspire to make effective changes 
should: 
1. Make the problem clear  
For example, by using the PHQ as an objective outcome measure to clarify the 
“symptom count” in depression and so support clinical decision making. This works 
best when used at every visit as part of routine care, and where the scores are 
understood by patients, GPs and specialists alike. Note that these measures are 
most closely aligned to prescribing decisions, since they do not ask “psychologically 
informed” questions.  
2. Make sure the whole system is captured 
Systems must be developed in partnership with primary and secondary care, 
integrating services across traditional boundaries. For depression, secondary care 
expertise will typically be deployed into primary care practices.  Such changes should 
be considered as complex interventions that require to link to, and make sense of, a 
range of therapeutic options: from self-help and community-based support to 
pharmacotherapy and tertiary-level specialist services. Changes required are often 
best  implemented simultaneously, since each should reinforce the others. 
3. Design a system that “flows downhill” 
Most importantly, changed systems have to be easier to use than the ones they 
replace. Otherwise they will require constant effort to maintain the new approach. 
For example, an emphasis on prompt, though brief, psychological therapy (based on 
guided self-help) for all who can benefit is more likely to be used than one that only 
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offers delayed access to therapy, even if  this might be more comprehensive or 
intensive.  
4. Use information to guide decisions 
Access to information is a fundamental requirement for both clinical treatment and 
service development. Staff and patients need outcome measures to adjust 
treatment in the light of response. The service delivery system needs to use process 
measures (wait times, caseloads, treatment duration, antidepressant use) to 
respond appropriately to demand.  
5. Identify and eliminate waste and duplication throughout the system 
Service delivery systems need to be refined so that they became not only efficient, 
but also accessible and easy to use for both clinicians and patients. Multiple 
referrals, handovers and assessments should be avoided. 
6. Ensure minimum effective doses of therapy and antidepressants are used 
 This is an obvious statement for antidepressants, where prescribers are keenly 
aware that the dose-response curve may be flat, while the dose-adverse effects line 
continues to rise. But this is not so obvious for psychological therapies, where the 
outcome of the duration and intensity of treatment is less clear-cut. While a 
prolonged dose of therapy is unlikely to harm a patient, it will harm others if it 
prevents them from being able to access services.   
 
Most of clinical workload for psychological therapies is defined not by the number of 
new referrals, but the number of sessions spent treating the people already in care. 
Unless we can be sure that eight sessions of treatment will be better than four (or 
even four better than two), we should provide fewer sessions and reinvest the 
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capacity this releases to maintain spread in helping more  
 
7. Treat staff as we would expect them to respond to patients 
With respect, generosity and interest. This means investing in training, and avoiding 
excessive hours of direct patient contact.  
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9. Postscript   
 
9.1   Output 
The Doing Well intervention described in this thesis has also been the subject of the 
following presentations, publications and awards. 
9.1.1 Presentations  
The evaluation set out in this thesis informed presentations by the author and/or other 
members of the Doing Well clinical team at the following conferences and academic 
meetings: 
 Royal College of Psychiatrists Annual Meeting (2006 & 2007) 
 British Medical Journal Quality Improvement in Healthcare (2006 & 2007) 
 European Association for Behavioural and Cognitive Therapies (2006 & 2007; paper 
accepted for 2009 but withdrawn by the author since unable to attend) 
 British Association for Behavioural and Cognitive Psychotherapy (2006 & 2008) 
 Scottish School of Primary Care, SSPC (2006) 
 WPA Thematic Conference on Depression and Relevant Psychiatric Conditions in 
Primary Care (2008) 
 European Congress of Psychiatry (2008) 
 Paper accepted for European Psychiatric Association Annual Meeting in 2010 but 
withdrawn by the author since unable to attend. 
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9.1.2 Publications 
The following publications directly relating to the Doing Well programme were accepted for 
publication or in press at the time of writing in February 2010: 
Practical Service Redesign: Helping GPs to Enhance Depression Care. Smith,M (2010) 
Chapter in The Oxford Guide to Low Intensity CBT Interventions, Oxford University 
Press, Eds Bennett-Levy,J., Richards,D., Farrand,P., Christensen,H., Griffiths,K., 
Kavanagh,D., Klein,B., Lau,M., Proudfoot,J., Ritterband,L., White,J., Williams,C. 383 
“Doing Well”: service use and clinical outcomes of a complex intervention to 
improve depression care. Smith,M., Ackland,L., O’Loughlin,S., Young,D., Pelosi,T., 
Morrison,J. (2010) Primary Health Care Research & Development.384 
 
9.1.3 Other 
The "Doing Well" team was awarded the NICE/Health Service Journal award for “Best 
Implementation of NICE Guidance” across all UK healthcare sectors in October 2006. 
Doing Well was shortlisted for a “Shared Learning Award” from NICE in 2007, and is 
published on the NICE website as an example of shared learning in “Implementation Policy”. 
The Doing Well service was visited by Tom McCabe, Deputy Minister for Health and 
Community Care in the Scottish Government in November 2004, and by Andrew Robertson, 
Chairman of NHS Greater Glasgow and Clyde in January 2010. The author was asked to 
present the outcomes of the Renfrewshire Doing Well programme to a delegation of World 
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Health Organisation officials visiting Scotland in October 2007, and to Shona Robison, then 
Minister for Health in the Scottish Government, in December 2007. 
 
9.2   Influence on Policy 
The Doing Well intervention described here was initially the product of national policy and 
Government funding. The findings from this programme and other areas in the “Doing Well 
by People with Depression” initiative have influenced the development of subsequent work 
on depression in the NHS in Scotland.   
9.2.1 Integrated Care Pathway for Depression 
The investment by the Scottish Government in its “Doing Well by People with Depression” 
programme led to the Doing Well project in Renfrewshire described in this thesis.  In 2007, 
Quality Improvement Scotland introduced integrated care pathways (ICPs) for five 
conditions including depression.250 The pathway development group included clinicians from 
three “Doing Well by People with Depression” areas (including the author).  Early learning 
from the initial evaluation of the “Doing Well by People with Depression” programmes was 
therefore incorporated into the final Integrated Care Pathway for Depression. The pathways 
seek to set standards of good practice and then measure variation from that standard by 
care providers. The condition-specific standards for depression are as follows: 
 “There is a record of the offer and uptake of assessment of need, leading to 
appropriate self-help and signposting within 4 weeks of initial presentation. 
 There is a record of the offer and uptake of depression-focused brief psychological 
therapies within 6 weeks. 
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 The decision to commence antidepressants/psychological therapy is informed by an 
objective measure of severity.  
 Specialist assessment and treatment is available for service users with treatment 
resistant, recurrent and chronic depression.” 
The emphasis on a comprehensive “assessment of need” (including self-help), the provision 
of prompt provision of “depression-focused brief psychological therapies” and the use of 
“objective measures” of depression severity to guide prescribing decisions were closely 
aligned to the findings of the Doing Well by People with Depression findings reported here 
and to the findings from other areas.  
The author was asked to become the clinical lead for the development of Integrated Care 
Pathways for Depression in NHS Greater Glasgow and Clyde in early 2008.  
9.2.2 Health Improvement, Efficiency, Access and Treatment Targets  
Health Improvement, Efficiency, Access and Treatment (“HEAT”) targets are a core set of 
Ministerial objectives, targets and measures for the NHS. The targets are set for a three year 
period and progress towards them is measured through the Local Delivery Plan process. In 
2007, the Scottish Government introduced a new “HEAT” target to stabilise and then reduce 
the defined daily doses of antidepressants by the year 2009-10, and to reduce 
antidepressant use thereafter.380 This target was supported by a “Mental Health 
Collaborative” funded by Government. The work of the Collaborative was designed to 
support the implementation of the Integrated Care Pathway for depression. The author was 
appointed National Clinical Lead to the depression work of the Collaborative in 2008.  
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10. Appendices 
 
10.1 Grades of evidence 
Evidence 
Grade 
SIGN NICE Matrix 
A At least one meta-analysis, 
systematic review, or RCT 
rated as 1++,  
and directly applicable to 
the target population;  or 
A body of evidence 
consisting principally of 
studies rated as 1+,  
directly applicable to the 
target population, and 
demonstrating overall 
consistency of results 
At least one randomised 
controlled trial as part of a 
body of literature of 
overall good quality and 
consistency addressing the 
specific recommendation 
(evidence level-I) without 
extrapolation 
 
At least one high quality  
meta-analysis or 
systematic  
review, or RCT 
of high quality aimed at 
target population 
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B A body of evidence 
including studies rated as 
2++ (i.e. High quality 
systematic reviews of case 
control or cohort studies, 
directly applicable to the 
target population, and 
demonstrating overall 
consistency of results; or… 
Well-conducted clinical 
studies but no randomised 
clinical trials on the topic 
of recommendation 
 
Well-conducted non 
randomized clinical 
studies or RCT of lower 
quality on the topic of 
recommendation directly 
applicable to the target 
population, and 
demonstrating overall 
consistency of results 
C A body of evidence 
including studies rated as 
2+ (i.e. well conducted 
case control or cohort 
studies with a low risk of 
confounding or bias,  
directly applicable to the 
target population and 
demonstrating overall 
consistency of results 
Expert committee reports 
or opinions and/or clinical 
experiences of respected 
authorities (evidence level 
IV). This grading indicates 
that directly applicable 
clinical studies of good 
quality are absent or not 
readily available 
Expert opinions and/or 
clinical experiences of 
respected authorities. 
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10.2 Introductory letter 
 
 
 
 
 
Private & Confidential 
 
Wednesday, 20 October 2004 
 
 
Dear, 
 
 
Dr         has referred you to “doing well” for help with depression. I would like to offer you an 
appointment with myself on 
 
[Date] at [Time] 
at [Surgery] 
 
We have sent you quite a lot of information with this letter. Inside the folder, you’ll find:  
 
• some information about “doing well” and the way we work 
• a general information leaflet about depression 
• some questionnaires that will help us understand how your depression is affecting you, 
and how you progress over the next few weeks 
• a form that asks for your permission to use some anonymous information about you to 
be used to monitor the way we work at “doing well”  
 
We know that some people find this too much to take in all at once. But the more you can 
read before we meet, the more time we are likely to have to work together on your 
depression.  
 
It would be especially helpful if you could try to fill in all the questionnaires in the yellow 
pack. Don’t worry if you can’t do them all. 
 
Please phone or email me if you have any questions- or if the appointment above doesn’t 
suit you.  
 
 
Yours sincerely, 
 
Appendices 283 
 
    p
10.3 Information leaflet about the Doing Well service 
 
 
What is ‘Doing Well’? 
Depression and low mood are very common problems. Some people recover within a few 
weeks without any extra help; other people need specialist treatment. ‘Doing well’ aims to 
find the right kind of treatment for you.  
 
Taking part in ‘doing well’ will mean that you get extra help in dealing with low mood or 
depression.  This help might be: 
• information about using ‘self-help’  
• advice and support about coping with depression 
• antidepressant medicine  
• some combination of all these things 
 
Being referred to ‘doing well’ should also mean that you:  
 have to wait less time before seeing a mental health specialist who can help 
 get the kind of treatment that’s right for you 
 have real choices about the approach you want to take 
 are able to meet with someone face-to-face to discuss your problems Who are we? 
We are a team of staff from various professional backgrounds:  
• Lynn Ackland  (Assistant Psychologist) 
• Stephen McGinness (Psychiatric Nurse, Project Manager) 
• Michael Smith (Consultant Psychiatrist) 
• Katie-Jane Sutherland (Occupational Therapist) 
• Diane Young (Psychiatric Nurse) 
Our different backgrounds and skills allow us to offer you a range of treatment options best 
suited to meet your needs.  
 
 
What happens at my first appointment? 
The appointment will normally be at your GP practice. Your GP will have asked you some 
questions about depression that form part of a ‘depression score’ on a ‘Personal Health 
Questionnaire’ (PHQ).  
 
People who have low scores on the PHQ often need little professional help to recover from 
their problems. Others who have high scores often need antidepressant medicine and/or 
talking therapies of different kinds to get well again. 
 
You will meet with a member of staff for 45 minutes initially. 
 
We will then discuss with you what kind of help may suit you best. Generally this might 
mean meeting with you again, and staying in touch by telephone, email or letter. You may 
also be offered the opportunity to join a group supporting people with depression.  
 
What is Self-Help? 
 
information 
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‘Doing Well’ 
New Sneddon Street Clinic 
Paisley 
PA3 2AD 
 
Tel:     0141 889 8075 
Email: info@doingwell.org 
Website: www.doingwell.org 
 
  
People who have mild/ moderate depression are not usually helped by from treatment from 
antidepressant drugs. But people often do benefit from learning ‘self-help’ techniques.  
‘Doing well’ staff can talk you through ways of helping yourself to recover more quickly.  
We can provide free copies of books and leaflets about recovering from depression, and 
discuss how they might apply to you. The aim of self-help is to allow you to work in your 
own time at your own pace. 
 
 
Other treatment options 
If you have a more severe depression, then it is likely that you may require antidepressant 
medication in addition to a psychological approach to coping with your depression.  We 
think that it’s important that you know the pros and cons about antidepressant medicine; 
how they work and what potential side effects they have. We’ll help you to choose whether 
you think they are the right treatment for you, and if so the kind of medicine you want to 
take.  
 
You will also have access to other forms of psychological interventions (talking therapies) 
which will aim to help you work through ways of dealing with any difficulties you may be 
having. 
 
Evaluation 
It is important for us to know that ‘doing well’ is working properly and that people find the 
programme helpful.  In order to check that the programme is working, we would like to 
collect some information about: 
• the people that take part  
• how they respond to  treatment  
• what they think of the service   
Any information gathered will be kept anonymous- you would never be able to be 
personally identified from any of the information we use as part of our evaluation. We will 
provide more information about this at your first appointment. You can, of course, choose 
not to take any part in the evaluation.   
 
Complaints 
If you have complaint about the service, care or treatment you receive please contact the 
project manager Stephen McGinness, in the first instance. This will  
give us the best chance to put right what has gone wrong and the opportunity to improve 
our service.  
 
Should the matter not be resolved satisfactorily, then a complaint can be put in writing to 
the designated complaints officer for an independent review. 
The designated complaints officer for the Renfrewshire and Inverclyde area is: 
Mr Robert Clark, Complaints officer, NHS Argyll & Clyde,  
Merchiston Hospital, Brookfield, Johnstone, PA5 8TY 
 
Complaints should then be acknowledged within 3 working days and responded to within 20 
working days.  
 
 
 
 
 
 
 
If 
you 
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feel you need to speak to someone these may be useful phone numbers: 
 
BREATHING SPACE: telephone helpline support 
0800 838587 (6pm- 2am) 
FIRST CRISIS: telephone and personal support for people in crisis in Renfrewshire  
0500 829 093 (11am-11pm) 
SAMARITANS - 08457 909090 (24hours) 
 
Weblinks: 
 
Information about depression 
www.rcpsych.ac.uk/info/help/dep/index.asp 
 
www.mind.org.uk/Information/Booklets/Understanding/Understanding+depression.htm 
 
Information about antidepressants 
www.netdoctor.co.uk/medicines/ 
 
Stigma and mental health problems 
www.seemescotland.org 
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10.4  Consent form  
 
 
 
DW: Doing Well by People with Depression 
Dykebar Hospital, Grahamston Road, Paisley, PA2 7DE 
 
tel:    0141 884 9085 
fax:    0141 884 9079 
email:    Michael.Smith@renver-pct.scot.nhs.uk  
web:   www.renver-pct.scot.nhs.uk 
 
 
 
 
17 March 2004, version 1.1 
 
 
Doing Well by People with Depression (DW) 
 
Your doctor has referred you to a new service in Renfrewshire for people with depression. It is called 
“Doing Well by People with Depression” (DW for short).  
 
Taking part in DW will mean that you get extra help in dealing with your depression. This might be: 
• “self-help” support  
• advice and support from staff specially trained in helping people with depression 
• antidepressant medicine  
• or some combination of these things  
 
Someone from the DW team will contact you soon to discuss what kind of help would suit you best. 
Some people choose a lot of input from the team; others prefer to manage things with little or no 
support from DWB. 
 
An important part of DW is that we monitor people’s response to depression treatment with a 
questionnaire called the “Personal Health Questionnaire”, or “PHQ”. You will be shown how to use 
the PHQ by one of the DWB team. 
 
It is important to us to know that DW is working properly, and that people find the programme 
helpful. In order to check that the programme is working, we would like to collect some information 
about the people that take part, how they respond to treatment, and what they think of the service.  
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This leaflet is to ask your permission to use information about the care you receive while taking part 
in the DW programme to help us evaluate it. The information used would be anonymous- nobody 
could identify you from the information we have. 
 
Before you decide whether or not to agree to our use of some anonymised information about your 
care, it is important for you to understand why the evaluation is being done and what it will involve.  
Please take time to read the following information carefully and discuss it with others if you wish.  
Ask us if there is anything that is not clear or if you would like more information.  Take time to 
decide whether or not you wish to take part. 
 
Thank you for reading this. 
 
 
What is the evaluation for? 
DW is meant to help people recover more quickly and more fully from depression. It is also meant to 
make sure that people only take antidepressant medicine where it is likely to help. We also aim to 
reduce the waiting time to see specialists in depression, and overall to provide a service that people 
find more satisfactory than usual GP or specialist care.  
 
In order to make sure we are doing what we seek to do, we need to monitor how the group of 
people in DWB are doing, and what they think of the new service.  
 
 
Why have I been chosen? 
Everybody with a new episode of depression or low mood who consults their GP in participating GP 
practices and Health Centres will be offered a referral to DW. We expect that several hundred 
people will take part as DW becomes available in more practices. Ideally, we would like to include all 
of these people in the evaluation. 
 
 
Do I have to take part? 
You have a choice about whether or not you want to take part in DW.  
 
If you do take part in DW, you also have a choice about whether or not we can use some of the 
information about your care in our evaluation of the programme. 
 
If you do decide to let us use some anonymous information about your care in our evaluation, you 
will be given this information sheet to keep and be asked to sign a consent form. If you decide to let 
us use this information, you are still free to withdraw at any time and without giving a reason.  A 
decision to withdraw at any time, or a decision not to take part, will not affect the standard of care 
you receive. 
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What will happen to me if I take part? 
Your GP will ask you some questions based on the PHQ, which is a way of measuring how severe 
people’s depression is.  
 
People who have mild depression do not benefit from treatment with antidepressant drugs. Instead 
of a prescription, your GP will ask if you’d like to be put in contact with a DW staff member who can 
talk you through ways of helping yourself to recover more quickly. These “self-help support workers” 
can give you copies of books and leaflets about recovering from depression, and talk you through 
how they might apply to you. There might be the opportunity to join classes on recovering from 
depression.  
 
If the PHQ shows that you have more severe depression, then it’s likely that antidepressant drugs 
will help you recover. We think that it’s important that you know all about antidepressant medicine, 
and that you have a choice to take antidepressants or not. To get most benefit from medicine- and 
talk through any questions or problems you may have- DW can put you in touch with a specialist 
depression nurse. 
 
If the PHQ shows that you have very severe depression, we will try to get you a prompt appointment 
with a psychiatrist. 
 
If at any point your depression is not improving as it should, monitoring things with the PHQ will help 
us to change or increase the kind of treatment you are having. 
 
The DW team will work out of your local GP practice, and will probably see you there. They may be 
able to visit you at home if that would be helpful. They may also contact you by phone with your 
permission. 
 
 
What do I have to do? 
All we ask of you is that you use the PHQ questionnaire (yourself, or with DW help) to monitor your 
progress. If you do not want to take medicine as it is prescribed for you by your GP, we would ask 
that you let us know about this. 
 
 
What are the alternatives for diagnosis or treatment? 
DWB is best thought of as “enhanced care”- making sure that the kind of care you would usually get 
from your GP is up to the very best standards. 
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What are the possible disadvantages and risks of taking part? 
We do not think there are any disadvantages or risks to taking part in DWB (see above). 
 
 
What are the possible benefits of taking part? 
DW aims to give you the best possible care for depression.  
 
If you agree to let us use anonymous information in our evaluation, this will help us improve the DW 
service for other people.  
 
 
When would I stop being part of DWB? 
You would stay in the programme until you recover from depression. You would be free to leave the 
programme (and continue to have care from your GP) at any time.  
 
 
What if something goes wrong? 
If you have any complaints about DWB, you should inform the programme manager, Stephen 
McGinness, in the first instance at the phone numbers or address above.  
 
There are no special compensation arrangements if you should be harmed in some way by taking 
part in the evaluation. However, if you are harmed due to someone’s negligence, then you may have 
grounds for a legal action but you may have to pay for it.  Regardless of this, if you wish to complain, 
or have any concerns about any aspect of the way you have been approached or treated during the 
course of this study, the normal National Health Service complaints mechanisms should be  available 
to you.’ 
 
 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept strictly 
confidential.  Any information about you which leaves the hospital/surgery will have your name and 
address removed so that you cannot be recognised from it. 
 
Your GP will be kept fully informed about your participation in DW.  
 
 
What will happen to the results of the evaluation? 
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The results of the evaluation will be used by the DW team to monitor and modify the kind of care we 
provide to people with depression. It will also be used to report on the progress of DWB to senior 
managers within NHS Argyll and Clyde, the Scottish Executive and academic doctors at Glasgow 
University. Aspects of the evaluation may be published in clinical journals or in a postgraduate thesis 
by Dr Michael Smith supervised at the University of Glasgow. Interested participants would be able 
to obtain a copy of any of these publications. 
 
Nobody participating in DW will be identified in any report or publication. 
 
 
Who is organising and funding the evaluation? 
DWB is funded by the Scottish Executive Health Department; some future costs may be covered by 
NHS Argyll & Clyde. There is no payment to any doctor or staff member for including people in the 
DW programme.  
 
 
Who has reviewed the evaluation? 
The evaluation has been reviewed and approved by the Research Ethics Committee in NHS Argyll & 
Clyde.  
 
 
Contact for Further Information 
Please contact Stephen McGinness or Dr Michael Smith at the number above if you have any 
questions about the evaluation or DW more generally.  
 
Thankyou for agreeing to take part in the evaluation. A copy of the information 
sheet and your signed consent form will be given to you to keep.  
 
DW: Doing Well by People with Depression 
Dykebar Hospital, Grahamston Road, Paisley, PA2 7DE 
 
tel:    0141 884 9085 
fax:    0141 884 9079 
eml:   Michael.Smith@renver-pct.scot.nhs.uk 
         Stephen.McGinness@renver-pct.scot.nhs.uk  
web:   www.renver-pct.scot.nhs.uk 
 
 
  
Centre Number: 
Study Number: 
Patient Identification Number for this evaluation: 
 
CONSENT FORM 
 
Title of Project:  Evaluation of Doing Well by People with Depression. 
Name of Researcher:  Dr Michael Smith 
 
Please 
initial 
box 
I confirm that I have read and understand the information sheet 
dated 17 March 2004  (version 1.1) for the above study and have 
had the opportunity to ask questions. 
 
 
I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my 
medical care or legal rights being affected. 
 
 
I understand that sections of any of my medical notes may be 
looked at by responsible individuals from NHS Argyll & Clyde.  I give 
permission for these individuals to have access to my records. 
 
 
I agree to take part in the above study. 
  
 
 
       
 
__________________________  ________  _______________ 
Name of Patient  Date  Signature 
 
 
 
__________________________  ________  _______________ 
Name of Person taking consent Date Signature 
(if different from researcher) 
 
 
 
__________________________  ________  _______________ 
Researcher Date Signature 
  
1 for patient;  1 for researcher;  1 to be kept with hospital notes 
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10.5  Assessment instruments  
 
 
 
 
 
 
 
 
 
 
Before your appointment… 
 
 
Inside this pack are three sets of questions that will 
help us understand more about how depression has 
affected you. They may also help to clarify particular 
areas or feelings that you are having problems with, 
and we can discuss this at your appointment. 
 
Please try to complete the questionnaires before you 
come to your appointment with us.  Take your time to 
read the questions over, and answer honestly. You may 
want to get help from someone if you find them 
difficult. Please bring the completed questionnaires 
with you to your appointment.  
 
It’s OK if you’re not able to fill in the questions, or 
would prefer not to.  
 
 
Thankyou 
 
 
 
 
Your 
name 
 
 
 
date 
 
 
 
  
1. How has depression affected your thoughts and 
feelings? 
 
Filling in this “Patient Health Questionnaire” (PHQ) will help us understand how 
your depression affects you now. It also lets you monitor how your mood changes in 
the next few weeks.  
 
Thinking about the last two 
weeks, how often have you been 
bothered by the following 
problems?  
 
Not at 
all 
 
Several 
days 
 
More 
than 
half 
the 
days 
 
Nearly 
every 
day 
 
Score 
 
  0 1 2 3  
 
1 
 
Little interest or pleasure in doing 
things. 
     
 
2 
 
Feeling down, depressed, or 
hopeless. 
     
 
3 
 
Trouble falling or staying asleep, or 
sleeping too much. 
     
 
4 
 
Feeling tired or having little 
energy. 
     
 
5 
 
Poor appetite or overeating. 
     
 
6 
 
Feeling bad about yourself—or that 
you are a failure or have let 
yourself or your family down. 
     
 
7 
 
Trouble concentrating on things, 
such as reading the newspaper or 
watching television. 
     
 
8 
 
Moving or speaking so slowly that 
other people could have noticed. 
Or the opposite—being so fidgety or 
restless that you have been moving 
around a lot more than usual. 
     
 
9 
 
Thoughts that you would be better 
off dead, or of hurting yourself in 
some way. 
     
     Total  
 
2. If you checked off any problems, how difficult have these problems made it for you to do 
your work, take care of things at home, or get along with other people? 
 
Not difficult at all Somewhat difficult Very difficult Extremely difficult 
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O O O O 
 
 
Total number of symptoms 
 
 Total score  
 
PHQ © Pfizer Inc; reproduced with permission  
  
2. How has depression affected your everyday activities?  
 
This “work and social adjustment scale” gives an indication of how your 
depression has affected you in your daily life.  
 
Please rate each of the following questions on a 0 to 8 scale: 
indicates no impairment or problems at all and 8 indicates very severe 
impairment or problems.  
  
 
1. Because of the way I feel, my ability to work is impaired 
 points 
0 1 2 3 4 5 6 7 8   
Not at all 
impaired  
Very severely 
impaired   
  
 
2.  Because of the way I feel, my home management (cleaning, 
tidying, shopping, cooking, looking after home or children, 
paying bills) is impaired 
 
 
0 1 2 3 4 5 6 7 8   
Not at all 
impaired  
Very severely 
impaired   
  
 
3.  Because of the way I feel, my social leisure activities (with 
other people, such as parties, bars, clubs, outings, visits, 
dating, home entertainment) are impaired.  
 
 
0 1 2 3 4 5 6 7 8   
Not at all 
impaired  
Very severely 
impaired   
  
 
4.  Because of the way I feel, my private leisure activities (done 
alone, such as reading, gardening, collecting, sewing, 
walking alone) are impaired. 
 
 
0 1 2 3 4 5 6 7 8   
Not at all 
impaired  
Very severely 
impaired   
  
 
5.  Because of the way I feel, my ability to form and maintain 
close relationships with others, including those I live with is 
impaired 
 
 
0 1 2 3 4 5 6 7 8   
Not at all 
impaired  
Very severely 
impaired   
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  TOTAL   
 
  
3. How would you rate your quality of life just 
now? 
 
 
By placing a tick in one box in each group below, please indicate which statements 
best describe your own health state today. 
 
Mobility 
I have no problems in walking about  
I have some problems in walking about  
I am confined to bed  
 
Self-Care 
I have no problems with self-care  
I have some problems washing or dressing myself  
I am unable to wash or dress myself  
 
Usual Activities (e.g. work, study, housework, family or 
leisure activities) 
I have no problems with performing my usual activities  
I have some problems with performing my usual activities  
I am unable to perform my usual activities  
 
Pain/Discomfort 
I have no pain or discomfort  
I have moderate pain or discomfort  
I have extreme pain or discomfort  
 
Anxiety/Depression 
I am not anxious or depressed  
I am moderately anxious or depressed  
I am extremely anxious or depressed  
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To help people say how good or bad a health state 
is, we have drawn a scale (rather like a 
thermometer) on which the best state you can 
imagine is marked 100 and the worst state you can 
imagine is marked 0. 
 
We would like you to indicate on this scale how 
good or bad your own health is today, in your 
opinion. Please do this by drawing a line from 
the box below to whichever point on the scale 
indicates how good or bad your health state is 
today. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Your own 
health state 
9 0 
8 0 
7 0 
6 0 
5 0 
4 0 
3 0 
2 0 
1 0 
100 
Worst 
imaginable 
0 
Best  
imaginable 
  
 
10.6  Information and confidentiality 
The following information was gathered at each visit, and recorded in Continuum, 
the standard electronic record-keeping system used by South Clyde Mental Health 
services: 
Patient information from SCI gateway: 
Name 
DOB 
Gender 
CHI 
Postal address & postcode 
Phone numbers 
Email 
 
GP information from SCI gateway: 
Name  
Surgery 
GP contact phone/email 
Problem list 
Current medication 
PHQ score (all 9 fields) 
 
‘Doing Well’ visit 1 (Assessment): 
"Doing Well" worker name 
Date, place of contact 
Record whether attended 
Register consent obtained 
PHQ score as above 
EQ-5D score (5 items) and WSAS 
Antidepressant taken and concordance 
Free text to record other info as relevant 
 
Subsequent ‘Doing Well’ visits: 
"Doing Well" worker name 
Date, place of contact 
Type of contact 
Record whether attended 
PHQ score as above 
Antidepressant taken and concordance 
Intervention Type (face-to-face contact or phone or email contact) 
Free text to record other info as relevant 
 
Final ‘Doing Well’ visit: 
"Doing Well" worker name 
Date, place of contact 
Record whether attended 
Reason for discharge  
Discharged to…  
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PHQ score and WSAS 
Antidepressant taken 
Free text to record other info as relevant 
 
Database reports 
Discharge letter 
Audit and evaluation measures 
Caseload list 
 
  
10.7 Care protocol for self-help support workers  
Self-Help Support Worker: outline care protocol 
 
NB  Patient needs, preferences, and progress with self-help, medicine or CBT 
approaches determined the actual number and nature of contacts.  
 
Contact 1 (face to face, 40- 60mins): 
Explain outline of first session and time allocated, and the purpose the sessions. 
Emphasise flexibility and responsiveness of joint plan.  
Review the information pack and respond to any questions 
Review the GP referral with patient, checking information held is correct 
Assessment of presenting problems and relevant history including drug and alcohol 
use and present and past medication. 
Repeat PHQ with patient, ensuring that the patient can complete it themselves 
Complete EQ-5D and WSAS 
Discuss intervention and discuss group work if appropriate  
Introduce ‘5 Areas Approach’ & select relevant self help chapters. 
Give brief description of causes, incidence and symptoms of depressive disorders, 
where appropriate and discuss educational/ informational materials. 
Guide patient in the use of the self help materials  
Explain the protocol for telephone contact 
Discuss evaluation and seek consent for information use. Record written consent 
where this is obtained. 
Liaise with family and carers as appropriate  
Close and arrange second contact 
Record relevant information on Torex 
 
Any further face to face contact (20-30 mins): 
Review mood, circumstances, PHQ* 
Review previous session’s self help materials 
Joint work on further SH chapters as appropriate 
Any physical difficulties reported should be recorded and referred back to GP in 
the first instance 
Close and arrange third contact 
If telephone contact arrange a suitable time  
Record relevant information on Torex 
 
Any telephone contact (10-15 mins): 
Review mood, circumstances 
Review previous session and progress with self help materials 
‘Encouragement and activation’ where appropriate 
If majority of contact is via telephone patients should be able to complete PHQ and 
inform staff of score at time of telephone contact 
Record contact on Torex 
 
Final contact (face to face, 20-40 minutes): 
Review mood, circumstances, PHQ*, WSAS 
Review previous session’s self help materials 
Joint work on further self help chapters as appropriate 
Decide whether input can be stopped. If no, repeat this session in future contacts. 
Discuss in supervision 
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If this is the final contact give patient discharge letter and CSQ** 
Record relevant information on Torex 
 
* Failure to progress as measured by PHQ may be an indication for a different kind 
of intervention; record and discuss with clinical supervisor. 
**CSQ will be given to patients with a self-addressed envelope to complete and 
post back to the project base.  
 
  
  
10.8 Care protocol for primary care liaison workers  
Primary Care Liaison Worker: outline care protocol 
 
NB  Patient needs, preferences, and progress with self-help, medicine or CBT 
approaches determined the actual number and nature of contacts.  
 
Contact 1 (face to face, 40-60 mins): 
Explain outline of first session, and purpose of sessions. Emphasise flexibility and 
responsiveness of joint plan.  
Review information pack, respond to any questions  
Review GP referral with patient, checking information held is correct 
Comprehensive mental health assessment including antidepressant therapy. 
Fill in antidepressant side effect tool, where appropriate and engage patient in 
education including antidepressant issues- purpose, effects, potential adverse 
effects and concordance. 
Repeat PHQ with patient, ensuring they can complete it themselves 
Complete WSAS and EQ-5D  
Discuss with patient and jointly decide the most appropriate intervention.  
Introduce ‘5 Areas Approach’ & select relevant self help chapters 
Give brief description of causes, incidence and symptoms of depressive disorders, 
where appropriate.  
A CBT framework of care will be adopted as model of choice for any interventions. 
Guide patient in use of self help materials 
Refer to ‘Doing well’ group work if appropriate  
Explain protocol for telephone contact 
Discuss evaluation and seek consent for information use. Record written consent 
where this is obtained 
Liaise with family/carers as appropriate 
Close and arrange second contact 
Record relevant information on Torex 
 
Any telephone contact (10-15 mins): 
Review mood, circumstances 
Review previous session re medicine, concordance, adverse effects, SH materials, 
CBT etc.; joint work on these issues as appropriate  
‘Encouragement and activation’ where appropriate 
If majority of contact is via telephone patients should be able to complete PHQ and 
inform staff of score at time of telephone contact 
Record relevant information on Torex 
 
Subsequent face to face contacts (type and duration flexible): 
Review mood, circumstances, PHQ*  
Review previous session re medicine, self help materials, CBT etc.; joint work on 
these issues as appropriate 
Side effect tool 
Continue education and discussion on concordance issues. 
Any physical difficulties reported should be recorded and referred back to G.P in 
the first instance 
Close and arrange subsequent contact 
Record relevant information on Torex. 
 
Final contact (face to face, 20-40 minutes): 
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Review mood, circumstances, PHQ*, WSAS 
Review previous session re medicine, self help materials, CBT etc.; joint work on 
these issues as appropriate  
Prepare/continue relapse prevention plan 
Give patient discharge letter and CSQ** 
Close session 
Record relevant information on Torex 
 
* Failure to progress as measured by PHQ may be an indication for a different kind 
of intervention; record and discuss with clinical supervisor. 
**CSQ will be given to patients with a self-addressed envelope to complete and 
post back to the project base 
 
 
  
  
10.9 Clinical examples 
The following examples of clinical cases were prepared by Doing Well service users with the 
help of a professional writer, and published with their permission on the Doing Well website 
at www.doingwell.org.uk 
10.9.1 Depression can be physical, as well as mental: Martin, 59 
 "I’ve been a hillwalker all my life. To climb something like Ben Lomond, usually takes me just 
seven hours or so - that’s going up and getting back down again. It’s about the equivalent of 
ten miles on level ground and until last year I could do it as quickly as I could in my twenties. 
But right now the most I can walk is about a mile and that leaves me exhausted. In the 
summer I went to visit family abroad and I wasn’t even strong enough to walk between the 
airport terminals. I needed to get someone to push me in a wheelchair. 
 The doctors assure me there are no physical reasons for this. I collapsed at work about 7 
months ago as a result of stress at work and this in turn caused me to suffer from 
depression.  The depression affected me mentally and physically.  I’m getting better, but my 
body is no where near back to what it was - I get tired very easily. I miss the hills, but the 
way one doctor put it to me was this: it’s as if my body is telling me that it needs a complete 
rest.  
I found the workbooks Doing Well gave me extremely helpful. I can see how some people 
find them daunting – they are like booklets, as much as ten pages long. I was handed my first 
one and I groaned because I’m a slow reader anyway. You do need to take the time over 
them but they really got me looking at things. You see yourself in different situations, and 
you start to work through the things that apply to you." 
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10.9.2 Antidepressants: Lorraine, 44  
"When Doing Well suggested I take anti-depressants I knew I couldn't go on as I was because 
I was in a downward spiral. 
 
"It was a surprise to me how well they worked - the improvement has been tremendous. 
 
"Now, I'm not bursting into tears every five minutes. I'm getting up in the morning. I'm 
coping with my work. I'm enjoying my work. I look forward to seeing my students, and I do 
my prep work at night - but a few months ago you'd have to drag me over hot coals to get 
me to do that. I'm enjoying life again. 
 
"I do still feel there is a stigma to it though. Even now there are very few people who know I 
am on anti-depressants. People see the difference in me: they see I'm looking happier but 
I'm not happy saying it's because I'm on the anti-depressants. 
 
"My husband doesn't know I'm on them, my children don't know I'm on them either. In a 
way I feel I've let myself down by taking them and that's something I have to deal with in the 
future. 
 
"I knew I had to take them to give myself a chance. Then after a while- about six weeks in my 
case - I woke up in the morning and realised I wasn't feeling terrible anymore. 
 
  
"My situation hasn't changed over the last three months - it is the same as it was. But now I 
feel I can cope with it."  
Lastly, I had the option to participate in the ‘doing well’ service at my GPs surgery.  What a 
great idea! 
 
10.9.3 Doing Well and antidepressants: Joanne, 33y 
 "the effect of therapy really surprised me..."  
I’m a doctor myself and I think that made me feel sceptical about the idea of going to see a 
therapist at the Doing Well clinic. I just thought I wouldn’t hear anything I didn’t already 
know.  
I had a twelve year relationship, from university through my 20s, which wasn’t going 
anywhere, and I was at an age – I’m 33 - where I felt I should be settling down, but wasn’t. 
 I knew the anti-depressants would get me through the low feeling I had – I have used them 
before - and give me a chance to get myself together. But the effect of the therapy really 
surprised me.  
I started to feel a lot better very quickly - so quickly I knew it couldn’t have been down to the 
drugs. Essentially, here was another healthcare professional reassuring me that what I was 
feeling was a genuinely problem.  
I have a lot of friends to talk to, and family, but I often felt I was whingeing by talking to 
them about this sort of thing, that I was just making an unnecessary fuss.  
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But here was another professional telling me I wasn’t just making a fuss, that the problems I 
felt I had were real. That was of enormous help to me from the start, and the lift really 
surprised me.  
One of the things I was concerned about was that the cycle of depressions would leave a 
permanent mark on me – this was who I now was. The therapist has helped reassure me 
that this was not the case and I feel more confident now of my own personality and 
individuality.  
I’m also a more philosophical person now. Recently, another relationship came to an end, 
with a different partner, and it really wasn’t as traumatic as I’d have expected it would be. I 
felt a dip, but I’ve recovered, and for me that is a huge leap forward. 
 
10.9.4 "I’ve learned to know how much I can cope with": Gerry, 52y 
 I’d challenge anyone to say they’d got lower than me. I suffered six deaths in quick 
succession, people from different generations, including a young cousin who died in their 
early 20s and my girlfriend. 
  
I’d not worked for a couple of years while I was looking after her, and then I found myself on 
my own, with no where to stay – because the flat had been in her name - and ostracised 
from my girlfriend’s family because they just didn’t want to know me.  
This was over ten years ago: I drove into a lay-by, I connected the exhaust pipe to the car 
cabin and I was ready to end it there and then. But I didn’t, I decided to go for help, instead. 
  
 I walked into the social work department and asked to see someone. They were very polite, 
I explained what I’d been going through for ten minutes, but then they told me ‘sorry, we’ve 
no one qualified to deal with you.’ 
 I tried another couple of places too, but there was nothing quite right – and I didn’t want to 
go on drugs but I went to the doctor and she suggested I use beta blockers. They keep me 
calm. The next thing I did was buy a caravan and head south. I spent a year walking along a 
beach. This was my time off work, if you like. It helped me get myself together and when I 
came back north. 
 I retrained in desktop publishing and that’s led to a couple of jobs, but I’ve left those on my 
own – I have other health problems too – but as Clint Eastwood said: ‘A man’s got to know 
his own limitations.’ I’ve learned to know how much I can cope with, and if I’m within those 
boundaries I can deal with the day to day. 
 Going to Doing Well, has helped in that. Therapy has given me someone to talk to, someone 
who knows what they are talking about, but who isn’t in your immediate family. I just wish 
they’d been around ten years ago, because I really needed them then. 
 
10.9.5 "I’d just think people were being self indulgent": Barbara, 41 
 One evening I was on the way home and I very nearly crashed my car. I was driving at about 
60mph on the motorway, on a route I took almost every day, but I all I was thinking about 
was my job because I was juggling five or six projects. I went to change lanes and almost hit 
someone else - I was clearly in the wrong.  
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That night I didn’t sleep – I realised things had to change. The next day I couldn’t face work 
because I felt like it had almost cost me my life.  
I went to see my GP and that was when I did my PHQ – the score was really high. Alarmingly 
high, actually.  
At the Doing Well clinic I used the workbooks and met up with the therapist. It was really 
good for me to have someone who wasn’t work related or family to talk to. It was like 
getting a neutral opinion of my life. It’s helped me understand how I was feeling and what 
led to it.  
You know, before this I never really believed in depression. I actually had a close friend who 
suffered from it but I would be like ‘oh just pull yourself together’. It sounds terrible thinking 
about it now, but that is what I used to think. I didn’t see it as a real thing I’d just think 
people were being self indulgent.  
I took two and a half months off work and since then I’ve actually changed my job. I was 
completely honest with my new employer at the interview and they’ve been great about it. 
Things have been going really well, I’m not taking on too much, and I’m realising there is 
more to life than just work.  
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